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Abstract 
Through a review of adherence literature and thirty qualitative interviews, a 
theoretical view of the adherence process has been created which enables an 
understanding of the process from initial awareness of need through to post-
consumption assessment. This view is proposed to answer the research 
question, what is adherence from a process perspective? 
It builds on Service-Dominant Logic to theorise the act of adherence for the first 
time. In this it views adherence as a complex relationship of interacting service 
(eco)systems. This takes the theoretical understanding of adherence beyond 
existing theories and models and into the act of consumption itself, thus providing 
theoretical visibility of the end-to-end process of adherence. 
The literature review and qualitative research identified six factors of adherence 
and three rules governing the adherence process. Perhaps surprisingly, 
interviews found little difference in causes of non-adherence between developed 
and developing worlds. A quantitative survey operationalised these adherence 
factors and rules through the development of a quantitative process of adherence 
derived from the qualitative process. However, due to survey limitations this 
research provided no additional insights. 
A new viewpoint on adherence is advanced. This considers adherence as a 
single act and therefore as an individual opportunity to be adherent. This permits 
a greater focus on the enablers and inhibitors of adherence at a point in time 
rather than it being averaged over many acts in different situations. 
It also includes a discussion of managerial implications, proposals for future 
research, and thoughts on research limitations. 
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Adherence; Service-Dominant Logic; Service Systems 
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1 Introduction to this Thesis 
1.1 Introduction 
This is a thesis about adherence as a process. Through literature reviews and 
qualitative research it develops a theoretical view of the adherence process. It 
also takes a first step towards testing the process quantitatively. It creates this 
process because currently there is limited theorisation of the end-to-end process. 
This is considered by many to be inhibiting the understanding of how people are 
adherent in their many different environments. 
The overarching research question is therefore, what is adherence from a 
process perspective? 
This chapter is structured as follows. Firstly a consideration of the adherence 
process shows that it is not well-defined theoretically. It then explains why an 
improved understanding is potentially important. The scope of this thesis is 
presented and its contributions to knowledge described. Finally it lays out the 
structure for the rest of the thesis. 
This is visualised in Figure 1. 
 
Figure 1: Chapter structure 
1.2 Current approaches to adherence 
Simplistically, adherence is consumption in accordance with instructions. This 
hides significant complexity in how adherence comes to be. Despite the use of 
behavioural theories in some papers, adherence is not well-defined theoretically. 
There are many practitioner-led operational definitions of the adherence process 
but these have a practical focus on issues inhibiting consumption or frequency of 
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consumption rather than providing a theoretical basis for why consumption may 
or may not occur. 
These theories and definitions tend to be specific to their environments and they 
offer few proposals as to how they might be extended to apply more widely. Yet, 
the fact that adherence is researched in many areas of medicine suggests that it 
is of importance in a wide range of environments. It is to be hoped that a greater 
understanding of the adherence process will give new perspectives into what 
takes place when consumption happens and offer new insights into how it might 
be possible to modify patient approaches to consumption. Adherence therefore 
deserves greater and more widely applicable theorisation. 
1.3 Contributions to knowledge 
In his seminal report for the World Health Organisation (WHO), Sabaté (2003 
p.xiii) said: 
“[Increasing adherence] may have a far greater impact on the health of the 
population than any improvement in specific medical treatments”. 
This explains the purpose of this research. Medicine adherence is around 50% in 
the developed world and may be even lower in the developing world (ibid.). It is 
to be hoped that this research will enable those in the healthcare sector, from 
pharmaceutical manufacturers to staff at rural health facilities, to assist patients 
to be more adherent and therefore to achieve improved health outcomes. 
As part of achieving these aims, this research has made several contributions to 
knowledge. 
The main contribution to knowledge of this thesis is the creation of a qualitative 
process of adherence. This is a response to the overarching research question. 
A second contribution is to consider a new understanding of adherence as an 
individual opportunity to be adherent rather than as an “average” of all 
consumption opportunities over a course of treatment. This perspective permits 
a closer focus on just what enables or hinders adherence at a point in time, when 
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as many as possible of the variables which influence adherence are as constant 
as possible. This approach is facilitated by the use of qualitative research which 
can engage with patients’ lived lives. 
Thirdly, it provides an enhanced understanding of adherence being the result of 
a complex relationship of service systems (Vargo & Lusch 2008; Akaka et al. 
2013; Vargo et al. 2008), otherwise referred to (Wieland et al. 2012) as service 
ecosystems (Vargo et al. 2011), and involving an interaction of factors of 
adherence throughout the process from initial recognition of absence to final 
assessment of the value of having been adherent. This understanding goes 
beyond the existing theories used in adherence research and into the heart of 
consumption. 
Fourthly, it has developed a quantitative process of adherence. This view could 
potentially inform quantitative research into adherence. 
A fifth contribution is the diagrammatic description of the flow of Service-
Dominant Logic (S-D Logic) (for example Vargo & Lusch 2004; Vargo & Lusch 
2008; Akaka & Vargo 2015). As part of developing a theoretical view of the 
adherence process the diagram has also been augmented in two ways. Firstly by 
the application of the Integrative Framework of Value (Ng & Smith 2012). 
Secondly with a visualisation of service ecosystems (Vargo et al. 2011) which 
integrate the concept of the “multiple self” (Bahl & Milne 2010) as a means of 
understanding the competing priorities of ecosystem institutions. This 
diagrammatic representation of S-D Logic provides the basis for the qualitative 
process of adherence. 
Sixthly, although the interviewees were not intended to be representative 
samples of their populations, the qualitative interviews suggested that reasons 
for non-adherence are broadly the same – although not necessarily for the same 
reasons – across developed and developing worlds. This surprising finding may 
have implications for future medicine formulations, since assumptions on agency 
and context may be causing adherence issues in the developed world in the same 
ways as for the developing world. 
 4 
  
A less significant seventh contribution lies in an extension of the list of causes of 
medicine non-adherence over and above the list of 55 causes identified in an 
important report, “Adult Meducation” (ASA & ASCPF 2006). 
1.4 Scope of this thesis 
In order to permit development of a theoretical process of adherence, this thesis 
focuses on adherence as a theoretical construct. 
Behavioural theories are sometimes invoked to understand adherence. Although 
behaviour can also be viewed as a form of adherence, it is out of scope except 
when such theories are analysed in the medicine consumption context. 
The motivation of a patient to consume is within scope. A detailed analysis of how 
motivation arises is not in scope. The assumption is that motivation arises 
internally to the patient. 
An analysis of context is included, but not how context as a whole comes to be. 
Change of adherence over time is in scope, but only as it relates to the way a 
single occasion for adherence is affected. 
1.5 Structure of this thesis 
Chapter 1 is this introduction. Section A builds the case from theory and literature 
for moving towards a theoretical view of the adherence process and establishes 
the Qualitative Propositions. Section B builds the processes. It firstly describes 
the qualitative research which delivers the qualitative process, then moves on to 
derive a quantitative process and describe its initial quantitative exploration. 
Finally conclusions, limitations and suggestions for further research are 
presented. Appendices contain background information and data.  
The structure of this thesis is shown diagrammatically in Figure 2. 
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Figure 2: Thesis structure 
1.6 Summary 
This chapter has proposed the research question, what is adherence from a 
process perspective? It has laid out the purpose of the thesis and defined its 
scope. It has also proposed its contributions to knowledge, of which the 
qualitative theoretical process of adherence is chief. Finally, it has documented 
the structure of the rest of this thesis. 
 6 
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Section A: Making the Case for Moving Towards a 
Process View of Adherence 
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2 Literature Review: Introduction 
2.1 Section introduction 
This section of the thesis makes the theoretical case for a process view of 
adherence. The first two chapters explore the concept of adherence, firstly 
outside of medicine consumption and then relating to medicine consumption. By 
doing this, it brings together factors of adherence which are then consolidated. 
Having done so, it evaluates the lens of Service-Dominant Logic to determine 
whether it can be used to structure the factors in a coherent way so as to form 
the basis of the theoretical process. The final chapter in Section A summarises 
the literature review and justifies the qualitative research which follows, 
establishing two Qualitative Propositions for investigation. By these means it 
makes the case for moving towards a theoretical process of adherence. 
The structure of Section A is therefore as in Figure 3. 
 
Figure 3: Structure of Section A 
2.2 Chapter introduction 
This chapter covers two main areas. The first considers the meanings of 
consumption before selecting the appropriate meaning for adherence. The 
second looks the current state of definitions of adherence. There is then a short 
consideration of how behavioural research can support the study of adherence.  
The structure of this chapter is therefore as in Figure 4. 
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Figure 4: Chapter structure 
2.3 Meanings of consumption 
There are two views of consumption. Each one derives from its own definition of 
value: “value in use” and “value in exchange” (Smith 1776 p.30). The first relates 
value to that which is achieved by use – “…it is use that determines a thing’s 
value…” (Marx 1959 p.51) – and the second to that which is achieved in 
exchange – “…money is the exact measure of the real exchangeable value of all 
commodities” (Smith 1776 p.39). Therefore, for those who consider that value 
occurs at the point of exchange, consumption refers to purchase. This is the more 
common usage, and where consumption theorisation has focused. Most theories 
of consumption of this type take an economic viewpoint, which has been 
described (Arnould 2007) as “a narrow one grounded in economics and 
psychology and dedicated to understanding and predicting purchase decisions”. 
However, for those who consider that value occurs at the point of use, 
consumption refers to use or experience. It is thought that use value was 
subordinated to exchange value as a result of the desire to measure national 
wealth and to facilitate international trade (Vargo & Lusch 2004). Since exchange 
value was easily measured as a form of national wealth while use value was not, 
exchange value predominated. Nevertheless, the two definitions of value 
continue in parallel and therefore there remain two definitions of consumption. 
For the purposes of this work, consumption will refer to use and not purchase. 
The scope of this thesis and its viewpoint are therefore that adherence is related 
to use and not to purchase. There is no meaning in adherence to purchase, 
except inasmuch as the act of purchasing is a type of behaviour. 
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2.4 Definitions of adherence 
The term “adherence” originates in the healthcare sector and so definitions of the 
word arise from there too. However, as will be demonstrated, there is no single 
agreed definition. 
A simplistic concept of adherence is that patients take their medicine as and when 
they should. 
The original term was “compliance”, which originated in the 1950s as the 
importance of the concept was beginning to emerge. However, this is hardly used 
now because of the implied power relationship between prescriber and patient. 
Therefore, the definition has developed over time to reflect improved thinking on 
patient empowerment and wider perspectives. The 2012 Ascertaining Barriers for 
Compliance (ABC) project (ABC Project 2012; Vrijens et al. 2012) presented its 
view of the development of thinking around adherence over the last 35 years in 
table 2.1 of its report (reproduced as Table 1). In this table it can be seen that the 
relationship develops over time, with “compliance… with the clinical prescription” 
in 1976, moving to the more general terms “compliance… with medical or health 
advice” in 1979, then “agreed recommendations” in 2003, and eventually 
incorporating “patient participation [in the] agree[ment]” in 2005. 
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Table 1: Development in definitions of adherence (ABC Project 2012 p.22) 
 
 
This addition of patient participation to the definition of adherence attempts to 
address the issue of the instructions being imposed on the patient. However, the 
range of adherence definitions used both in theory and in practice do not fully 
reflect these enhancements. See examples in Table 2 (definitions used in papers 
with a practice focus) and Table 3 (from papers with a more theoretical focus). 
From these tables it is clear that both the more theoretical as well as the practice-
based papers show some tendency to follow the development of thinking shown 
in Table 1, but that the penetration of more recent thinking is patchy in both theory 
and practice. Some of the definitions are so restrictive that it is unlikely that any 
patient could be deemed adherent, for example the idea (Sandy & Connor 2015) 
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that there are five ways that a patient could be non-adherent: “…altered their 
dose, forgotten to use the medication, stopped taking it for a while, decided to 
miss out on a dose, and taken less than instructed”. On the other hand, some 
definitions tend in the opposite direction. One definition of non-adherence is a 
failure to collect medication for two months (Kripalani et al. 2007), while Gore-
Langton et al. (2015) define adherence as patient self-reporting as having being 
adherent. This shows that there are multiple definitions of the term and little 
agreement as to which should be used (Becker 1985). 
The problems caused by the range of definitions in Table 2 and Table 3 are stated 
by van Dulmen et al. (2007), who explain that the large variety of definitions 
complicates adherence assessments across multiple studies. It is also evident 
that varied definitions lead to different patients being considered adherent and 
therefore subject to interventions, and so affect measurement of outcomes. 
 
Table 2: Sample definitions of adherence: practice-focused papers 
Year Definition Reference 
2002 “the extent to which a patient’s behavior (in terms of taking 
medication, following a diet, modifying habits, or attending 
clinics) coincides with medical or health advice” 
McDonald et al. 
2007 “% of Prescribed pills taken… >80% of prescribed pills 
taken… [non-adherence is] failing to collect medications for 2 
consecutive months” 
Kripalani et al. 
2015 “[non-adherence is] lack of correct behavior” Tsega et al. 
2015 “the extent to which patients follow the instructions given for 
prescribed medications” 
Chew et al. 
2015 “both compliance (proximity to treatment recommendation 
often simplified as the number of doses taken divided by the 
number of prescribed doses) and persistence (how long the 
medication is taken)” 
Touskova et al.  
2015 “self-reporting to have correctly taken the entire course of 
treatment” 
Gore-Langton et al. 
2015 “[non-adherence is] the extent to which [patients] have 
altered their dose, forgotten to use the medication, stopped 
taking it for a while, decided to miss out on a dose, and taken 
less than instructed… adherence being defined as answering 
“never” to all five” 
Sandy & Connor 
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Table 3: Sample definitions of adherence: theoretical and review papers 
Year Definition Reference 
2007 “the extent to which patients follow the instructions they are 
given for prescribed treatments” 
Munro et al. 
2009 “the extent to which the patient’s behaviour matches agreed 
recommendations from the prescriber” 
Nunes et al. 
2011 “initiating the prescription, actual dosing in relation to the 
prescription, and persisting with treatment” 
Eliasson et al. 
2012 “the extent of conformity to treatment recommendations with 
respect to the timing, dosage, frequency, and duration of a 
prescribed medication” 
Gadkari & 
McHorney 
2013 “the process by which patients take their medications as 
prescribed. Adherence has three components: initiation, 
implementation, and discontinuation” 
Kardas et al. 
2014 “correctly taking the full therapeutic course of treatment” Bruxvoort et al. 
2014 “those who reported to have taken the treatment as 
recommended (in terms of timing and dosage) with no tablets 
remaining” 
Banek et al. 
2015 “a ratio of the number of drug doses taken to the number of 
doses prescribed over a given time period” 
Morrison et al. 
 
Definitions in these tables attempt to quantify adherence more comprehensively 
but a common one, for example used by Morrison et al. (2015), simply states that 
adherence is the ratio of medicine consumed to medicine prescribed. Because 
this is easy to measure it is often the one used in practical studies even though 
true adherence may be masked by this. For example, simple ways to falsify true 
adherence by this definition include taking more than the prescription to make up 
for gaps, taking the right dose of medication but at the wrong times, or simply 
disposing of the medicine. 
van Dulmen et al.'s (2007) view of the problems relating to the diversity of 
definitions is repeated in many reviews of adherence research. One reason is 
that it prevents quantitative meta-studies. Because of this, the ABC Project 2012 
(table 2.2 p.25) proposed a detailed definition for adherence (emphasis in 
original): 
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“The process by which patients take their medications as prescribed, 
composed of initiation, implementation and discontinuation. 
“Initiation occurs when the patient takes the first dose of a prescribed 
medication. 
“Discontinuation occurs when the patient stops taking the prescribed 
medication, for whatever reason(s). 
“Implementation is the extent to which a patient’s actual dosing 
corresponds to the prescribed dosing regimen, from initiation until the last 
dose. 
“Persistence is the length of time between initiation and the last dose, 
which immediately precedes discontinuation”. 
In this definition “Implementation” is closest to the normal definition of adherence, 
while the additional terms provide extra detail in the practice of adherence. Some 
researchers after 2012 pick up on elements of this detailed definition. For 
example Kardas et al. (2013) use all terms except persistence, and Touskova et 
al. (2015) use persistence but then refer to implementation as compliance. 
However, most just ignore the additional terms. Since the measurement of 
adherence in its traditional sense is inconsistent, it is unlikely that this enlarged 
definition will prove easier to operationalise. 
This study therefore aims to take a more theoretical perspective on adherence 
and the process of being adherent. This is not necessarily to replace operational 
definitions but to provide a greater understanding of the factors which may 
determine why adherence is achieved or non-adherence caused. It may be that 
this theoretical view of the process of adherence could support the development 
of more rigorous operational definitions. 
2.5 Relationship between consumption and behaviour 
It is necessary to consider why behavioural theories are sometimes called upon 
in theorisation of consumption. Warde (2005 note 6) explains that consumption 
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is simply a type of behaviour. Secondly, Arnould (2007) refers to consumption 
behaviour theory, thus linking consumption with behaviour. These ideas may 
demonstrate why, on occasions when the healthcare sector’s thoughts on 
adherence are theorised, behavioural theories such as the Theory of Planned 
Behaviour (Ajzen 1985) and the COM-B model (Ripple 1955) are sometimes 
appealed to. 
As a result, although behaviour outside of adherence is out of scope of this thesis, 
behavioural theories will be assessed for their support of consumption adherence 
when they are invoked. 
2.6 Summary 
The definition of consumption chosen for this work has been indicated as 
pertaining to use and not purchase. The many definitions of adherence have been 
considered, but as yet no definition has been derived for this study. It has been 
recognised that behavioural theories are sometimes incorporated into 
considerations of adherence.  
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3 Adherence Outside of Medicine Consumption 
3.1 Introduction 
The purpose of this chapter is to explore the concept of adherence outside of 
medicine consumption. This is done in order to identify any contribution that such 
research might make towards the development of a theoretical view of the 
process of adherence. Research in this area is relatively limited compared to that 
of medicine consumption. 
The structure of this chapter is as in Figure 5. 
 
Figure 5: Chapter structure 
3.2 Literature review 
There is research into adherence outside of medicine consumption. Some of it 
relates to consumption, for example diet, smoking and drinking. Other papers 
mention behavioural adherence in a medical context; these are included here 
because of the limited amount of consumption-specific literature. These studies 
are localised in scope and make no attempt to theorise more widely than the 
empirical research from which it is derived. 
McCullough & Willett (2006) investigated adherence to the Dietary Guidelines for 
Americans. They determined that higher adherence led to a longer period before 
succumbing to a major chronic disease. They did not theorise but simply reported 
their statistical study. There are many other similar studies which compare 
people’s adherence to various diets and guidelines in relation to morbidity and 
mortality (for example Schröder et al. 2004; Guo et al. 2004; Fargnoli et al. 2008; 
Sofi et al. 2008). These, too, report rather than theorise. If adherence is defined 
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in such papers then measures relate to conformance to a dietary pattern or to 
achieving higher scores on an index. 
There are some dietary adherence studies which go further. They generally 
indicate issues affecting adherence. St John et al. (2008) found an association 
between childhood obesity and a low level of family income. Povey et al. (2000) 
used the Theory of Planned Behaviour to identify a moderating link between 
perceived social support and healthy eating. Robinson et al. (2014) found that 
messages about social norms were more effective in achieving healthy eating 
than an injunction to eat healthily. Adherence was again not defined but can be 
assumed to be related to a level of intake of particular types of food. 
A study in Nigeria on the use of mosquito nets for prevention of malaria (Russell 
et al. 2015) demonstrated that adherence to their use as bed nets was around 
three-quarters of the households possessing a net. The definition of adherence 
in this study was that a net was used the previous night. Discussion suggested 
that social support affects their use. 
Several studies investigate actions against smoking. While most relate to anti-
smoking medication there are some which focus on behaviour, either of the 
smoker or their support network. 
One study in Netherlands (Segaar et al. 2007) looked at how nurses’ behaviour 
affected smoking cessation on cardiac wards. In this study, adherence by nurses 
to an anti-smoking process was measured simply by whether they had 
implemented the process. 
Another piece of research (Persky et al. 2005) explored smokers’ adherence to 
a cessation program. This measured adherence through assessments by a 
counsellor of attendance at clinic and the smoker logging the extent of their 
smoking. 
A descriptive study (Jacobs et al. 2014) considered adherence to the US Public 
Health Service’s Clinical Practice Guidelines for Treating Tobacco Use and 
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Dependence of stop-smoking apps delivered on Facebook. There was no 
definition of adherence as such. 
A further study (Terra et al. 2008) assessed whether attendance at Alcoholics 
Anonymous in Mexico was correlated with abstinence, adherence being 
measured by frequency of attending sessions. In all these studies there was no 
intention to theorise adherence as such, but simply to describe levels of 
adherence – as each one defined – to programs and practices. 
3.3 Contributions to a process view of adherence 
The main finding from this literature is that there was little assessment of causes 
of adherence or non-adherence, and therefore a lack of contributions to 
understanding the process of adherence. Where there was an indication it was 
mainly concerned with social pressure or support. If a theory was used in support 
of the research it was the Theory of Planned Behaviour. 
3.4 Summary 
This examination of adherence studies in the areas of non-medicine consumption 
and healthcare-related behaviour has shown that most have either very simple 
definitions of adherence or do not explicitly define it, thus failing to take a process 
view of adherence. There is no theorising in most of these papers but those that 
do either explore adherence using the Theory of Planned Behaviour or recognise 
the impact of social aspects. These two factors will be taken into account in 
moving towards a theoretical process of adherence in this research. 
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4 Adherence in Medicine Consumption 
4.1 Introduction 
This chapter investigates the contribution of medicine consumption studies to 
creating a theoretical view of adherence. This is by far the most prolific area of 
adherence research. The relevant literature is reviewed below. 
The structure of this chapter is as in Figure 6. 
 
Figure 6: Chapter structure 
4.2 Overview 
Adherence to instructions for medicine consumption is a very basic requirement 
for health. Indeed, McColl-Kennedy et al. (2017) refer to it as “Comply[ing] with 
basics” yet non-adherence is a significant worldwide issue. For example, it has 
been estimated that 125,000 people die each year just in USA as a result of non-
adherence (Burrell & Levy 1984); figures for other parts of the world are not 
known. In the developed world half of patients are not fully compliant with their 
prescription instructions (Sabaté 2003; Marcus 2013; Brown & Bussell 2011), and 
it is thought that the proportion of non-adherence is higher in the developing world 
(Sabaté 2003). Since adherence is so central to outcomes, it is unsurprising that 
the World Health Organisation has stated that improvement in adherence levels 
could be more important than improved medicine (Sabaté 2003 p.xiii), and that 
access to medication is necessary but not sufficient for successful treatment of 
disease. Therefore the opportunities for health improvements delivered through 
improved adherence could be significant. 
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4.3 Relevant reports 
Much practical research has been done into the issue of adherence (Brown & 
Bussell 2011; Sabaté 2003). Sabaté's seminal World Health Organisation report 
is particularly germane. Peterson et al. (2003) found 95 studies on adherence. 
More recently, a review of reviews (van Dulmen et al. 2007) identified a total of 
38 systematic literature reviews of adherence papers. A simple search (below) 
indicated that over 1200 (or more probably almost 19,000) medicine adherence 
papers have been published. The field of adherence research is therefore 
continuing to expand. 
Sabaté's World Health Organisation report is a milestone in the field. Building on 
his work, another empirical report (ASA & ASCPF 2006) categorised 55 causes 
of non-adherence using the five “dimensions” of Sabaté's report. This was 
produced jointly by the American Society of Consultant Pharmacists and 
American Society on Aging and provides a useful summary of causes. More detail 
of each of these reports is considered here. 
4.3.1 World Health Organisation report, 2003 
Sabaté (2003) identified five interacting sets of causes inhibiting adherence which 
he categorised within five dimensions. These were causes arising from the 
patient’s socioeconomic status, their relationship to the health system and to 
therapy, their own issues, and their condition (see Figure 7). There was no intent 
to perform a theoretical analysis of how these causes relate to each other. They 
are simply empirical. Sabaté’s report has been cited over 4500 times. 
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Figure 7: Five interacting dimensions of adherence (Sabaté 2003) 
4.3.2 Adult Meducation, 2006 
The report written by the American Society of Consultant Pharmacists and 
American Society on Aging (ASA & ASCPF 2006)⁠, “Adult Meducation”, has 
perhaps the most practical list of issues affecting adherence that has been 
produced to date. It used the five dimensions propounded by Sabaté for WHO 
(Figure 7) to create a detailed table of 55 causes that can affect adherence (Table 
4). While these 55 causes make a useful contribution, they have no underlying 
theoretical basis and are simply the result of observations. There is also some 
repetition and overlap in the list, such as “Medications with social stigma attached 
to use” and “Feeling stigmatized by the disease”, “Medication cost” and “High 
drug costs, copayments, or both”. However, despite these minor weaknesses it 
can provide a basis for assessing the validity of qualitative interviews. If the 
interviews only find a small subset of the list then it would imply a limited coverage 
of known causes. However since the scope of the list is limited to the USA it may 
be expected that additional causes can be uncovered in a set of interviews that 
include input from Western Europe and the developing world. In fact, one 
assumption was that causes of non-adherence in the developing world would be 
different to those in the developed world, but in interviews this was found not to 
the case. 
 24 
  
Table 4: The 55 causes reported to affect adherence (ASA & ASCPF 2006) 
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4.4 Literature review 
4.4.1 Quantitative analysis of adherence papers 
It is challenging to determine how many papers on medicine adherence have 
been written. Two types of search were performed: searching the MEDLINE 
database for papers in academic journals, and using Google Scholar. MEDLINE 
is the primary component of PubMed and contains over 23 million references to 
journal articles in the field of life sciences. The results of these searches, shown 
with Google search terms, are listed in Table 5. 
 
Table 5: Results of searches for adherence papers 
Search term MEDLINE Google Scholar 
“medicine adherence” 18792 1220 
+“medicine adherence” +theory 312 427 
+“medicine adherence” +“self efficacy” 578 216 
+“medicine adherence” +“grounded theory” 66 56 
+“medicine adherence” +TPB 14 31 
+“medicine adherence” +TRA 3 22 
+“medicine adherence” +HBM 5 30 
+“medicine adherence” +CHBM 1 0 
+“medicine adherence” +”COM-B” 0 3 
 
“self efficacy” (the term also finds “self-efficacy”) relates to Bandura’s Theory of 
Self-Efficacy (Bandura 1977; Bandura 1997; Bandura 1982). “TPB” is the Theory 
of Planned Behaviour; “TRA” is the Theory of Reasoned Action, “HBM” is the 
Health Belief Model, and “CHBM” is the Children’s Health Belief Model. “COM-B” 
is a behavioural model for which the name is not an abbreviation. These theories 
and models are discussed later. 
Although Google Scholar correctly shows that there are adherence studies 
making use of COM-B, the MEDLINE figures more accurately represent the 
importance of this field of research. Grounded Theory was included in the search 
since it is a method of analysis rather than a theory applied to the research; this 
allowed it to be excluded from the list of papers which apply a theory of behaviour 
to the research. 
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Since MEDLINE’s figures are more realistic than those of Google Scholar, one 
reason for the disparity might be the wide variety of journals in which adherence 
research is published. While the journal Patient Preference and Adherence 
naturally has a large number of adherence papers, a sample of others includes 
the Bulletin of the World Health Organisation, AIDS Care, the Journal of Clinical 
Hypertension, Frontiers in Pharmacology, the Journal of the American Medical 
Association, BMC Health Services Research, the British Journal of 
Pharmacology, Medical Care, Quantitative Health Research, Drugs, the Journal 
of Clinical Pharmacy and Therapeutics, the Health Psychology Review, Patient 
Education and Counselling, New England Journal of Medicine, PloS One, 
Research in Social and Administrative Pharmacy, Transactions of the Royal 
Society of Tropical Medicine and Hygiene, the Malaria Journal, and by no means 
least the Journal of Service Research. The breadth of journals in which 
adherence research is published may inhibit Google Scholar from finding them 
all. It also means that there is no single high-ranking journal in which adherence 
research is published except perhaps the Journal of Service Research. 
Unsurprisingly, the journal which appears to have the highest focus is Patient 
Preference and Adherence, an online journal. 
Therefore, taking MEDLINE’s figures as accurate, they suggest that less than 2% 
of research references a behavioural theory. Even if those of Google Scholar 
were to be closer to being representative, around 45% of medicine adherence 
research references a behavioural theory. However, a review of the use of theory 
in medical research (Painter et al. 2008) indicated that almost 70% of research 
which referenced a theory was “influenced by theory” rather than using it. If this 
figure were to be applied to Google Scholar’s figures in Table 5 then only 16% of 
medicine adherence research actually adopts a theory; if applied to MEDLINE’s 
figures then the number is less than 1%. 
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4.4.2 Themes in adherence papers 
Reviewing the relevant literature, it is possible to identify a number of themes. 
This assessment of themes makes good use of systematic literature reviews and 
so-called “reviews of reviews” in an aim to ensure best coverage of the literature. 
The van Dulmen et al. (2007) review of reviews looked at 38 systematic reviews, 
identifying the interventions and successes referenced in each. The range of 
evaluated interventions was wide, but in many papers the processes followed 
were inconsistent and under-reported. One interesting comment in their paper 
was about the idea of repackaging tablets in dosage groups rather than 
individually. While this may be intuitively obvious as an intervention, they stated 
that no theoretical research had been conducted into whether this actually 
improved adherence. Their cautious perspective was justified by another 
literature review (Connor et al. 2004) which discovered that there is uncertainty 
about its effectiveness. While this review of reviews attempted to divine 
theoretical justifications for interventions, any which they did find were restricted 
to particular interventions rather than providing an overarching understanding of 
the adherence process. Perhaps due to the non-optimum methods that they saw 
in so many pieces of research, their review found that only 45% of interventions 
resulted in improved adherence, and only 33% in improved outcomes. 
Another systematic review in the same year (Kripalani et al. 2007) looked at 38 
papers describing randomised control trials. It too found significant heterogeneity 
between papers such that a pooled analysis was not possible. They called for 
additional research into which causes are most responsible for changes in 
adherence. 
A systematic review by Haynes et al. (2008) found that there are “only a few 
relatively rigorous trials of adherence interventions”, while those that do exist 
“provide little evidence” that adherence can be consistently improved without 
significant expenditure in clinical settings. Such bold statements do not give much 
hope for improvement without a change of approach aimed at gaining a deeper 
understanding of the real causes of adherence. 
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Kardas et al.'s (2013) review of reviews brought together a list of causes of non-
adherence from 51 reviews. Its conclusion from this wide survey was that most 
so-called causes actually had uneven effects on adherence. This is true of many 
papers: causes of non-adherence are postulated and investigated but seen 
ultimately to have an inconclusive effect. Based on reviews and reviews of 
reviews it is tempting to believe that inconsistent methods, lack of theory, and 
failure to understand adherence at a qualitative level all have an impact on the  
identification of the true causes of non-adherence in people’s ever-changing lived 
lives. 
Continuing to move forwards in time, a systematic literature review (Fuangchan 
et al. 2014) of antimalarial drug adherence also created its own list of causes 
from the 16 papers it reviewed. However, as found in other reviews, a lack of 
underpinning theories and inconsistent approaches between papers meant that 
“immense disparity” was found in methods, reporting and conclusions. 
Finally in this series of systematic reviews and reviews of reviews, a synthesis by 
Rathbone et al. (2016) of qualitative research identified themes relating to dislike 
of medicines, patient perceived need, medicine side effects, medicine cost, and 
medicine regimen. Echoing thoughts from earlier reviews, and giving credence to 
the importance of the overarching research question in this thesis, its authors 
opined that there is much still to be learned from qualitative research into what 
adherence actually “is”. 
Leaving aside systematic reviews, some themes are apparent when looking at 
individual papers. Firstly, there is a theme in the literature focused on patient 
motivation to adhere (Seiders et al. 2014; Kreps et al. 2011; Kok et al. 2012; 
Cornford & Lichtner 2014; Neiheisel et al. 2014; Firlik 2013). These generally 
assume that motivation is the key to increasing adherence. 
As seen above, a second theme is papers which attempt to determine causes of 
non-adherence. These are empirical rather than employing a theoretical 
framework (Horne et al. 2005; Vermeire et al. 2001), and generally provide lists. 
Perhaps the most notable list is in the Adult Meducation report discussed above 
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(ASA & ASCPF 2006) with its list of 55 causes placed within a structure based 
on Sabaté's five dimensions (2003). Later papers tend to repeat the same causes 
in different ways (Jackson et al. 2010; Fischer et al. 2010; DiMatteo et al. 2007), 
but there appears to be a growing focus on how a patient’s beliefs about medicine 
affect their adherence. 
A third theme is medicine characteristics. Papers report problems such as tablet 
size or medicine taste, and relative preferences for one formulation over another 
(Stewart et al. 2016; Hill et al. 2007; Bhosle et al. 2009; Mennella et al. 2013). 
These characteristics relate to the medicine itself plus patients’ interactions with 
it. However, this theme is very sparsely populated, the assumption being, as 
intimated above, that motivation overcomes negative characteristics. 
A fourth is the focus on instructions. Since adherence must involve instructions 
this is not surprising, but research into this is not as extensive as might be 
expected. However, a significant earlier review by Horne et al. (2005) reported 
that patient recall of verbal instructions was less than 50% and that writing down 
the instructions helped with adherence. Another paper (Osterberg et al. 2005) 
reported on the importance of instructions being as simple as possible. 
Fifthly, many papers consider patient characteristics. While it is suggested that 
personality traits are not good predictors of adherence, there is evidence that 
patient beliefs are important (McHorney & Gadkari 2010). 
Sixth and finally in this list of themes, very many papers discuss the need for, or 
evaluation of, multiple forms of intervention to improve adherence rates. This is 
discussed in two reviews of reviews (Peterson et al. 2003; Kardas et al. 2013). 
Kardas et al. (2013) suggested in their review that “multifaceted interventions may 
be the most effective answer”, but at the same time they found that many of the 
reviewed papers reported mixed or limited success (for example Ruppar et al. 
2008; Demonceau et al. 2013; Rowe et al. 2007). It is nonetheless a potentially 
important seam of literature which will be thought about in greater detail later. 
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As can be inferred from the above, there are papers which recognise the need to 
think about dyads. However, these tend to be the dyad of patient and prescriber 
rather than, for example, patient and medicine or medicine and consumption 
environment. An in-depth review stated that no cause of non-adherence has been 
“consistently related” to adherence nor is “fully predictive” (Vermeire et al. 2001). 
They continued by saying that a cause of “the lack of progress” in adherence 
research is the absence of the “crucial factor: the patient’s perspective”. They 
also found no mention of theory in their “comprehensive review” covering 30 
years of research. 
4.5 Limitations of current research 
There are three limitations with the practical research mentioned above. Firstly, 
most research has had a primarily Western focus and may not be completely 
applicable in the developing world. Secondly, there has been a concentration on 
age-related issues in USA and HIV/AIDS-related issues in sub-Saharan Africa. 
Thirdly, while the research may identify causes affecting adherence it generally 
does not analyse them theoretically or introduce any comprehensive theories to 
understand them. These are now considered in turn. 
4.5.1 Western focus of research 
The majority of adherence research focuses on the West, and most of that is 
performed in USA. A small sample of such research includes Ogedegbe et al. 
(2003), Sandy & Connor (2015), Haynes et al. (2008), Martin et al. (2012), 
DiMatteo (2004), and Kardas et al. (2013). 
While any research into adherence is to be welcomed, a bias towards one region 
of the world may miss regional or even country-based differences in the causes 
of non-adherence. For example, the preference in one country for pills over 
injections may be inverted in another. Nevertheless it was discovered in this 
research that, despite finding such differences between countries in sub-Saharan 
Africa, causes of non-adherence were very similar. This suggests that 
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improvements in medicine formulations for the developing world could also 
benefit adherence in the developed world. 
4.5.2 Developing world research 
Most developing world adherence research has been HIV/AIDS-related. Of this, 
the majority has been in sub-Saharan Africa where AIDS is most prevalent 
(AVERT 2015). HIV/AIDS research has been performed in Botswana (Bisson et 
al. 2008), Ethiopia (Tsega et al. 2015), Nigeria (Adewuya et al. 2010), South 
Africa (Dahab et al. 2008), Tanzania (Roura et al. 2009), Uganda (Weiser et al. 
2010), Zambia (Murray et al. 2009), and Zimbabwe (Skovdal et al. 2011). This 
HIV/AIDS focus is not surprising since leading NGOs are working to address 
HIV/AIDS and treatment must continue throughout the patient's life in order to be 
effective, thus motivating pharmaceutical manufacturers. 
However, there is more general adherence research in Africa such as by Kok et 
al. (2012) and Munro et al. (2007). Other examples in sub-Saharan Africa include 
Tuberculosis – often associated with HIV/AIDS – in South Africa (Atkins et al. 
2010) and Tanzania (van den Boogaard et al. 2012), and also hypertension in 
South Africa (Cassimjee & Suleman 2009). 
This research has been of practical rather than theoretical intent. It is therefore 
likely that further important information on causes of non-adherence, including 
details which may be specific to particular medicines or be geographically 
localised, still remains to be captured. Although in general the causes of non-
adherence in both developed and developing worlds were found to be similar it 
is accepted, for example, (Reynolds 2013) that developing world patients may 
have different wants and needs in terms of medicine taste, texture or package 
size. 
4.5.3 Lack of theoretical consideration 
As was discussed above, there is generally a lack of theoretical grounding seen 
within what is largely practice-based empirical research. Behavioural scientists 
and other researchers have proposed some theories to explain non-adherence, 
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but these do not seem to resonate with the needs of practitioners if the counts of 
such papers above are reasonable estimates. 
However, there are some exceptions. The main theory used in adherence 
research is Self-Efficacy Theory. Some researchers have looked to the Theory of 
Planned Behaviour (for example Wu & Liu 2016; Al-Swidi et al. 2014). Other 
researchers have reached out to Ripple's (1955) COM-B model (including 
Eliasson et al. 2011). A few adherence researchers also endorse health-specific 
models. The most commonly used theories and models are described next in 
order to understand their contributions and limitations. 
4.6 Relevant behavioural and health-specific models 
The following models are sometimes invoked by adherence researchers, though 
often to provide guidance rather than actually being used. Therefore they are 
described in this section in order to understand their potential contributions to the 
development of a theoretical view of the adherence process. 
4.6.1 Theory of Self-Efficacy 
The Theory of Self-Efficacy was propounded by Bandura in 1977. He defined 
“self-efficacy as one's belief in one's ability to succeed in specific situations or 
accomplish a task” (ibid.). He considered that behaviour could be explained by a 
person’s “expectations of personal efficacy [which] are derived from… 
performance accomplishments, vicarious experience, verbal persuasion, and 
psychological states” (ibid.). Diagrammatically, he viewed behavioural 
expectations as per Figure 8 which is reproduced as-is from his 1977 paper. This 
shows that, in his view, expectations of efficacy should be distinguished from 
expectations of outcome. 
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Figure 8: Bandura’s Theory of Self-Efficacy (Bandura 1977) 
From the figure it is possible to identify this theory as being based on what has 
become known as the “expectancy-value” family of models (Atkinson & Reitman 
1956; Eccles et al. 1983). That is, a person’s performance in a task can be 
explained by their expectation of the level of success – their perceived self-
efficacy – combined with the expected value to them of the task (Wigfield & 
Eccles 2000). This implies that someone who has a task that can be performed 
easily and which has significant value to them will be more motivated to perform 
it than if they consider it to be difficult and/or of low value. 
As seen below, this theory is subsumed into the Theory of Planned Behaviour 
and therefore requires no further consideration. 
4.6.2 Theory of Reasoned Action 
The Theory of Reasoned Action, often abbreviated as TRA, was developed by 
Fishbein & Ajzen in 1975. The two authors developed a model which showed 
how beliefs, attitudes and intentions could be understood to predict behaviour. 
This model was illustrated in the book which launched the theory and is 
reproduced as-is in Figure 9. As with Self-Efficacy Theory, it is an expectancy-
value theory. 
This model was eventually recognised as having several limitations. Its main 
assumption is that intention must lead directly to behaviour. A drawback is that a 
person’s perception of success and value may not ultimately be accurate. Over 
time this simple model had to be modified to take account of wider issues not 
originally considered but which were found to arise in empirical research. Ajzen 
himself therefore superceded it with the Theory of Planned Behaviour. 
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Figure 9: Theory of Reasoned Action (Fishbein & Ajzen 1975) 
4.6.3 Theory of Planned Behaviour 
In 1991 Ajzen (1991) took a look back at his Theory of Planned Behaviour (TPB) 
that he had propounded in 1985 (Ajzen 1985) as a follow-on to the Theory of 
Reasoned Action. The theory was illustrated in the 1991 paper and is portrayed 
as he created it in Figure 10. 
He stated that the key enhancement of this theory over the earlier Theory of 
Reasoned Action was the incorporation of the person’s perception that they had 
behavioural control over their actions. In his 1991 review, Ajzen stated that this 
addition to the Theory of Planned Behaviour was required because one of its 
limitations was that it did not recognise personal freedom to act. He went on to 
explain that inhibitors to action included time, money, skills and social support, 
and that these vary by time and place. In this enhancement he incorporated 
elements of the person’s resources and their environment. He also continued to 
accept that the theory measured intentions rather than action. 
The theory includes certain elements of behaviour which are relevant to a process 
of adherence. These are the person’s attitudes or beliefs, subjective norms which 
include perception of social support, and behavioural control which is a part of 
perceived self-efficacy. 
While there have been calls to “retire” the Theory of Planned Behaviour 
(Sniehotta et al. 2014), others either wish to extend it in various ways to make it 
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more fit for purpose (Armitage 2015; Conner 2015) or have already done so 
(Didarloo et al. 2012). The latter was done specifically for adherence research, 
adding a formal measurement of perceived self-efficacy to the theory although it 
could be argued that it is simply part of perceived behavoural control. As such, 
Bandura’s Self-Efficacy theory is subsumed into the Theory of Planned 
Behaviour. 
 
Figure 10: Theory of Planned Behaviour (Ajzen 1991) 
As with the Theory of Reasoned Action, the limitation of this theory is that it 
reaches only as far as the intention to act. There is an implicit assumption that 
intention leads directly to behaviour but this link is not theoretically justified. By 
omitting such justification for this assumption it overlooks the significant possibility 
that it is not always true. This must also be considered for the theoretical process 
of adherence. 
4.6.4 Health Belief Model (HBM) 
The first health-specific model to be reviewed is the Health Belief Model (HBM). 
This originated as a theory relating to the use of preventive health services in the 
1950s before being applied to adherence (Janz & Becker 1984; Rosenstock 
1974). This is claimed as a major organising framework for understanding 
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adherence. However, it is a typical expectancy-value model in that it is based on 
two variables, the value of a person’s goal and an estimation of whether any 
particular action will help with achieving it. In the health context, these two 
variables translate into the importance to the patient of getting well and the 
patient’s expectation as to whether a health action such as taking medicine will 
contribute to their improvement. 
The model mentions three patient beliefs, which later became four dimensions 
(Rosenstock 1974 p.330): personal susceptibility to a disease, disease severity, 
benefit of action and perceived barriers to action. As mentioned, these all relate 
to beliefs and expectations so the actual value eventually achieved not explored. 
Janz & Becker’s paper, a systematic review of 46 studies of the HBM, also 
mentions that a stimulus is necessary to trigger the decision-making process 
(Janz & Becker 1984). In addition it stated that research on this has been very 
limited. The authors emphasise that HBM is a psychosocial model that relates to 
attitudes and beliefs, therefore does not reach as far as the act of consumption. 
This is repeated in a book critiquing the model (Rapoff 2010). Janz & Becker 
suggest that some health behaviours are habitual or undertaken for non-health 
reasons, and recognise that there are some circumstances where health 
behaviours may be prevented by external issues such as medicine cost and 
issues which exist within the patient’s medicine consumption environment. 
This model, while including the patient’s motivations and some elements of 
environment, does not fully consider either the patient or the environment and 
does not investigate the attributes of the medicine at all. Becker (1985) says that 
the most powerful dimension is the one relating to barriers, and within that 
dimension the main concerns are social approval and the lack of self-efficacy. 
4.6.5 Children’s Health Belief Model (CHBM) 
The second health-specific model is linked with the first. The Children's Health 
Belief Model (CHBM) (Bush & Iannotti 1990) is based on HBM and integrates 
other behavioural theories: Social Learning Theory, Cognitive Development 
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Theory and Behavioural Intention Theory. It includes the four dimensions of HBM 
but considers that there are other causes which contribute to overall adherence, 
including the child’s level of autonomy and the influence of the child’s 
parent/guardian. 
As with HBM, this is an expectancy-value model. It introduces two moderators in 
the form of autonomy and parental influence, the first of which relates to 
perceived personal freedom to act and the second another manifestation of social 
support. At the time of Rapoff's (2010) book, only one study had actually used 
the model fully, and in that study medicine consumption itself was not measured. 
4.6.6 COM-B model of behaviour 
“COM-B” refers to the four elements of this simple model: (1) Capacity, (2) 
Opportunity, and (3) Motivation, combining together to produce (4) Behaviour. 
See Figure 11 for a diagrammatic representation of the model. This has been 
derived from the description of the theory in Ripple's 1955 paper, which does not 
include a diagram of the model. The focus of her paper was on behaviour of 
Social Services clients in relation to the services being provided to them by their 
caseworker. 
 
Figure 11: COM-B model after Ripple (1955) 
Ripple noted in her paper that the main components had already been recognised 
earlier. The three drivers of behaviour were originally specified in an earlier book 
(Towle 1954 p.86). However it was Ripple who recognised their importance, 
operationalised the model, and brought them together in the format of Figure 11. 
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Each of the three input factors was defined in detail in Ripple's (1955) paper. 
Capacity related to a person’s capability to act; Opportunity looked at self-efficacy 
and support within the environment; Motivation focused on the trigger of 
discomfort and perceived self-efficacy. This recognises the importance of self-
efficacy and social support once again. However, as with other models there is 
an assumption that readiness for action leads directly to it. 
4.7 Analysis of medicine adherence research 
The empirical research creates some useful groupings of causes of non-
adherence but does not try to generate any theoretical basis for them. Rather 
than focus on theory, practitioners tend to use existing practical definitions of 
adherence or create their own definitions as the basis of their work. 
As we have seen, the main theories – the Self-Efficacy Theory, the Theory of 
Reasoned Action, the Theory of Planned Behaviour, the Health Belief Model and 
the Children’s Health Belief Model – are used by practitioners, though not as 
widely as might be expected. The COM-B model is rarely used. The theories are 
typical expectancy-value models with a particular focus on value as relating to a 
priori expectations, and so they relate strongly to expectancy rather than the final 
realisation of value. It is necessary to go beyond them in order to gain a wider 
perspective of adherence, one that does not stop at the point of intention and that 
explains a greater proportion of what affects adherence. 
Therefore it seems reasonable to suggest that medicine adherence remains 
under-theorised. It is mainly a practitioner-led field as a result of efforts to address 
mainly age-related non-adherence in North America and to improve HIV/AIDS 
treatment in sub-Saharan Africa. Non-adherence in most conceptualisations is 
primarily blamed on insufficient patient motivation (for example Hill et al. 2007; 
Munro et al. 2007; Svarstad et al. 1999; Seiders et al. 2014; Holmes et al. 2016). 
It is therefore clear that there is scope for moving towards a theoretical view of 
the process of adherence, since improvements could lead to significant health 
benefits for large numbers of people. 
 39 
  
4.8 Contributions to a process view of adherence 
From this literature review of medicine adherence there emerge several 
contributions to a process view of adherence. Perhaps the clearest contribution 
is that research which uses expectancy-value theories finds that self-efficacy and 
social support are major determinants of adherence. Considering themes, 
motivation is thought to be important, as are medicine characteristics and patient 
characteristics, particularly beliefs. Clear and appropriate instructions are also 
determinants of adherence. Other papers highlight the importance of subjective 
norms, the importance of the patient-doctor relationship, and the patient’s ability 
to act coupled with potential inhibitors of action. It must be remembered that the 
theories focus only on the intention to act, which is no guarantee of action 
especially when external inhibitors are considered. 
4.9 Summary 
This survey of the literature of medicine adherence has highlighted the lack of 
theory in most research. However, it has indicated the use of or reference to some 
theories in a minority of papers. Such theories have limited coverage of the initial 
stages of adherence and do not extend to consumption. Because there is no 
theoretical basis for most practical research, there is much disagreement on 
theories which might be used and a lack of consistent application of theories 
where they are used or referenced. 
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5  Analysis and Consolidation 
5.1 Introduction 
This chapter analyses the literature reviewed in earlier chapters to identify 
themes. It then brings them together into three constructs under the headings of 
patient, medicine and environment. These themes are then expanded and 
defined under those three headings, and three reasons for consumption 
introduced. 
The structure of this chapter is therefore as in Figure 12. 
 
Figure 12: Chapter structure 
5.2 Analysis 
From the analysis of non-medicine consumption these points were seen in the 
literature. (1) There was little assessment of determinants of adherence or non-
adherence. (2) Where there were indications of causes they were mainly 
concerned with social pressure or support. (3) If theory was used in support of 
the research it was generally Self-Efficacy Theory or the Theory of Planned 
Behaviour. 
From the analysis of medicine consumption these points were seen in the 
literature. (1) Self-efficacy and social support are major determinants of 
adherence. (2) Motivation is thought to be important. (3) Medicine characteristics 
affect adherence. (4) Patient characteristics affect adherence, particularly beliefs. 
(5) Clear and appropriate instructions are also determinants of adherence. (6) 
Norms are important for adherence. (7) The patient’s ability to act along with 
potential inhibitors of action are important to consider. (8) The relationship 
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between patient and healthcare provider can be important to adherence. (9) If a 
theory was used in support of the research it is usually Self-Efficacy Theory, the 
Theory of Planned Behaviour or the older Theory of Reasoned Action. 
There is overlap in these two lists. It is therefore possible to combine them into 
rationalised list of eight components. The following elements have been found to 
be important in adherence. (1) Social pressure or support. (2) Self-efficacy. (3) 
Motivation. (4) Medicine characteristics. (5) Quality of instructions. (6) Patient’s 
ability to act. (7) Inhibitors of action. (8) Patient-doctor interaction. 
Although the above three theories are most often used to support empirical 
research, they are only expectancy-value theories and so any validity for actual 
consumption depends on the patient understanding their potential future. They 
have no direct link with action; they stop at the point of intention to be adherent 
and so cannot take the act of consumption into account. However, intention is no 
guarantee of action especially when external inhibitors are present at the point of 
consumption. This is a weakness in all expectancy-value theories, and means 
that there is no overall theoretical process of adherence that supports an 
understanding from prescription to consumption. It is necessary to go beyond 
these theories if a holistic process of adherence is to be created. 
5.3 Consolidation of factors 
It is possible to consolidate these factors. Analysing the list, there appear to be 
three main categories: the patient, the medicine and the environment. For the 
purposes of adherence, the patient can be defined by their motivation, their self-
efficacy (or ability to act), and their beliefs about themselves and the medicine. 
The medicine can be thought of as its characteristics and the instructions. The 
environment can be considered to consist of the support or lack of support from 
social care or pressure – which in this research is assumed to include the 
relationship with the healthcare provider – and the inhibitors or enablers of action. 
It will be useful to look in turn at each of these categories and the factors identified 
as being part of them. 
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5.4 Categories, factors and rules 
5.4.1 Patient 
For the purposes of this research, a patient is someone who consumes medicine. 
Patients may take their medicine for a number of reasons. Since a patient is a 
consumer in this sense it is reasonable to invoke wider consumption literature. 
Motivation, the ability to act and beliefs are also explored. 
Two important questions are what consumers do and why they do it. Many 
authors define consumption as the integration of resources to create value for the 
consumer (for example Siltaloppi & Vargo 2014; Hibbert et al. 2012; Peters 2014). 
Resource integration is the process by which the consumer uses their capabilities 
in order to use the consumable with the purpose of creating value in use. These 
capabilities align with the patient’s ability to act, their beliefs, and their motivation. 
Patients bring these to adherence as resources in order to create value in use 
from the medicine. 
The environment should provide other resources in support of the patient’s 
intention to be adherent. The process of resource integration, if consumption is 
to take place, requires that sufficient of the right resources are brought together. 
This is described as there being sufficient resource “density” for value in use to 
be achieved (Michel et al. 2007; Normann & Ramírez 1993). 
For example, taking medicine may require a tumbler and some water. These are 
provided by the environment occupied by the patient. If these resources are not 
available then the patient may not be able to be adherent on that occasion. 
Motivation has been identified as an important factor in why patients are 
adherent. At a basic level, Bhaskar (1993) stated that “absence” is the root cause 
of consumption. In the case of medicine consumption that absence relates to the 
patient’s lack of health. This absence may also be the required “stimulus” to 
action (Janz & Becker 1984). The process of “absenting of absence [is] manifest 
in the satisfaction of desire” (Bhaskar 1993 p.43). Mingers (2011) identifies this 
process as a “feedback system… always trying to close the gap (absent an 
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absence) between the desired state of the system and the actual state of the 
system”. 
While the term “desire” is a potentially emotive word, for Bhaskar it had no moral 
overtones. Similarly, Ilmonen (2011 p.57) simply equates desire with a “specific 
need” for an “object”. That object in this context is the medicine. He speaks of 
“needs and wants” (ibid. p.45), discussing how “the condition of need” becomes 
“a specific need, i.e. want” (ibid. p.48) through “identification [with] its object” (ibid. 
p.49). There is therefore a four-step progression. (1) Absence (of health). (2) This 
awakens a need (for a medicine). (3) This leads to the three equivalent ideas of 
desire, want or specific need (for a particular medicine). (4) Finally this results in 
“absent[ing] the absence” (of health) through obtaining and consuming the 
medicine, thus closing the loop in the system and restoring health. 
A level of motivation – perhaps an increasing level – is required to move from one 
step to the next in this four-step progression. However, a lack of movement 
through these steps does not imply that motivation is not present. It is 
fundamental to Bhaskar’s philosophy of Critical Realism (Bhaskar 2008 p.36) that 
“countervailing causes” may cause “generative mechanisms” such as motivation, 
which “endure even when not acting”, to remain “unrealized” in practice (ibid. 
p.xxxi). This therefore recognises that the patient may not consume even when 
motivated if there are forces acting which prevent it. In our example this may be 
that a tumbler or water is not available, thus preventing the patient from moving 
from desire for health to the health expected as a result of the consumption of 
medicine. This is a potentially important consideration when considered against 
expectancy-value theories which assume readiness for action always leads to 
action. 
However, there may be more to why patients take their medicine than just the 
fulfilment of their wish to regain health. Joy & Li (2012) observe that consumption 
decisions are “complex, often riddled with ambivalence, internal contradictions 
and even pathology”. This observation is potentially explained by the Dialogical 
Self Model (Bahl & Milne 2010). This proposes that a person’s internal dialogues 
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demonstrate the existence of “multiple narratives reflecting multiple selves” which 
represent “multiple realities”. They go on to say that consumption is viewed 
differently by each self, while a “meta-self maintains a more balanced 
perspective… as a synthesizing activity” overall. 
Perhaps the Dialogical Self Model does help to explain Joy & Li's conclusions. It 
certainly indicates that there are potentially multiple purposes to consumption and 
that they may be in conflict. Three consumption purposes, or goals, have been 
defined (Barbopoulos & Johansson 2016) as gain (functional, utilitarian), hedonic 
and normative. 
In overview, the utilitarian goal takes the rational, objective, functional utility-
maximising viewpoint. This is the one assumed to be operating in adherence 
decisions. 
The hedonic goal relates to emotions, either positive or negative, and was 
identified by Hirschman & Holbrook (1982) as a result of empirical research. In 
adherence this may be relevant if, for example, consumption is performed in the 
presence of an otherwise-absent loved one or in a hospital with unpleasant 
connotations. Hirschman & Holbrook (1982) make three propositions regarding 
hedonic consumption. (1) “In some instances, emotional desire dominates 
utilitarian motives in the choice of products”. (2) “[C]onsumers imbue a product 
with a subjective meaning that supplements the concrete attributes it possesses”. 
(3) “[H]edonic consumption is tied to imaginative constructions of reality”. These 
propositions suggest that rational adherence decisions can be overruled by 
influences such as the emotions aroused by a medicine, the intangible attributes 
of a medicine, and internal views of reality which may not match objective reality. 
Point three is especially relevant when considering expectancy-value theories. 
Though hinted at originally in the Theory of Planned Behaviour, the normative 
goal was added to the first two by Barbopoulos & Johansson (2016) and is 
applicable to the consumer abiding by external restrictions. In the case of 
adherence this may be pertinent to the patient’s support being present or 
otherwise, and their wish to engage with support from the appropriate source. It 
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may be also that the patient discovers that support varies depending on the 
environment in which they find themselves or perceive themselves to be. In 
addition, it is argued that the patient’s perceived or actual environment will 
determine the nature of the norms they abide by. 
Finally in this consideration is the importance of patient beliefs. Earlier analysis 
has indicated that these are seen to be of significant importance. Interestingly, in 
the conclusion to his paper on the Theory of Planned Behaviour Ajzen (1991) 
opined: 
“…there is plenty of evidence for significant relations between behavioral 
beliefs and attitudes toward the behavior, between normative beliefs and 
subjective norms, and between control beliefs and perceptions of 
behavioral control”. 
In this analysis he is referring to beliefs, norms and external controls. It may be 
more sensitive in this context to rename “controls” to “instructions”. Some might 
also at times rename “beliefs” to “values”, for example in the list provided by 
Hibbert et al. (2012) of “values, norms, and required patterns of behavior”, but 
the intent is the same. 
5.4.2 Environment 
Within this research, the environment is the situation in which the patient 
consumes the medicine. It is the combination of all of the aspects of the particular 
consumption situation which contribute to or detract from consuming the 
medicine in order to achieve value in use. 
Returning to the earlier example, the tumbler and the water are part of the 
patient’s environment. These are enablers of consumption. 
Also as indicated above, another element of the environment is the support 
provided – or otherwise – by others. This includes the patient-doctor relationship. 
This viewpoint has been considered in the light of the Dialogical Self Model and 
is positioned here as being dependent on which environment the patient is in or 
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perceives that they are in. The norm rule, discussed above, relates directly to the 
environment. 
This environment is usefully visualised by Easton (2010)⁠, who links it with the 
Critical Realist “contingent relationship”. This refers to relationships which are 
“neither necessary nor impossible” to exist. This outlook implicitly recognises that 
the environment can vary since the relationships between elements of the 
environment do not necessarily obtain over time. There are many variables, 
which may include the time of day, the location, the availability of required 
contextual elements, and even the patient’s capabilities at that time. This 
perspective suggests that even with all those specified elements place in the 
value creation environment the patient may still not take their medicine. This 
could be due, perhaps, to a lack of capability or a suddenly reduced desire, and 
shows how the patient must contribute their capabilities in order for them to create 
value. In this it is possible to see “contextual variety” (Ng & Briscoe 2012), which 
affects the patient’s ability to realise value in use. 
5.4.3 Medicine 
At its simplest, a consumable is something which can be consumed. In these 
thoughts the consumable is the medicine. The medicine provides its resources 
into the consumption environment, where its resources are combined with the 
patient’s resources to create value in use. The medicine’s attributes may 
contribute to the patient being adherent or may detract from it. Features 
detracting from adherence may be, for example, that it is bitter or too large to 
swallow, or its formulation – tablet, injectable, etc – may be unacceptable to the 
patient. 
The medicine’s instructions are another contribution of the medicine into the 
consumption environment. Without accurate and accurately remembered 
instructions it is likely that adherence will not occur. 
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5.4.4 Beliefs, norms and instructions 
From the foregoing, and referencing Ajzen (1991), it is possible to see that there 
in fact three “rules” which contribute to determining whether adherence will be 
achieved by the patient: beliefs, norms and instructions. It is reasonable to 
assume that these are always operating concurrently in any particular 
consumption context, and that they may either be aligned or in conflict. 
5.5 Unit of analysis 
Mainstream adherence research continues to define adherence as complying 
with instructions over the course of treatment. This means that it overlooks the 
fact that adherence to a course of treatment involves multiple separate 
opportunities to adhere to the instructions. 
As may have become apparent in the analysis above, there is another way to 
conceptualise adherence. That is, that overall adherence is made up of a series 
of individual opportunities to consume. The circumstances each time may be 
different and should therefore be considered separately rather than as a 
homogenous whole as is currently the case. Each opportunity ultimately reveals 
its own decision and level of success. 
Therefore, the unit of analysis in this research now turns to each opportunity to 
be adherent rather than considering adherence as an amorphous whole. In this 
way it can investigate causes of adherence and non-adherence as individual 
events. The whole is then the sum of each event, such that the total of the events 
over time then becomes the mainstream view of adherence. The aim of taking 
this approach is to enable analysis of causes of adherence and non-adherence 
at a point in time in order to understand the particular consumption situation at a 
time when all the many variables are as constant as possible. This is in contrast 
to taking what might be called averages of non-adherence reasons, especially in 
quantitative research which does so over many patients. It is clear from research 
to date that this averaging approach is unable to form a clear and consistent 
explanation of adherence within an overarching view of the process. 
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Taking this approach puts emphasis not only on the intention to be adherent at 
that point in time, but equally on whether consumption actually takes place. 
Behavioural models as used in adherence research are not able to do this. As a 
result of this omission, this literature review has not so far been able to investigate 
this important aspect of adherence. This research therefore needs a way of 
theorising actual consumption at a point in time. It explores this topic in the next 
chapter, evaluating a way of understanding consumption at the point at which it 
takes place: the lens of Service-Dominant Logic. 
5.6 Summary 
This chapter has analysed the adherence factors arising from the literature review 
and grouped them into categories. These were seen to be the patient, the 
medicine and the consumption environment. A review of the factors in their 
groups was then performed, and consumption rules identified – beliefs, norms 
and instructions – arising from Hirschman & Holbrook (1982), Barbopoulos & 
Johansson (2016) and Ajzen (1991). It then took the position that in order to 
understand adherence more accurately it needs to be looked at as a series of 
individual opportunities to be adherent rather than consider it as an average of 
consumption over time. Finally, it raised the subject of the moment of 
consumption as a development of existing theories which stop at the intention to 
consume. 
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6 The Act of Consumption 
6.1 Introduction 
Since mainstream behavioural theory has been shown to terminate its relevance 
at the point of the decision, this chapter evaluates the lens of Service-Dominant 
(S-D) Logic as a way of understanding the actual act of consumption. This may 
extend, or with the additions to S-D Logic discussed later potentially replace, the 
expectancy-value theories considered so far. This is because, by design, they 
can only explain the consumption process up to the point of the decision and it is 
necessary to go beyond these to get a more holistic perspective of the adherence 
process. S-D Logic is evaluated at this point since it focuses on consumption and 
may therefore provide new insights into adherence. This supports the unit of 
analysis since S-D Logic implicitly focuses on a single consumption event. 
The structure of this chapter is as Figure 13. 
 
Figure 13: Chapter structure 
6.2 Service-Dominant Logic 
6.2.1 Overview 
As discussed previously, there are two competing ideas of value. The mainstream 
view of value is that value is embedded in goods during manufacture and 
distribution. Customers acquire that value at the point of purchase – value in 
exchange (Smith 1776). Smith’s other view of value – value in use – is the one 
underpinning this research. It is here that S-D Logic concentrates. In the original 
paper launching S-D Logic written by Vargo & Lusch (2004), the value in 
exchange viewpoint was referred to as “Goods-Dominant Logic” to distinguish it 
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from their new (or in their opinion the original) perspective. This is, that value is 
assessed at the point at which consumption takes place. The basis of S-D Logic 
is embodied in 11 “Foundational Premises” (Vargo & Lusch 2008; Lusch & Vargo 
2014; Vargo & Lusch 2015). The list can be found in Appendix A. 
S-D Logic research states that “Service” in S-D Logic is not the same as 
“services” which are often mentioned in contradistinction to goods. S-D Logic’s 
Service is considered to subsume both goods and services (firstly in Vargo & 
Lusch 2004). 
As discussed earlier, the process of creating value in use requires the provision 
of resources from the patient, the medicine and the environment. S-D Logic refers 
to the value thus created as “value-in-context” because the value in use is created 
in the consumption environment, or context. Because value-in-context is created 
by the patient from this combination of their own and the medicine’s resources 
plus the resources within the context, the value creation process is referred to as 
“resource integration” (Vargo & Lusch 2008). This recognises that the consumer 
must synchronise the use of resources in order to create value. As seen in earlier 
discussions, the patient’s resources are their ability to act, their motivation and 
their beliefs, while the resources of the medicine are its attributes and its 
instructions. 
S-D Logic claims that, because value-in-context cannot be delivered by medicine 
suppliers in isolation but has to be created by the patient using their resources, 
suppliers can only offer “value propositions” to patients (for example Lusch et al. 
2014). These are provided to patients in the form of medicines or “offerings” (Ng 
& Smith 2012). It is the patient who determines the value of a medicine as they 
perform “value cocreation” (firstly in Vargo & Lusch 2004). This implies that each 
patient may cocreate more, less or different value from the same medicine 
because of the differing resources of the patient and the context and their differing 
responses to the resources of the medicine. 
Because both patient and medicine supplier contribute to the value that is 
cocreated, S-D Logic refers to both consumers and suppliers as “actors” 
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(Giddens 1984; Vargo & Lusch 2011) to indicate their equality in the value 
cocreation process. At this time “patient” and “supplier” will be maintained to aid 
clarity but their equality is recognised and accepted. The term “context” will 
however be used from this point since it is a term which S-D Logic uses as an 
equivalent to “environment” used so far. 
S-D Logic states that in the process of generating value-in-context the patient’s 
primary resource is their “agency”, which is defined as their skills and 
competencies, or in the terms of the discussion above, their ability to act. These 
skills and competencies are referred to as “operant resources”. This distinguishes 
them from the “operand resources” which are resources which need action to be 
taken on them, such as medicine. The patient’s operant resources interact with 
what the value proposition provides, which are “affordances” manifest as 
resources (Ng & Smith 2012). The patient’s agency (operant resources) and the 
resources provided by the value proposition’s affordances are integrated by the 
patient in context to cocreate value (ibid.; Vargo & Lusch 2006 p.283). 
In all this can be seen a triad of patient, medicine and context. Exactly how they 
interact to cocreate value is not yet seen. Therefore to begin to illuminate this it 
is necessary to position them within the framework of S-D Logic. This requires 
firstly that S-D Logic be visualised. 
6.2.2 Visualising S-D Logic diagrammatically 
The proposition of this section is that the parts of S-D Logic come together as 
depicted in Figure 14 below. Some of the points above will be repeated here for 
ease of reading. Later, this visualisation will be extended in support of achieving 
a more detailed perspective of the act of consumption. 
The basis of cocreation of value is that the patient integrates resources from the 
supplier, the context and themselves (Vargo & Akaka 2009). The patient’s 
resources are their skills and competencies (within which can be seen beliefs and 
motivation), otherwise referred to as agency, which may be enabled or restrained 
by the consumption context (Ng & Smith 2012). Resource integration only 
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happens in context. The value created is context-dependent (Flint et al. 2014), 
and is determined in use. 
Resources need to be recognised as such before they can become part of the 
value cocreation process. Until they are so recognised they remain as “potential 
resources” (Peters 2014). Potential resources provided by suppliers are referred 
to in S-D Logic as affordances, and affordances become resources when acted 
on (consumed) in context. Their source is the supplier’s offering, or in other words 
the value proposition of the medicine (Ng & Smith 2012). 
Value-in-context is therefore cocreated by the patient in context using the 
resources provided by the medicine supplier’s value proposition plus resources 
from other providers. As per Ng & Smith (2012), those resources are delivered 
as affordances – potential resources – by the offering, otherwise referred to as 
the value proposition. 
In summary, the supplier’s value proposition offers affordances which become 
resources in the consumption context. Further resources arise from other value 
propositions which exist in the consumption context. The patient brings skills and 
competencies to apply their agency on the resources, performing value 
cocreation activities to produce value-in-context. This is visualised as Figure 14. 
 
Figure 14: Service-Dominant Logic diagrammatically 
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This figure provides us with several useful insights. Firstly and obviously is the 
importance of context to the cocreation of value-in-context. Secondly, agency 
acts in context on resources but the affordances of the medicine are independent 
of context because they are not necessarily recognised as resources until the 
consumption context becomes apparent. Thirdly, other value propositions also 
provide resources in context, and the patient integrates these resources with the 
resources of the medicine’s affordances arising from its value proposition to 
create sufficient density to achieve value-in-context through the process of value 
cocreation. The interaction of these multiple service systems (Vargo & Lusch 
2008), including the patient, the medicine provider, the providers of other 
resources, and elements of context, is needed if adherence is to be achieved. 
Reconsidering the example of the patient consuming medicine using a tumbler 
and water, the medicine is the value proposition of the supplier and provides its 
resources into the context of medicine consumption. Also in context are the 
tumbler and the water, provided by other suppliers as value propositions. The 
patient’s agency – the resources they provide into the context – allows them to 
put water into the tumbler, put the medicine into their mouth, and drink the water 
so as to swallow the medicine. If there were to be a problem in the consumption 
context, for example a tumbler was not available, then another water container 
may be sought. A cup, which had not been noticed before, might be spotted and 
brought into the consumption context to hold water. The cup’s affordance as a 
means to hold the water to swallow the medicine was always present out of 
context, but had never before been required for this use and brought into context. 
6.2.3 Assessing S-D Logic against the requirements 
The patient, the medicine and, importantly, the consumption context are 
recognisable in – and recognised by – S-D Logic. This therefore permits it to 
extend the expectancy-value theories discussed earlier which terminated before 
the point of consumption. 
S-D Logic provides greater understanding of the fact that adherence can only be 
achieved when the operand resources of medicine are available in the 
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consumption context along with those of other value propositions, so as to permit 
the value cocreation process of adherence to proceed. It also confirms that the 
patient’s agency must be sufficient for them to provide suitable operant resources 
in order for them to be adherent. It is this complex interaction of service systems 
which both highlights and also explains the challenges of understanding 
adherence, and therefore the need for a theoretical process view of adherence. 
However, there are three points which still need clarification. Firstly, in common 
with the previously investigated behavioural theories, S-D Logic does not 
explicitly recognise the possibility of consumption not taking place. That is, it does 
not recognise non-adherence. It is already visible from the foregoing that there 
are potentially many reasons for non-adherence embodied in the patient, the 
medicine and the context, but a more formal assessment would be worthwhile in 
moving towards a process view of adherence. 
Secondly, it is obvious that adherence is intended to provide value. However, it 
is necessary to consider when and what value is cocreated, and how it is 
assessed. 
Third and lastly, there is a need to think about the three “rules”. The instructions 
have been proposed to be one of the medicine’s affordances. The patient’s 
beliefs have been positioned as contributing to the patient’s agency. But the norm 
rule has not yet been accurately located. It may be that the concept of service 
ecosystems will contribute to greater understanding. 
The next two sections investigate these points. Firstly the norm rule, followed by 
non-adherence and assessing value cocreation. 
6.2.4 S-D Logic service ecosystems 
One thing which may help clarify the relationship of the rules to context is a 
consideration of a relatively recent S-D Logic development, service ecosystems 
and their associated institutions (Akaka & Vargo 2015; Vargo et al. 2011; Greer 
et al. 2016). This concept refers to (Lusch & Vargo 2014 p.161): 
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“…relatively self-contained, self-adjusting system[s] of resource-
integrating actors connected by shared institutional arrangements and 
mutual value creation through service exchange”. 
This definition is a refinement of that used for the concept of the service system, 
and the two terms can be used interchangeably (Wieland et al. 2012). However, 
“service system” focuses more on connection of systems through value 
propositions (Vargo et al. 2008) while “service ecosystem”, as seen above, is 
more to do with the systems in which the patient resides. Therefore, while 
recognising their essential equivalence, in this discussion the terms will continue 
to be used in the senses as here presented. 
These systems are flexible, loosely coupled, and may be temporary. A patient 
can be in several service ecosystems at the same time (Greer et al. 2016) and 
service ecosystems may be nested (Vargo & Lusch 2015). Each service 
ecosystem has its own institutional arrangements, or “rules of the game” (ibid.). 
To progress this concept it is useful to visualise what a combination of service 
ecosystems might look like in the patient’s consumption context. An idea of one 
potential combination out of very many possibilities is shown in Figure 15. The 
service ecosystem labelled “Supplier of value proposition” represents the 
ecosystem which defines the institutional arrangements – including the rule of 
instructions – for consuming the medicine. If the patient is fully aligned with only 
that service ecosystem then it is to be expected, all things being equal, that they 
will be fully adherent. However, the patient is likely to be at least partially aligned 
with other ecosystems, and these may turn out to be different ones at each 
adherence opportunity. 
Service ecosystems are therefore important elements of the consumption context 
and help shape the value cocreation process. However they are not the total 
context since this includes potentially many items required for the value 
cocreation process such as the previously considered tumbler and water. 
Nevertheless, the fact that a patient can be in many service ecosystems 
simultaneously may explain three things from previous discussions. 
 58 
  
 
Figure 15: Possible service ecosystems represented diagrammatically 
The first is the “multiple self” (Bahl & Milne 2010). A patient’s decision-making will 
vary depending on which of the service ecosystems and their institutional 
arrangements they have in focus. It may be that each ecosystem is equivalent to 
a “self” in Bahl & Milne's theory. The observation that consumption decisions are 
“complex, often riddled with ambivalence, internal contradictions and even 
pathology” (Joy & Li 2012) can be understood by reference to service ecosystems 
as a result. What is perceived to be good in one service ecosystem may not be 
in another, hence the reported “ambivalence” and “contradictions”. The concept 
of service ecosystems may therefore help to explain the “multiple self”. 
The second is the rule of norms. Each service ecosystem’s “rules of the game” 
provide the norms that the patient must take into account or benefit from 
depending on the level of relatedness they feel to any particular ecosystem (de 
Brabander & Martens 2014). Decision-making will depend on which service 
ecosystem takes precedence. Therefore it is likely that the norms rule relates to 
one or more of the service ecosystems in which the patient exists or perceives 
themselves to exist. Which set of norms takes precedence will depend on the 
ecosystem which gains most attention in the adherence decision. 
Based on this, it may be possible to see in these service ecosystems the origins 
of the varying levels of support which a patient believes they are receiving at any 
point. It may be that an alignment with one ecosystem will bring – or be perceived 
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to bring – support, while alignment to another will prevent that support from being 
present or being perceived as being there. This may be a very practical thing: if 
the patient shuns one service ecosystem in favour of another then the support 
from the first may be withdrawn for that particular opportunity for adherence. 
The third relates to hedonic value cocreation. Here Consumer Culture Theory can 
contribute. This theory recognises that there are “differences in consumer 
emotional and imaginal response to products [which] appear closely tied to a 
variety of subcultural differences” (Hirschman & Holbrook 1982). Membership of 
the different, potentially competing, subcultures may be represented by 
occupying various service ecosystems. 
Therefore, the patient may take into account their own beliefs, the norms of one 
or more service ecosystems, and the instructions of the supplier’s service 
ecosystem when coming to a decision on whether or not to be adherent. If they 
do not follow the instructions of the medicine supplier then they may not cocreate 
the value-in-context that was intended, but that is a decision for the patient. It is 
for them to decide whether the results are satisfactory or not, since it is always 
the patient who assesses that value. This may be associated with changes to 
adherence over time. 
6.2.5 S-D Logic value cocreation assessment 
It can be assumed that the patient seeks to cocreate value-in-context. Therefore 
they need to understand in advance what value might be created and then 
determine afterwards what value was actually created. While they may recognise 
that the value cocreation process delivers value-in-context, if the medicine is 
effective then there should be longer-lasting value which remains after being 
adherent and which is probably more important than the value that was created 
in context. 
One way of explaining the way in which patients assess value both in advance of 
and following consumption is the Integrative Framework of Value (Ng & Smith 
2012). This framework was built on the foundation of S-D Logic. It proposes a 
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model whereby patients can assess what they perceive to be of value to them in 
the process of being adherent. It defines two types of value. 
The first type of value is “Phenomenal-Consciousness value” (P-C value). This is 
equivalent to the value cocreated in context. It is referred to as “…the raw 
experience of creating value (goodness) in interactions around the experience… 
the phenomenon of lived experience… the actual engagement and use 
experience of the offerings”. This may link to Hirschman & Holbrook's (1982) 
proposal that “…hedonic responses may be viewed as the essence of the usage 
experience”, since P-C value is experienced rather than assessed. 
The value that is assessed rather than experienced is the second type of value, 
“Access-Consciousness value” (A-C value). The term refers to the way that value 
is assessed outside of context, either in advance of consumption or in retrospect. 
This is described as “…the perception, introspection and memory (or imagination) 
of P-[C] value before (ex ante) and after (ex post)… the perception of goodness 
that drives choice ex ante and valuation ex post” (emphasis in original). 
Their depiction of their model is shown in Figure 16. As can be seen, Ng & Smith 
reference the elements of S-D Logic using the epithet of “facets”. 
Ng & Smith (2012) identify a “paradox” at the heart of their model. That is, that P-
C value is the value created by the patient at the moment of value cocreation, yet 
it can never truly be assessed since as soon as the A-C value assessment activity 
commences the patient must exit from the “raw experience of creating value”, 
even if only momentarily. 
This implies that value is cocreated at the P-C level for as long as the act of 
consumption continues. For some medicines the “act” may therefore incorporate 
not just the moment of consumption but its effects. For example, consuming 
medicine may happen in a moment but its effects may not become apparent for 
minutes or hours. Ideally, only when the patient can assess both the moment and 
the effect – the entire episode – can a complete ex post A-C value be captured 
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for the adherence event. However, an interim ex post assessment can be made 
at any time, implying that the judgement on A-C value may change over time. 
 
Figure 16: Integrative Framework of Value (Ng & Smith 2012) 
A-C Value ex ante is all about perception of what will happen during value 
cocreation. This appears to mirror expectancy-value theories; until the moment 
of consumption all is perception and expectation. A-C value assessments can 
commence even before the medicine is obtained. However, ex ante assessments 
of value cocreation can only ever be perceptions of what might happen rather 
than the certainty of what will. Because the moment of value cocreation is 
unknown in advance, advance assessments of agency and affordance may be 
proven to be misjudgements once value cocreation is attempted in reality. S-D 
Logic focuses on the moment of value cocreation in situations where everything 
is in place for adherence, whereas it important also to consider possible 
inaccurate advance expectations of P-C value and ex post A-C value. It is also 
necessary to be aware that there may be contexts where resources are limited 
or missing. In such circumstances, the value cocreation process may not deliver 
the expected value-in-context. In addition, expected outcomes may not be 
achieved even when the planned behaviour commences. In the consumption 
moment, resources and/or agency may initially be present at a sufficient level to 
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start the process but not be enough to complete it. It therefore seems that A-C 
value judgements do not just take place before and after the P-C value-cocreating 
episode, but also during it. 
However, a potential limitation of the Integrative Framework of Value model is 
that it does not explicitly explain its feedback loop. It perhaps suggests a loop 
straight back from ex post to ex ante A-C value assessments. This omits the early 
steps in the adherence process, so this understanding of the feedback loop would 
not fully explain how it may operate in practice nor where it feeds into future 
adherence decisions. However, on the assumption that such a loop feeds back 
into the process at appropriate points, this viewpoint could contribute to 
explaining changes to adherence over time. 
6.2.6 Consolidation of S-D Logic 
After its evaluation in this chapter, it is concluded that S-D Logic has shown itself 
to be a potential basis for understanding adherence. Figure 14 depicted this. To 
extend the model to identify where the norms rule and perceptions of social 
support fit, the concept of occupying multiple service ecosystems and abiding by 
their institutions was introduced. Finally, the Integrative Framework of Value was 
considered as a means of understanding how at least a proportion of adherence 
may change over time. 
Figure 17 is an attempt to understand how the concept of multiple service 
ecosystems with the Integrative Framework of Value might contribute to a greater 
understanding of adherence. Some comments on this diagram are necessary. 
Firstly, since service ecosystems relate to norms and support, it seems 
reasonable to position them as forming part of the patient’s consumption context. 
Because they contribute to the decision on whether to consume, it would be 
natural to place them between resources and the point of ex ante value 
assessment. This is to show that they are part of the context and to make their 
role in decision-making clear. However, on a more practical level this review is 
 63 
  
likely to happen as part of the ex ante A-C value assessment and so for easier 
visualisation it may ultimately be simpler to place them there. 
Secondly, it is clear that Ng & Smith's (2012) Integrative Framework of Value has 
P-C value at the point of value cocreation while A-C value ex ante and ex post 
are outside of the consumption context. To show this, Figure 17 adds two steps 
to the framework, one before and one after the adherence (value cocreation) 
step. Having positioned this, it is important to recognise that A-C value is also 
assessed during that process but that this by definition removes (perhaps only 
temporarily) the patient from the P-C value cocreation process. The Integrative 
Framework of Value implies a feedback loop, but its target is undetermined. 
The diagram of S-D Logic is enhanced with these two constructs in Figure 17. 
This is referred to here as the initial process of adherence. From this diagram and 
the foregoing considerations seven points arise. 
 
Figure 17: Enhanced diagram of S-D Logic: initial process of adherence 
Firstly, the value proposition of the medicine must reach the patient if it is to be 
consumed. It must be provided at a cost which the patient can afford, and at a 
location which is attainable. This indicates that the patient’s agency includes the 
means (money and ability to reach the point of supply) to acquire it. 
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Secondly, the patient must have a way of identifying one or more medicines which 
could meet their need in context, or in other words to know what value 
propositions are available and to perceive their affordances. Without this 
knowledge adherence is not possible. 
Thirdly, the patient must perceive that they have sufficient agency – operant 
resources provided by their skills and competencies including motivation and 
beliefs – to be able to take the medicine, or in other words to act on the resources 
provided by the value proposition of the medicine in order to cocreate value. 
Without this perception of capability the adherence attempt may not commence. 
Fourthly, the patient must perceive that they have all of the other value 
propositions in their context – the appropriate density of resources – which are 
required to successfully cocreate value. If the patient does not have, or does not 
perceive that they have, all the co-requisites in context then the adherence 
attempt is unlike to commence. 
Fifthly, once the patient has the medicine, is motivated to consume it, and 
perceives that they have the agency, then they must assess the A-C value to 
decide whether to go ahead and attempt to cocreate value. This assessment will 
consider the perspectives of the multiple service ecosystems in which they exist 
and their connectedness to those ecosystems, and will weigh up the pros and 
cons of being adherent within each one of them. If their assessment is negative 
in relation to their most important service ecosystem then it is unlikely that 
adherence will commence. 
Sixthly, once a decision has been taken to consume, the patient moves to 
execute the process of value cocreation in order to cocreate value-in-context or, 
in other words, to be adherent. At this point the perceptions of agency and 
resources are tested against reality. If agency is lacking, or resources are missing 
or are exhausted, then adherence will commence but will not be successful. If the 
rule of instructions is accurate and followed correctly then consumption is 
adherent and the supplier of the medicine would expect the patient, all things 
being equal, to cocreate the offered value-in-context from the medicine. However, 
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if instructions are incorrect or are not followed correctly then value cocreation may 
not be successful. 
Seventh and finally, following value cocreation, the patient will assess the A-C 
value ex post to determine the nature and level of value created. This assessment 
will feed back in some way into future decisions to consume (ex ante A-C value 
assessment), and it seems likely that this assessment will contribute to the 
patient’s experience for future adherence opportunities. 
At this point it is not important to form a clear understanding of where the 
feedback loop from the ex post A-C value assessment might land. However, it is 
clear that such a loop is part of the patient’s overall assessment process. 
6.2.7 Service-Dominant Logic summary 
S-D Logic appears to provide a framework for understanding the process of 
adherence at the point of consumption which goes beyond that which 
expectancy-value behavioural theories can achieve. Some of what might be 
considered to be potential limitations of the framework seem to be addressed by 
the two later additions. Firstly, a greater understanding of context is provided by 
the notion of contradictory overlapping and nested service ecosystems; this is 
potentially a contribution to understanding the rule of norms. Secondly, a clearer 
picture of value assessment is offered by the Integrative Framework of Value. 
6.3 Changes to adherence over time 
Although this research emphasises adherence as a point-in-time opportunity to 
adhere or not, the consideration of the feedback loop within the Integrative 
Framework of Value provides the chance to raise some questions relating to 
adherence over time based on A-C value assessments. All changes over time 
may be assessed at any place in the adherence process, but perhaps there are 
three key places. Firstly through A-C valuation ex post after adherence is 
attempted. Secondly at the point of ex ante assessment before an adherence 
attempt. But thirdly, changes may only be identified at the point at which 
adherence is attempted, or in other words at the point of value cocreation. 
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If the patient changes then that may drive change over time. The patient is 
represented by agency, beliefs and motivation in this adherence research, so a 
change in the patient implies a change in one of these three factors. Such change 
may lead to higher or lower adherence and therefore affect the level of adherence 
at each opportunity to adhere. 
If the medicine changes then this may lead to change. The medicine is 
represented by its affordances here. Therefore a change in medicine would mean 
a change in this factor. As before, this may increase or decrease point-in-time 
adherence at different times. 
If the context changes then this may lead to change. The context is represented 
by the norms of in-focus service ecosystems and by the context itself. Changes 
to either of these could lead to an increase or decrease in point-in-time adherence 
at different times. 
Through this brief assessment it is clear that it is profitable to think of adherence 
as an individual opportunity to consume since the many variables which 
contribute to being adherent are as constant as they can be at a point in time. 
Taking adherence to mean being compliant over the period of the course of 
treatment is also valuable, but of necessity it must average all the factors over 
time. This means that the detail of what happens at each adherence opportunity 
is inevitably missed. Building a greater understanding of what drives adherence 
requires deep knowledge of individual adherence attempts which is most easily 
achievable through qualitative research. 
This perspective may help to explain why multiple-intervention studies often 
report limited success. By averaging adherence over a course of treatment – and 
especially over a cohort in quantitative research – while promoting various 
adherence interventions throughout the course, may show each intervention as 
being of limited benefit overall. By contrast, visualising adherence as a series of 
separate events may reveal that for each adherence opportunity a particular 
individual intervention is just what is required at that instant even though on 
average its effect is limited. 
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6.4 Summary 
This chapter has evaluated S-D Logic and confirmed that it can form the basis for 
understanding the act of adherence. In addition, it can provide insights into the 
end-to-end adherence process. This permits theorisation of adherence beyond 
the expectancy-value theories. 
It has also suggested that the Integrative Framework of Value can explain not 
only decision-making leading up to adherence, therefore potentially replacing 
those theories in this process view of adherence, but can also shed light on the 
thinking which takes place after the adherence attempt. 
The inclusion of service ecosystems and their institutions has helped in 
understanding the complexity of decision-making due to the patient occupying 
multiple ecosystems simultaneously. It has also contributed an appreciation of 
both the sources of adherence-encouraging social support and the reasons why 
it might not be forthcoming. 
The visualisation of S-D Logic with these elements included is an aid to moving 
beyond this point in the research. 
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7 Literature Review: Summary and Conclusions 
7.1 Introduction 
This chapter brings together the threads from the literature review and the 
analysis in the foregoing chapters and sets out the reasoning, justification and 
development of Qualitative Propositions for the next stage of this research, the 
qualitative empirical work. 
The structure of the chapter is as in Figure 18. 
 
Figure 18: Chapter structure 
7.2 Literature review summary 
The basic working definition of adherence that was used to initiate this research 
was taking medicine according to instructions. The definition of consumption 
selected was that which relates to value in use rather than value in exchange. 
Value in use is to do with eating, drinking, coming into contact with services, and 
the like, rather than purchasing. In making this choice, research on economics 
and consumerism was excluded. 
The review commenced with a survey of the definitions of adherence used in the 
healthcare sector. This review discovered that there is no single agreed definition 
of adherence. Instead, there are very many practice-based definitions used in 
research, both in practical empirical work and in more theoretical papers. 
Firstly, it looked at adherence in healthcare other than medicine consumption. 
Some prior research was uncovered. Where theorisation was found it tended to 
be restricted to the immediate research scope with little attempt to expand it to 
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inform any other adherence research. However, there was some contribution to 
thinking on the process of adherence. Although it tended to show that there was 
little assessment of the root causes of adherence or non-adherence, it did 
demonstrate that when there was it mainly talked about the importance of social 
pressure or support. In research which did invoke theory it tended to be Self-
Efficacy Theory or the Theory of Planned Behaviour. 
Interest then switched to medicine consumption. This was more fruitful in 
uncovering both reasons for non-adherence and also theorisation on why these 
might be. Firstly, the World Health Organisation report (Sabaté 2003) was found 
to be a mainstay of medicine adherence research, albeit at a practical level. 
Secondly, Adult Meducation (ASA & ASCPF 2006) was seen to build on this to 
identify and group 55 causes of non-adherence. 
The review then progressed to review medicine adherence research. Over 1000 
papers were found, according to Google Scholar (almost 19,000 in MEDLINE). 
Of these, about 45% (Google Scholar) or 1% (MEDLINE) of papers invoked a 
theory in support of their research, Taking account of a paper by Painter et al. 
(2008) which stated that almost 70% of research referencing a theory was 
actually influenced by theory rather than invoking it, this suggests that only 
around 16% (Google) or less than 1% (MEDLINE) of research actually uses 
theory as a foundation. 
Several key themes were identified in the survey of medicine adherence papers. 
These were taken forward to contribute to developing the qualitative process of 
adherence. 
Next was a discussion of limitations in current research. This highlighted that 
most research was performed in the developed world, that developing world 
research was largely about HIV/AIDS and, as restated above, most research was 
not underpinned by theory. In the exceptions to omitting theory, Self-Efficacy 
Theory or the Theory of Planned Behaviour were the most used. Other research 
included theories and models such as the Theory of Reasoned Action, the COM-
B model, the Health Belief Model and the Children’s Health Belief Model. These 
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were explored as a basis for later discussion, identifying particularly their inability 
to theorise the actual act of adherence and therefore the need to move beyond 
them. 
Following that, an assessment was made of this body of literature’s contribution 
to a theoretical process of adherence. This assessment identified that 
expectancy-value theories were used, that self-efficacy and social support were 
major determinants of adherence, that motivation and beliefs were also important 
in the patient’s decision, and that medicine characteristics played a part. 
Finally in the medicine adherence review, a chapter drew all these elements 
together to discuss the factors and to group them into three: the patient, the 
medicine and the adherence environment. It then analysed these groups before 
identifying the unit of analysis and the definition of adherence to be used in the 
rest of this research: the adherence opportunity afforded to a patient to consume 
a single dose of medicine in context. 
Service-Dominant Logic was then considered as a means to understand both the 
single opportunity to be adherent and what actually happens in consumption. This 
builds on expectancy-value theories which cease theoretical analysis at the 
decision stage of the adherence process. The result of this exploration led to the 
creation of an initial theoretical process of adherence for use in qualitative 
research. 
7.3 Qualitative research justification 
The literature review demonstrated that there is no theoretical model which 
explains adherence throughout the process. Some theories help to envisage the 
early parts of the process focusing on motivation, but none are able to support an 
understanding of what happens at the point at which adherence should occur. 
This is a gap in the adherence literature. 
An assessment of Service-Dominant Logic suggested that it could inform the 
consumption act within the adherence process, and potentially also augment or 
replace the theories which have hitherto been used to illuminate some of the 
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earlier stages of the adherence process. While qualitative studies of adherence 
have been performed, none have used the lens of S-D Logic as their basis or 
approached adherence as point-in-time opportunity to adhere. As Rathbone et 
al. (2016) state very clearly: 
“Qualitative research enables rich, detailed data to be collected and 
analyzed, allowing novel perspectives to be generated and phenomenon 
to be explored at a fundamental level, ontologically and epistemologically. 
That is to say, qualitative research can help identify what a phenomenon 
‘is.’ The need for this kind of fundamental qualitative research has been 
systematically identified in the adherence literature”. 
It is reasonable to state that it is still unclear what adherence “is”. The research 
question remains unanswered: what is adherence from a process perspective? 
This remains the focus of this research. 
Until Service-Dominant Logic was applied to the question of adherence there had 
been no suitable theoretical means to bring together patient, medicine and 
context. However, the initial process of adherence created from theory has not 
yet been shown to be reasonable in practice. This gap needs to be filled in order 
to determine whether in practice S-D Logic is a firm basis for a theoretical process 
of adherence. For this reason the thesis moves on to an exploratory exercise of 
qualitative research. 
7.4 Development of Qualitative Propositions 
It is not necessary to show through qualitative interviews that each of the 
inhibitors identified in the literature review actually exists in practice. Others’ 
research has already shown this to be the case. What is necessary is to show 
that adherence can be explained in practice by this initial process. That is, the S-
D Logic-based initial view of the process of adherence needs to be assessed 
through practical research before it can be considered to be a candidate to 
support a theoretical process view of adherence. To achieve this it is necessary 
 73 
  
to evaluate whether the factors of adherence can be placed within the initial view 
via qualitative research. 
The qualitative research therefore aims to do two things. 
The first objective is to contribute that “rich, detailed data” of lived lives into the 
research process in order to gain a deeper understanding of adherence at the 
level of an individual opportunity to adhere. This has not been done before. One 
measure of its success will be whether this approach identifies further causes of 
non-adherence which can be added to list of 55 causes of ASA & ASCPF (2006), 
while another will be whether the interviews recognise the six factors of 
adherence. Success in this objective will provide support for the second. 
The second objective is to show in practice that the initial view of the process of 
adherence is a valid means to understand adherence by showing that the non-
adherence factors already discussed can be logically placed within it. This use of 
S-D Logic to explore point-in-time adherence through factors is new. 
The first step in operationalising factors of adherence within this process view 
and testing them quantitatively was also taken. The quantitative research 
hypotheses are developed and justified in the chapter between the qualitative 
and quantitative research. However, the quantitative research was unsuccessful 
because of flaws in design and implementation. 
7.4.1 Qualitative Proposition 1: identification of adherence factors 
and additional non-adherence causes 
As indicated earlier, this first objective is to contribute rich, detailed data of lived 
lives into the research process in order to gain a deeper understanding of 
adherence at the level of the individual opportunity to adhere. While qualitative 
adherence research has been done before, it has not been done with the focus 
on the individual adherence opportunity. 
The initial measure of its success will be that it covers all the ground of the six 
adherence factors identified in the literature review. This will help to confirm the 
validity of the interview data. This results in Qualitative Proposition 1a. 
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Qualitative Proposition 1a: It is possible to uncover all adherence factors 
within the interviews. 
The second measure of its success will be whether this approach identifies further 
causes of non-adherence which can be added to list of 55 causes of ASA & 
ASCPF (2006) (Table 4). This results in Qualitative Proposition 1b. 
Qualitative Proposition 1b: Further causes of non-adherence will be 
uncovered over and above the 55 causes already catalogued. 
These Propositions are also intended to lend support to Proposition 2. 
7.4.2 Qualitative Proposition 2: validation of the S-D Logic model 
The use of S-D Logic to explore point-in-time adherence through factors is new 
and so it is necessary to confirm empirically that S-D Logic provides this support. 
Therefore the objective of the Proposition is to understand how the factors of 
adherence already discussed can be positioned within the initial process of 
adherence. If a model of placement, reasoned in advance, can be shown to be 
aligned with qualitative research then the model can be considered to be 
supported. This results in the second Proposition. 
Qualitative Proposition 2: The initial adherence process derived from S-
D Logic provides a foundation for the final qualitative process. 
7.5 Summary 
The chapter has provided a detailed analysis of the literature review, established 
the justification for performing qualitative research, and laid out the Propositions 
for that research. It has made the case for moving towards developing a process 
of adherence in at least two ways: current expectancy-value theories cannot 
explain the whole end-to-end adherence process; and there is a need to 
understand how so-called causes of non-adherence work out in patients’ 
perspectives in their many and varied consumption contexts. 
The research now moves on, firstly to an exploratory qualitative exercise with the 
aim of creating a structural qualitative view of the process of adherence, and 
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secondly to quantitative research in order to create a quantitative view of the 
adherence process and so operationalise major elements of adherence. These 
are introduced, reported on and analysed in Section B. 
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Section B: Moving Towards a Process View of 
Adherence 
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8 Research: Introduction 
8.1 Section introduction 
Section B provides introductions, results, analyses, and conclusions for the 
empirical research. 
It firstly explains and justifies the research philosophy, ontology, epistemology 
and methodology. 
The method, results, analysis and conclusions of the qualitative work are then 
presented. The resulting qualitative process of adherence is the main result of 
this research. 
Between the qualitative and quantitative research is developed the quantitative 
view of the process of adherence based on the qualitative research. 
Following this are presented the methods, results, analysis and conclusions of 
the first test of the quantitative theoretical process of adherence. This first test of 
the model was intended to determine the possible contributions of quantitative 
analysis to understanding adherence. The quantitative process of adherence is 
the main result of this research; the quantitative results need to be treated with 
extreme caution. 
Therefore the structure of this section is as per Figure 19. 
 
Figure 19: Structure of Section B 
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8.2 Chapter introduction 
The purpose of this chapter is simply to introduce the research. 
The structure of this chapter is seen in Figure 20. 
 
Figure 20: Chapter structure 
8.3 Summary 
This short introductory chapter has explained the structure of Section B of the 
thesis. 
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9 Research Philosophy, Ontology, Epistemology and 
Methodology 
9.1 Introduction 
This chapter describes the philosophical basis for the theory and practice of this 
thesis. This is Critical Realism. Having considered this, it moves on to the 
ontology and epistemology which emerge from this philosophy, and finally to the 
methodology for the research. This chain is documented and justified. 
This chapter is therefore structured as in Figure 21. 
 
Figure 21: Chapter structure 
9.2 Why Critical Realism? 
The overarching philosophical viewpoint taken for the research is Critical Realism 
(Bhaskar 2008; Bhaskar 1998). 
This research entails learning from individuals about their own experiences. 
Therefore a philosophy is required which recognises that there exists a world 
which includes our socially determined knowledge about reality, while at the same 
time there is a world where adherence has a real definition which remains the 
same whether individuals recognise it or not. These two worlds exist in parallel, 
the external world independent of our experience of it and an internal world which 
is our understanding of adherence. In other words, patients have their own views 
of reality which may or may not match true reality but which nevertheless are real 
to them in the domain of the actual even if they do not reflect what another would 
recognise as their reality. 
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This view is supported by Critical Realism. Once this philosophy is chosen, 
ontology and epistemology are decided also. 
9.3 Philosophy 
Critical Realism emerges from scientific realism while recognising the importance 
of societal impact on science which thus requires the inclusion of researchers’ 
engagement in their research. It therefore rejects positivism which assumes the 
researcher is completely dispassionate. Its aim is to synthesise two views of 
research, namely the social character of science and the stratification of science 
(Bhaskar 2008 p.xxx). One of its key claims is that (ibid. p.1): 
“[N]ot only is a constant conjunction of events not a sufficient, it is not even 
a necessary condition for a scientific law”. 
Bhaskar (ibid. p.2-3) argues that Critical Realism requires that the three domains 
of “the real, the actual and the empirical are distinct”, or as stated in reverse order 
by Danermark et al. (2001), “what we experience, what actually happens, and the 
underlying mechanisms that produce events in the world” are distinct. Bhaskar 
illustrates this by Table 6, reproduced from Bhaskar (2008 p.2). What this means 
is that there is a reality of “structures”, “causal laws” or “tendencies” which exist 
independently of whether we know about them or not; there are events at the 
actual level which, if they arise, do so as a result of the causal mechanisms acting 
at the real level; and there are things which we may or may not perceive at the 
empirical level which are the result of the causal laws acting. In other words (ibid. 
p.7), “tendencies may be possessed unexercised, exercised unrealised, and 
realised unperceived (or undetected) by men”. 
 
Table 6: Real, Actual and Empirical, after Bhaskar (2008 Table 0.1) 
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A constant refrain of Critical Realism is that of the difference between open and 
closed systems. Bhaskar (2008 for example p.23) points out repeatedly that only 
in closed systems where everything is held constant apart from the experimental 
variables do mechanisms reliably deliver the same results time after time, and so 
it is only for closed systems where predictions can reliably be made. In open 
systems there are multiple influences which cannot be held constant, so the same 
result cannot be assumed either to happen or not to happen for the same reasons 
each time. This is the basis of his point that constant conjunctions of events are 
neither necessary nor sufficient. The result of this is that science – physical and 
social – must seek for underlying explanations rather than just epistemological 
constancy. This provides justification for the qualitative social science research 
where people’s realities, sometimes referred to as “perspectivism” because 
knowledge is local and contextual, can be collected and deeper structures 
inferred. While this approach may not enable a complete grasp of the real 
domain, it can at least help to make sense of the events which make up the actual 
domain – the working of people’s perceptions of institutions acting or not acting 
to deliver experiences. 
In this discussion is seen the influence of the open system of context on 
adherence. The patient’s perceptions of themselves and the medicine are 
similarly a manifestation of the actual in the space of empirical – the perceptions 
may or may not be an accurate representation of the true reality. Considering the 
three rules, all could be said to exist in the real, but a patient’s understanding of 
them is only an interpretation of the real as perceived in the actual space. There 
will then be an acceptance or rejection of them in the empirical space depending 
on whether they are acting in the patient’s mind at the time. 
9.4 Ontology 
Bhaskar’s starting point for science (Bhaskar 2008 p.13) is, “What must the world 
be like for science to be possible?”. He shows that rather than focusing on 
epistemology we should be looking at ontology – the knowledge itself, and not 
how we discover it. Danermark et al. (2001) extend this viewpoint into the social 
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sciences by asking the question, “What properties do societies and people 
possess that might make them possible objects for knowledge?”. This fits very 
well with much of Service-Dominant Logic including service ecosystems and 
institutions, where the institution can be viewed as existing in the domain of the 
real, and which may or may not act and may or may not be perceived by an 
individual. A particular ecosystem may or may not therefore affect someone’s 
thinking depending on whether it is perceived and depending on whether it is 
“acting” in that person’s life at that time. Each person has their own view of reality 
based on those two things, but there still remains the domain of the real which 
may or may not be accurately represented in a person’s perceptions of the 
combination of service ecosystems/institutions. 
Bhaskar takes things further. He points out (Bhaskar 2008 p.36) that: 
“[generative] mechanisms endure even when not acting; and act in their 
normal way even when the consequents of the law-like statements they 
ground are, owing to the operation of intervening mechanisms or 
countervailing causes, unrealised”. 
Once more, this has echoes in Service-Dominant Logic such that, as has become 
apparent, a lack of resources (context, agency, affordances, etc) may prevent 
value cocreation even though the generative mechanism of motivation exists. 
Another important element of Critical Realism is emergence. Bhaskar (1993 p.49) 
describes this as: 
“In emergence, generally, new beings (entities, structures, totalities, 
concepts) are generated out of pre-existing material from which they could 
have been neither induced nor deduced”. 
There is a close parallel between Critical Realism and S-D Logic’s concepts of 
service systems, where the system cannot be reduced its constituent parts but is 
emergent from them. Service systems in their complexity must be researched as 
wholes and not as sums of parts. 
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9.5 Epistemology 
As indicated above, Critical Realism focuses on ontology rather epistemology. It 
takes the view that experiences are independent of the domain of the real, such 
that knowledge of an object is not the same as the object itself. It is therefore not 
possible to define something – mechanisms, causal laws, tendencies – only by 
what is perceived since they exist independently of the observer. This leads to an 
epistemologically cautious approach to knowledge, since true reality may not be 
easy or even possible to perceive. 
It is important that the research gives the participants the full opportunity to 
present their views of reality without constraint or judgement. This implies that the 
research encompasses interpretivist and potentially constructivist perspectives 
as well. This fits well with Critical Realism’s epistemological caution, which 
recognises that people have their own views of reality without these being the full 
reality – that is, all individual perceptions of reality are partial. These perspectives 
have therefore been fully recognised in the research. 
9.6 Methodology 
9.6.1 Introduction 
The methodology for this research must support the need to investigate the 
phenomenon of adherence in patients whilst taking account of the preceding 
discussions on ontology and epistemology. In order for the research propositions 
and hypotheses to be investigated, the methodology must permit an 
understanding of the phenomenon of adherence in the context of contemporary 
events while having no control of those events. It must encourage individuals to 
discuss the world as they see it without judgement, recognising that each 
patient’s worldview is legitimate. Critical Realism supports this since it accepts 
that empirical experience of the real mechanisms acting at the actual level is 
different for each patient even though that reality does exist behind experience.  
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9.6.2 Chosen approach 
The desires were twofold. Firstly, from the literature to build an initial process, 
from this derive Qualitative Propositions, and then to check the alignment of those 
Propositions with interview results. Secondly, to establish hypotheses from the 
qualitative research and explore them quantitatively. This led to the selection of 
a mixed methods approach to a case study. 
Case studies support a range of methods which can be triangulated together to 
deliver research results. Yin (2013 p.16) defines the case study as: 
“…an empirical inquiry that: investigates a contemporary phenomenon 
(“the case”) in depth and within its real-world context… especially when 
the boundaries between phenomenon and context may not be clearly 
evident”. 
It is not desirable to perform experiments on patients. Nor is it possible to control 
for variables when there are so many, both known and unknown, in the open 
system of the world. Even if it were possible, solely using such an approach would 
only permit the testing of pre-determined causes of non-adherence; part of the 
research has been to uncover currently unknown or undocumented causes. 
The requirements led to research in two parts. Input to the qualitative research 
was the initial process of adherence which was developed from an analysis of 
the literature on patient, medicine, context and the three rules. The qualitative 
research took this initial view and generated Qualitative Propositions. It then 
explored these propositions in the case of medicine adherence, obtaining a rich 
knowledge of adherence in lived lives through interviews in order to recognise 
known non-adherence causes and to identify new causes. From this it created a 
quantitative process and evaluated the quantitative hypotheses by means of a 
survey. Sadly, the quantitative hypotheses were not supported as a result of 
imperfect design and implementation of the survey. 
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These requirements led to the choice of semi-structured interviews or “guided 
conversations” (Yin 2013 p.110) to obtain “insights, explanations, and meanings 
related to certain occurrences” (ibid. p.111). 
Qualitative research is valuable in order to explore the “why” and the context, and 
such supports the perspective of Critical Realism. As Yin (2013 p.16) says, 
“A case study is an empirical enquiry that 
 investigates a contemporary phenomenon (the “case”) in depth and 
within its real-world context, especially when 
 the boundaries between phenomenon and context may not be clearly 
evident”. 
This therefore permits the building and refining of theory in parallel to data 
analysis because it permits a focus on reasons rather than just outcomes. As 
Dubois & Gadde (2002) state: 
“… we have found that the researcher, by constantly going ‘back and forth’ 
from one type of research activity to another and between empirical 
observations and theory, is able to expand his understanding of both 
theory and empirical phenomena”. 
This process is referred to as retroduction or abduction (Mingers et al. 2013). 
Therefore, this approach is perfect for creating and validating conceptual 
processes qualitatively. 
There are several possible options to defining a case. The simplest is a single-
case study with field research performed in one location. Beyond that is a two-
case study, which opens up several possibilities. The first is field research 
performed in two similar locations in one country; the second is two different 
locations in one country; the third is two similar locations in two countries; the 
fourth is two different locations in two countries. “Different” here relates to 
elements which may affect adherence. 
Initially, a perspective was taken that there would be significant differences in the 
issues found in the developed and developing worlds. Therefore the fourth 
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approach to the case study was taken. In the qualitative interviews it was quickly 
discovered that this was not the case. Although some differences emerged due 
to the natures of the two environments of the developed world of UK and the 
developing world of (primarily) sub-Saharan Africa, there were also strong 
overlaps and equivalences in findings. Therefore the third approach was 
substituted for the fourth, the two environments being treated as essentially the 
same. This meant that no breakdown of the two locations was performed during 
analysis. 
The analysis approach for the qualitative research was aimed at examining the 
validity of the initial process. The quality of the interview results was tested in two 
ways. Findings from the multiple sources and literature were triangulated. A 
Critical Realist-aligned approach based on Systematic Combining (Dubois & 
Gadde 2002; Dubois & Gadde 2014) was used to develop conclusions. This 
permitted an assessment of the initial adherence process emerging from the 
literature review, and its refinement into what is referred to as the qualitative 
process of adherence. 
A first step was taken towards analysing the qualitative process of adherence 
quantitatively by use of a survey. A significantly simplified view of the adherence 
process, the quantitative view, was constructed for statistical analysis. Statistical 
techniques were used in an attempt to understand the interactions of the factors 
assessed in the survey. This did not lead to definitive results, but provided useful 
pointers for future steps if thought desirable. 
9.6.3 Conclusion 
The research method selected was a mixed methods approach of qualitative 
research to explore the validity of and to extend the initial view in order to create 
a qualitative theoretical process, followed by quantitative research to evaluate a 
quantitative viewpoint. 
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9.7 Summary 
A combination of mixed methods – qualitative semi-structured interviews and 
quantitative survey – was used to support the selected philosophy with its 
resultant ontology and epistemology. The methodology supports this approach. 
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10 Qualitative Research Method 
10.1 Introduction 
This chapter considers methods used in the qualitative research, namely the use 
of qualitative semi-structured interviews. It starts with an overview of the 
approach followed by more detailed explanations of the methods used in 
investigating the two Qualitative Propositions. It shows the alignment of the 
qualitative work with the propositions. 
The structure of the chapter is as in Figure 22. 
 
Figure 22: Chapter structure 
10.2 General approach 
A series of semi-structured interviews was arranged with people who were willing 
to talk about their past experience of taking medicines. They were located in 
various environments ranging from a comfortable urban environment in a 
developed country through to an impoverished rural environment in a developing 
country. Much thought was put into how to cover both the developing and 
developed world with a range of ages and in a variety of situations. 
Interviewees were selected using purposive sampling (Teddlie & Yu 2007). Initial 
interviews were performed with contacts in UK. Following that, interviews were 
arranged with contacts in a range of developing countries including Kenya, 
Tanzania, Kazakhstan and Nigeria. These were intended to explore situations in 
the developing world, primarily sub-Saharan Africa. This purposive sampling was 
aimed at obtaining information from “a broader group of cases” and to enable 
“comparisons among different types of cases” (ibid.). It therefore made use of 
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both typical case sampling and outlier sampling since it included interviewees at 
all stages of life in both developed and developing world environments. 
Over time, further interviews were performed in countries other than those 
mentioned above in order to build the widest picture and to understand their 
relationship to the initial findings. Most of the later interviews used snowball 
sampling, with earlier interviewees encouraging their acquaintances to 
participate, but typical case and outlier sampling methods continued to be used 
where the opportunity arose. 
A total of 30 interviews were performed over a period of just over 5 months from 
the end of December 2014 to early June 2015. Table 40 in Appendix B.4 provides 
a detailed list of interviewees. All interviewees were given the opportunity to 
review the Participant Information Leaflet (Appendix B.1) and to confirm their 
willingness to participate via the Consent Form (Appendix B.2). The ethics of the 
approach were approved by BSREC through Warwick Medical School (Appendix 
B.3). 
Some interviews were performed face to face but most were by phone or by 
exchange of written lists of questions and responses. For face-to-face and phone 
interviews, recordings were made using a recording application on a mobile 
phone. Most interviews lasted for about 25 minutes. Nvivo10 and manual means 
were used to extract and code these interviews from the full transcripts. Coding 
can be found in the tables in Section 11.3 and Appendix B.6. Since the purposes 
of the interviews were to gain qualitative insights in support of Qualitative 
Proposition 1 and to assess interview validity in support of Qualitative Proposition 
2, it was not important that every conceivable combination of age, environment 
and country be included in the research as long as the research was indeed 
robust. The general approach of Systematic Combining (Dubois & Gadde 2002; 
Dubois & Gadde 2014) was used to revise the initial process based on empirical 
findings. 
Interviews were perused line-by-line to identify and extract phrases. These were 
then both assigned against the eight subordinate propositions of Qualitative 
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Proposition 2, and as reasons for and against taking medicine in support of 
Propositions 1a and 1b. 
10.3 Qualitative Proposition 1 
The purpose of this Proposition is to assess the quality of data emerging from the 
qualitative interviews in support of Proposition 2. In addition, it might be expected 
that deeper, though unmeasurable, value would be found in the interviews 
beyond these quantifiable assessments. The Propositions are restated here. 
Qualitative Proposition 1a: It is possible to uncover all adherence factors 
within the interviews. 
Qualitative Proposition 1b: Further causes of non-adherence will be 
uncovered over and above the 55 causes already catalogued. 
The propositions are stated quantitatively since otherwise they may be open to 
counterargument. 
The interview transcripts were assessed in two different ways to investigate these 
propositions. Both analyses were done separately for developed and developing 
worlds as a means of comparison before being brought together. The initial 
assumption was that there would be large differences between the results of the 
“control” interviews of UK interviewees and the developing world interviewees. In 
fact, it was discovered that there were very few differences, thus permitting the 
amalgamation of the results. 
10.3.1 Qualitative Proposition 1a 
For Proposition 1a, the interview extracts were brought together under data-
derived codes. These codes were then consolidated in categories with positive 
and negative attributes for each. These were then further grouped in a taxonomy. 
Without changing their meanings, the labels of the taxonomy were then revised 
to match the naming convention of the adherence factors. 
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10.3.2 Qualitative Proposition 1b 
For Proposition 1b, the interview extracts were perused for causes of non-
adherence. These interview causes were then compared against the 55 causes 
for non-adherence (ASA & ASCPF 2006). Each interview cause was recorded 
along with the interviews which mentioned them. Causes in the 55 not found in 
the interviews, and causes in the interviews not found in the 55, were then 
presented. 
10.4 Qualitative Proposition 2 
The second proposition developed for the qualitative research was: 
Qualitative Proposition 2: The initial adherence process derived from S-
D Logic provides a foundation for the final qualitative process. 
The approach taken was first to establish a potential positioning of adherence 
factors within the initial process and then to assess this positioning through 
interviews. 
It is necessary to consider the six factors of motivation, beliefs, agency, 
affordance, consumption context and norms. Some of these factors may be 
applied to the initial view in multiple places while some elements of the process 
may support more than one factor being applied. Each factor will be positioned in 
turn. 
Firstly, motivation. This is an attribute of the patient which contributes to their 
agency. It may therefore be placed within the process prior to Agency. It may also 
be present in the decision on whether to consume so could therefore also be 
placed on the A-C value ex ante assessment, and be present in the ex post 
assessment also. Because motivation is likely to affect earlier decisions, 
additionally it may be present in the choice as to whether to obtain the medicine. 
Secondly, beliefs. This is a rule within the patient which contributes to their 
agency and so may be placed in the same places as motivation. It may also be 
present in the decision on whether to consume so could therefore also be placed 
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on the A-C value ex ante assessment, and in the ex post value assessment. As 
with motivation, it may contribute to whether the medicine is obtained. 
Thirdly, agency. This the source of the patient’s resources which are brought into 
the consumption context and so can be placed on Agency. It may also be present 
in the decision on whether to consume and whether to consume again so could 
therefore also be placed on the A-C value ex ante and ex post assessments. It 
may also be involved in actually identifying the appropriate medicine to obtain, 
and therefore may be placed between the medicine’s Value Proposition and its 
Affordances. 
Fourthly, affordance. This is the source of the medicine’s resources which are 
brought into the consumption context and so may be placed on Affordances. 
Since affordance also includes costs, both financial and access-related, it may 
also be present in the medicine’s Value Proposition. Also, since costs may be 
included in the ex post assessment of value, affordance may also be placed at 
this point. 
Fifthly, norms. These are rules within the context which are taken into account by 
the patient when making a decision to consume and so may be overlaid onto the 
picture of service ecosystems. The positioning of service ecosystems within the 
consumption Context was done in order to emphasise that they are part of that 
context, but they contribute to the A-C value ex ante assessment and potentially 
the ex post assessment also. Therefore although the placement of norms 
appears to be correct it may be appropriate to consider it to be part of that ex ante 
and ex post assessments and so be placed there instead. 
Sixthly, context. This is obviously the consumption Context. It also encompasses 
contributions to context of other value propositions required to consume the 
medicine. 
Seventh and finally, the process of value cocreation must be brought into the 
picture since this represents consumption. This is present as Adherence in the 
view of the process. 
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These possibilities can be enumerated, if necessary grouped, and then 
tentatively applied to the initial process ready for testing their alignment with 
interview content. The resulting application can be seen in Figure 23, and are 
described in detail below. 
Group 1 represents the costs of obtaining the medicine and relates to the 
medicine’s value proposition, leading to its affordance. It also represents the 
levels of motivation and beliefs of the patient. 
Group 2 represents the patient’s motivations and beliefs as they are applied to 
medicine consumption. 
Group 3 represents the agency of the patient in being able to identify the correct 
medicine, and the affordability of the medicine which therefore contributes to its 
affordance. 
Number 4 represents the sum total of the patient’s agency brought into the 
medicine consumption context. 
Number 5 represents the contribution of all the value propositions other than the 
medicine which are required for the patient to consume the medicine. 
Number 6a represents the norms which contribute to the consumption decision. 
Norms is part of the context but also contributes to the decision so number 6 is 
split into two parts. 
Group 6b represents the motivation, beliefs and agency which contribute to the 
consumption decision in relation to the medicine’s affordance, perception of the 
norms and the anticipated context. Considering number 6 as being in two parts 
shows that both parts operate together. 
Number 7 represents the actual consumption event, or value cocreation. This 
entails a coming-together of patient and medicine in context, thus engaging all 
factors at once. 
Number 8 represents the ex post assessment of value based on the realities of 
motivation, beliefs and agency together with affordance, norms and context.  
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The three purposes of the qualitative research as related to these factors are to 
investigate whether these placements are valid, to determine whether they 
represent the three constructs in a feasible way, and to explore them in depth. 
The interviews will contribute to this by helping to ascertain whether the 
suggested factors are present in each group, thus supporting the alignment of 
Qualitative Proposition 2 with the reality of the interviews.  
As a working model of these placements, Figure 23 represents the foregoing 
groupings which can now be assessed qualitatively. 
 
 
Figure 23: Initial process with group placements 
More formally, Qualitative Proposition 2 can be allocated its own subordinate 
propositions within the overall proposition. Since these placements represent 
potential inhibitors or enablers of adherence, these subordinate propositions will 
take that perspective in order to evaluate the underlying reasons for each, thus 
linking each with the factors that they include. Therefore the subordinate 
propositions propose that each of the placements is correct and are made up of 
the factors discussed. This approach leads to the subordinate propositions listed 
in Table 7. These are referred to as “S1”, “S2”, etc. These subordinate 
propositions were used as input to the interviews. 
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Table 7: Subordinate propositions for Qualitative Proposition 2 
No. Stage in the process Enabler/inhibitor 
S1 
 
Obtaining the medicine The costs of obtaining the medicine, both money and time – 
medicine affordance, patient motivation and beliefs 
S2 Contribution to agency The patient’s motivations and beliefs 
S3 Identification of 
medicine 
The patient’s agency identifying the correct 
medicine/affordances of the medicine 
S4 Perception of agency Total of agency 
S5 Availability of items in 
context 
The context containing all required for medicine 
consumption 
S6a 
 
S6b 
A-C value assessment 
ex ante 
The patient’s recognition of norms in taking the 
consumption decision 
The patient’s motivation, beliefs and agency in taking the 
consumption decision, in relation to the medicine’s 
affordance and the context 
S7 
 
Value cocreation (P-C 
value) 
The patient’s motivation, beliefs and agency 
The medicine’s affordances 
The context and norms 
S8 
 
A-C value assessment 
ex post 
The patient’s motivation, beliefs and agency with respect to 
the medicine’s affordances, and the context and norms 
 
10.5 Development of research questions 
Based on the approaches, a set of questions was developed to explore the six 
factors. These are listed in Table 8. The table shows the linkage between the 
questions and the subordinate propositions, but the same questions also 
supported investigations into non-adherence. Asking a range of questions which, 
although supportive of the propositions did not map one-to-one, allowed a richer 
picture of interviewees’ experiences to emerge. 
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Table 8: Questions referenced to subordinate propositions 
Research question Subordinate 
proposition 
reference 
What medicine do you wish to share your experiences of? Please 
comment separately for each medicine 
 
Is this your first time with this medicine or is it a repeat prescription? S1, S3, S8 
How far was it to a pharmacy? S2 
How much did it cost you to buy the medicine? S1 
Did you obtain the medicine? S1, S2, S6b 
If you obtained the medicine, how did you feel about it at the time? S4, S8 
Did you actually plan to consume it in line with the prescription? S2, S8 
Did you know how to take this medicine? How do you know? S7 
Please describe your physical surroundings on various occasions 
when the prescription said you should consume? Who and what 
was there and not there? 
S1 
What were you thinking and feeling? S4 
How were your physical and mental health? S4, S6a 
Did you actually consume at that time? S6a, S7 
What helped you to consume or prevented you from consuming? S1, S5, S6, S8 
Is there anything about the medicine that makes it hard for you to 
take it? What would make it easier for you? 
S1, S4, S5, S6b, 
S7,S8 
If you had the choice, how would you like to take this medicine? S7, S8 
Anything else you want to say about what makes it easy or difficult 
to take medicines for you personally? 
S1, S4, S5, S6a, S7 
 
10.6 Summary 
A two-case study was used to investigate the Propositions and the initial view of 
the process of adherence. 30 interviewees contributed their input, which was 
transcribed to form the basis for analysis of reasons for non-consumption. 
Through this approach, working propositions were generated in order to derive 
analytic generalisations (Yin 2013 p.41) so as to compare the qualitative research 
against the initial process. The research explored the level and nature of 
constraints and their impact on adherence in order to create and assess any new 
findings. 
For potential future research results were separated into the two types of context: 
developed and developing worlds. Following the discovery that the results 
emerging from both contexts were essentially the same, this separation was not 
used in the main research in this thesis. 
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11 Qualitative Research Results and Analysis 
11.1 Introduction 
This chapter records and analyses the results of the qualitative research. Its 
purpose is to determine from the results whether the Qualitative Propositions 
align with the results. After an initial discussion of overall results, it firstly analyses 
results for Propositions 1a and 1b then secondly the results for Proposition 2. 
It is therefore structured as in Figure 24. 
 
Figure 24: Chapter structure 
11.2 Initial discussion 
Table 9 provides a summary of interviewees categorised in several ways. 
A total of 30 interviews were performed over a period of just over 5 months from 
the end of December 2014 to early June 2015. Table 40 in Appendix B.4 provides 
a detailed list of interviewees. The range of interviewees was purposively 
sampled to obtain views from different age ranges and types of location. While 
the USA is not represented, the developed world viewpoint is present in the UK 
interviews. In addition, the developing world, represented in the main by sub-
Saharan Africa, was not focused on HIV/AIDS like the majority of Africa-based 
research has tended to be. The interviews therefore should be able to contribute 
fresh perspectives to the adherence debate. 
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Table 9: Summary of interviewees 
Category Value Number of interviewees 
Sex Male 
Female 
11 
19 
Age range <20 
20-40 
40-60 
>60 
1 
12 
10 
7 
World – developing Total 
Of which: 
 Egypt 
 Kenya 
 Kazakhstan 
 Nigeria 
 Tanzania 
 Uganda 
 Zambia 
 Zimbabwe 
24 
 
1 
14 
1 
1 
4 
1 
1 
1 
World – developed UK 6 
Type of location City 
Town 
Village 
3 
9 
18 
Medicine Antibiotics 
Cough medicine 
Malaria medicine 
Painkillers 
Other 
5 
2 
11 
4 
8 
Medicine cost Free 
<£1 
£1-£2 
£2-£3 
>£3 
Unstated 
6 
8 
6 
2 
3 
5 
Distance to obtain medicine <1km 
1-2km 
3-4km 
5-6km 
>7km 
Unstated 
8 
11 
3 
4 
2 
2 
 
Some of the developing world interviewees were highly impoverished, as some 
interview content demonstrated. For example, interviewee KN04 was just one 
who mentioned the problem of being adherent when they were too poor to afford 
three meals per day. Their role as interviewees was only permitted by use of 
either very basic mobile phones or borrowed phones. However, such contextual 
restrictions were not confined to the developing world: UK01 said that at times 
they did not have water to consume their medicine. As can be seen, interviewees 
in both UK and Africa shared the majority of causes of non-adherence. 
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11.3 Qualitative Proposition 1 
11.3.1 Proposition 1a 
This proposition focuses on interview coverage with regard to the adherence 
factors emerging from the literature review and used as part of the Proposition 2 
discussions. The purpose is to determine whether the interviews contained all six 
factors. 
The raw material for the analysis required for this Proposition will be found in 
Table 41 and Table 42 in Appendix B.6. These tables list transcript codes derived 
from the data, examples of interview extracts, and interview reference codes. The 
results of bringing together all the transcript codes together will be found in Table 
10. These are simply the raw codes copied from those tables to permit a move 
towards focusing on the coding and away from the detailed interview content. 
Codes consist of a category followed by “positive” or “negative” to indicate 
whether code assists or inhibits consumption, followed by detail of the effect. 
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Table 10: Coding of interviews – random order 
Code Code 
Distance, positive, close Beliefs, positive, others 
People, positive, present Instructions, negative, unclear, written 
Content, negative, unknown Regimen, positive, acceptable 
Motivation, positive, last resort Regimen, negative, complex 
Cost, positive, low Regimen, negative, forgot 
Instructions, positive, clear, written Instructions, negative, unclear, verbal 
Reminder, positive, alarm Routine, negative, absent 
Taste, negative, bitter Routine, positive, present 
Size, negative, big Cost, negative, herbal, low 
Formulation, negative, injection Beliefs, negative, value 
Effects, negative, side, specific Stop, negative, busy 
Taste, positive, sweet Storage, negative, unsafe 
Distance, negative, far Instructions, negative, foreign language, verbal 
Beliefs, negative, others, stigma Instructions, negative, foreign language, written 
Food, positive, present Utensils, negative, missing 
Food, negative, absent Branding, positive, known 
Beliefs, negative, foreign origin Diagnosis, negative, foreign language, verbal 
Beliefs, negative, lack of faith Taste, negative, bad 
Course, negative, long Effects, negative, bad 
Stop, negative, replaced by other Effects, negative, side, general 
Stop, negative, run out Beliefs, negative, others, too dependent 
Stop, negative, keep Beliefs, negative, profit, pharma 
Beliefs, positive, stay well Beliefs, negative, profit, herbal 
Beliefs, positive, get well Stop, negative, better 
Regimen, negative, unacceptable Effects, positive, others 
Cost, negative, high Effects, negative, others 
Instructions, negative, misunderstood Stop, negative, discarded 
Instructions, positive, clear, verbal Access, negative, hard 
Course, positive, acceptable Formulation, positive, liquid 
Water, negative, absent Regimen, negative, unexpected 
People, negative, absent Smell, negative, bad 
Water, positive, present Beliefs, positive, confidence 
Formulation, positive, injection Size, positive, small 
Beliefs, negative, pointless Effects, positive, side, none 
Reminder, positive, general Access, positive, easy 
Formulation, positive, tablet Motivation, negative, tired 
 
The first step in making sense of the interview codes is to group them by category. 
This is done in Table 11. The first term in each code defines the coding category, 
then each category is split into positive and negative attributes. The table is then 
created from these groups. 
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Table 11: Coding of interviews – grouped by category 
Coding category Positive attributes Negative attributes 
Distance close far 
Access easy hard 
Cost low high 
  herbal, low 
Diagnosis  foreign language, verbal 
Instructions  foreign language, verbal 
  foreign language, written 
 clear, verbal unclear, verbal 
 clear, written unclear, written 
  misunderstood 
Utensils  missing 
People present absent 
Content  unknown 
Norms  others, stigma 
Branding known  
Beliefs others others, too dependent 
 confidence lack of faith 
  foreign origin 
  profit, pharma 
  profit, herbal 
  value 
  pointless 
Motivation last resort  
 stay well  
 get well  
  tired 
Stop  keep 
  replaced by other 
  discarded 
  better 
  busy 
  run out 
Effects others others 
 side, none side, general 
  side, specific 
  bad 
Taste  bad 
 sweet bitter 
Formulation tablet  
 liquid  
 injection injection 
Regimen  unexpected 
 acceptable unacceptable 
  complex 
  forgot 
Reminder general  
 alarm  
Water present absent 
Food present absent 
Size small big 
Smell  bad 
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Coding category Positive attributes Negative attributes 
 
Course acceptable  
  long 
Routine present absent 
Storage  unsafe 
 
Table 11 permitted the identification of several similar categories. These were 
used to create a simple taxonomy. This is shown in Table 12. 
 
Table 12: Categories grouped into taxonomic categories 
Taxonomic 
categories 
Categories 
Product-related Content, Branding, Effects, Taste, Formulation, Size, Smell, 
Instructions, Regimen, Distance, Access, Cost, Diagnosis 
Environment People, Utensils, Reminder, Water, Food, Storage, Norms 
Patient-related Course, Routine, Stop 
Beliefs Beliefs 
Motivation Motivation 
 
Assessing these major taxonomic categories, they were compared with the initial 
process, Figure 17. From this it is possible to align each one with more 
recognisable categories. This is shown in Table 13. 
 
Table 13: Taxonomic categories converted to process terminology 
Category Common terminology 
Motivation Motivation 
Patient-related Agency 
Environment Context, Norms 
Product-related Affordance 
Beliefs Beliefs 
 
Finally, comparing this taxonomy in Table 13 with the initial process, it is possible 
to see all six adherence factors present. This bottom-up analysis of interviews 
implies that the interviews had good coverage of the six factors. It suggests that 
Proposition 1a has good alignment with the interviews. 
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11.3.2 Proposition 1b 
This Proposition requires the analysis of interview responses and their 
comparison with the five dimensions from Sabaté (2003) and the list of 55 causes 
of non-adherence from ASA & ASCPF (2006). This was performed by extracting 
all stated reasons for non-adherence found in the interviews. The tables below 
list the interviews which manifest those causes.  
This analysis of the “Dimension” tables below indicates that all but ten of the 55 
causes were seen in the interviews. This suggests that the interviews achieved 
good coverage of the main causes of non-adherence. It is perhaps 
understandable that those which were not in interviews are missing as a result of 
them either requiring the interviewee to expose themselves to what may be an 
unacceptable degree or needing to be inferred by the interviewer. For the second 
type, on-the-ground observations and interviews with medical staff would have 
assisted in their identification. 
 
Table 14: Comparison of previously identified inhibitors with research – 1 
Social and Economic Dimension Seen in interview 
Limited [relevant] language proficiency EG01 KS01 UK02 
Low health literacy KN03 KN04 KN07 KN08 KN11 KN13 KN14 
UK01 
Lack of family or social support network KN08 KN11 UK01 UK02 ZI01 
Unstable living conditions; homelessness  
Burdensome schedule KN03 UK01 UK02 
Limited access to health care facilities KN03 KN07 KS01 TZ04 
Lack of health care insurance EG01 
Inability or difficulty accessing pharmacy KN03 KN04 KN07 KN08 KN10 KN11 KN12 
KS01 TZ01 TZ04 UG01 
Medication cost KN03 KN04 KN08 KN09 KN10 KN11 KN12 
KN13 KN15 KS01 NG01 TZ02 TZ04 UG01 
Cultural and lay beliefs about illness and 
treatment 
KN05 TZ02 
Elder abuse  
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Table 15: Comparison of previously identified inhibitors with research – 2 
Health Care System Dimension Seen in interview 
Provider-patient relationship EG01 UK05 
Provider communication skills KS01 UK04 UK05 UK06 
Disparity between the health beliefs of the 
health care provider and those of the patient 
EG01 NG01 UK05 ZM01 
Lack of positive reinforcement from the 
health care provider 
UK01 UK05 
Weak capacity of the system to educate 
patients and provide follow-up 
UK05 
Lack of knowledge on adherence and of 
effective interventions for improving it 
UK05 
Patient information materials written at too 
high literacy level 
EG01 KS01 
Restricted formularies; changing medications 
covered on formularies 
KN01 KN03 KN08 KN09 KN13 NG01 TZ02 
UK04 ZM01 
High drug costs, copayments, or both KS01 
Poor access or missed appointments KN03 KN07 KN08 KS01 TZ01 TZ04 UK04 
Long wait times UK04 
Lack of continuity of care  
 
Table 16: Comparison of previously identified inhibitors with research – 3 
Therapy-Related Dimension Seen in results? 
Complexity of medication regimen KN12 KS01 TZ04 UK01 UK04 UK05 UK06 
ZM01 
Treatment requires mastery of certain 
techniques (injections, inhalers) 
UK01 
Duration of therapy KN03 KN04 KN07 KN09 KN11 KN13 KN14 
UG01 
Frequent changes in medication regimen KN03 UK04 
Lack of immediate benefit of therapy KN03 
Medications with social stigma attached to 
use 
KN03 TZ02 
Actual or perceived unpleasant side effects EG01 KN01 KN03 KN04 KN06 KN07 KN08 
KN10 KN11 KN12 KN15 NG01 TZ02 TZ03 
TZ04 UG01 ZI01 ZM01 
Treatment interferes with lifestyle or requires 
significant behavioral changes 
KN03 KN15 TZ04 UK01 UK02 
 
Table 17: Comparison of previously identified inhibitors with research – 4 
Condition-Related Dimension Seen in interview 
Chronic conditions KN04 KN15 KS01 
Lack of symptoms KN01 KN03 KS01 TZ01 TZ03 TZ04 UK05 
ZM01 
Severity of symptoms KN04 KN08 KN09 KN12 KN14 KN15 
Depression KN09 
Psychotic disorders KN10 
Mental retardation/developmental disability  
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Table 18: Comparison of previously identified inhibitors with research – 5 
Patient-Related Dimension Seen in interview 
Visual impairment  
Hearing impairment  
Cognitive impairment  
Impaired mobility or dexterity  
Swallowing problems KN01 KN03 KN04 KN08 KN09 KN11 KN13 
UK04 UK06 ZM01 
Knowledge about disease KS01 NG01 
Perceived risk/susceptibility to disease KS01 UK04 
Understanding reason medication is needed EG01 NG01 TZ04 UK05 ZM01 
Expectations or attitudes toward treatment KS01 TZ01 TZ04 
Perceived benefit of treatment EG01  
Confidence in ability to follow treatment 
regimen 
EG01 KS01 
Motivation EG01 KN01 KN03 KN07 KS01 TZ01 TZ02 
UG01 UK01 ZM01 
Fear of possible adverse effects EG01 KN01 KN03 KN06 KN07 KN08 KN11 
KN12 KN15 NG01 TZ02 TZ03 TZ04 UG01 
ZI01 ZM01 
Fear of dependence  
Feeling stigmatized by the disease KN03 TZ02 
Frustration with health care providers  
Psychosocial stress, anxiety, anger KN10 KN12 
Alcohol or substance abuse  
 
However, as expected as a result of performing interviews in UK and sub-
Saharan Africa rather than USA, even as comprehensive a list as the 55 causes 
did not capture all causes emerging from the interviews. Table 19 lists those of 
the 55 causes not in the interviews on the left, and those found in interviews which 
are not in the 55 causes on the right. Sample interviews where the latter were 
found are also shown. This table supports Proposition 1b. The interviews have 
uncovered 19 new reasons for non-adherence beyond the 55 causes. 
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Table 19: Comparison of ASA & ASCPF (2006) and research findings 
In ASA & ASCPF (2006) 
but not this research 
In this research but not ASA & ASCPF 
(2006) 
Seen in 
interview 
Unstable living conditions Concern with medicine content EG01 
Elder abuse Verbal instructions in foreign language EG01 
Long wait times Written instructions in foreign language EG01 
Lack of continuity of care Pharmaceutical industry profits EG01 
Depression Herbal medicine industry profits EG01 
Psychotic disorders Feeling better KN03 UK05 TZ01 
Mental retardation Lack of food KN03 KN04 TZ01 
Visual impairment Lack of water KN08 UK01 
Hearing impairment Concern that medicine is of foreign origin NG01 
Alcohol/substance abuse Lack of faith leading to need for medicine TZ02 
 One medicine being replaced by another KN03 
 Medicine kept for future occasions KN03 NG01 TZ01 
UK05 
 Medicine kept for family need KN03 NG01 TZ01 
 Instructions misunderstood UK01 KN05 
 Difference between written and verbal 
instructions 
KZ01 
 Lack of routine UK01 
 Lack of safe storage TZ04 
 Forgetfulness KZ01 TZ03 
 Run out of medicine UK04 
 
Similar causes of non-adherence were seen in both developing and developed 
worlds. For example, a lack of food and water for taking tablets was mentioned 
in both environments yet these reasons were not mentioned in the list of 55 
causes. This suggests that interviews are of significant importance both to 
understand non-adherence reasons in detail and also to expand the list of known 
reasons. Extending the list is not easy with quantitative surveys. 
11.4 Qualitative Proposition 2 
The coding of interview extracts against the subordinate propositions and by 
adherence factors is shown in the eight tables below. These are examples of 
content, not necessarily a full list of extracts per subordinate proposition. 
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Table 20: Interview content matched to S1, Obtaining the medicine 
No. Factor Interview example Interview 
code 
S1 Motivation Just down the road from our flat 
I used it as a last resort 
I have to go 4km away 
I’m distressed for getting better 
5km from home. Travelled by Nissan… 
I found [it] after going to various pharmacy shops 
…after moving to the third shop I did obtain the medicine 
…used a motorbike 
4 hours [to get medicine] 
EG01 
KN01 
KN02 
KN03 
KN04 
KN07 
KN08 
KN13 
TZ01 
 Belief …the branding just makes you trust it more 
I had confidence that it will relieve my pain 
Felt good because I had been informed about its 
advantages 
Hopes came with the prescription 
I knew soon I would be well 
EG01 
KN09 
KN10 
 
KN13 
KN14 
 Affordance We pay. At the hospital sometimes we don’t pay 
Ksh450 [£3.01] 
Ksh300 [£2] 
Fairly expensive for Kazakhstan 
When you’re attacked by malaria it’s whether you can 
rush to the pharmacy to buy 
Some cannot afford the full dose 
KN02 
KN11 
KN13 
KZ01 
TZ04 
 
TZ04 
 
Table 21: Interview content matched to S2, Contribution to agency 
No. Factor Interview example Interview 
code 
S2 Motivation I wouldn’t [finish the course] even if the GP said “make 
sure you finish the course” 
I wanted to get relieved 
Because the medicine is so bitter, drop it from taking the 
whole dose 
I never want to take drugs 
…just don’t want to take medicine at all 
EG01 
 
KN07 
TZ04 
 
UK04 
ZM01 
 Belief I don’t know really what I’m taking tablets for UK05 
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Table 22: Interview content matched to S3, Identification of medicine 
No. Factor Interview example Interview 
code 
S3 Agency You don’t have a clue, they’ve given you a bottle, you 
can’t speak the language 
I knew how to take them 
I knew by the doctor’s prescription and advice 
This particular medicine and another one cost more 
expensive 
I just get the diagnosis and I go for other medications 
EG01 
 
KN04 
KN12 
KZ01 
 
ZM01 
 Affordance It was in Arabic…  
I had to ask my parents to decode the curvier writing 
If you don’t have money you can just take some local 
medicine 
EG01 
KZ01 
TZ04 
 
Table 23: Interview content matched to S4, Perception of agency 
No. Factor Interview example Interview 
code 
S4 Agency We figured out the written instructions 
you get many people who can’t even read 
I did not take it at that time because I was hungry and 
tired 
[the dosage] would have been a bit of a guess 
I was so tired 
I didn’t put it on my back very often because it was hard to 
get to 
I fill the containers… for 7 days 
I got a little box with a week of separated compartments 
EG01 
EG01 
KN04 
 
KZ01 
TZ02 
UK01 
 
UK02 
UK06 
 
Table 24: Interview content matched to S5, Availability of items in context 
No. Factor Interview example Interview 
code 
S5 Context The medicines here… don’t come with a spoon 
We cannot afford three meals a day so it was hard to take 
the tabs in the afternoon 
There was no body 
I lacked water for taking medicine 
I had eaten since the prescription required that 
Clean water 
We are poor we can’t afford most of the requirements. 
Sometimes we have a single meal a day 
Took it with a drink 
EG01 
KN04 
 
KN07 
KN07 
KN15 
TZ02 
UG01 
 
UK03 
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Table 25: Interview content matched to S6, A-C value assessment ex ante 
No. Factor Interview example Interview 
code 
S6a Norms my husband was there, sometimes 
my mum… she’s basically telling me it’s not good [to take 
medicine] 
Also, experience from other people 
stigma… you are viewed in a different manner 
It’s better for someone to make sure you get the full dose 
Grandmother was there with me 
Coming from a family where… my grandparents would not 
allow me to take medicine 
I try as much as possible to get it at home 
I never wanted to take that medicine because that I feared 
for stigma 
My wife is the one who was always reminding me to take 
it 
People should finish the dose as prescribed by the doctor 
Someone else did it [for me] 
With the family 
Most of the time it was just me and [wife] 
[wife:] “Have you taken your tablets?” 
EG01 
EG01 
 
KN03 
KN04 
KN06 
KN11 
KZ01 
 
NG01 
TZ02 
 
TZ03 
 
TZ03 
UK01 
UK04 
UK04 
UK05 
S6b Motivation You realise it’s hard for me [to wake at midnight] 
I knew that the disease is dangerous. If maybe I could 
default then I could have been maybe in danger 
KN03 
TZ02 
 Belief this thing about the pharmaceutical industry and how 
they’re making a profit 
Also because it’s foreign 
Natural ones are better than synthetic 
Sometimes they say that the tablets are weak 
I wouldn’t like to be putting a lot of stuff into my body that I 
didn’t know what it was doing 
I hear about these doctors saying about how conventional 
medications affect the liver 
EG01 
 
NG01 
NG01 
TZ02 
UK06 
 
ZM01 
 Agency …I felt desperate 
It took a while and was hard to put on 
KN08 
UK01 
 Affordance It’s big and bitter 
the size of the pill… the taste 
I hate the bitterness and largeness of tabs 
Some medicines are bitter… 
…tablets are in large sizes and so swallowing becomes a 
problem 
The size is too big and bitter 
Bitterness of the medicine 
Bitter 
Large to swallow and my throat is small 
They don’t taste well when you swallow them 
KN01 
KN03 
KN04 
KN07 
KN08 
 
KN09 
KN11 
KN12 
KN13 
TZ03 
 Context I remember if I want to eat I have to take medicine 
Getting up and going to bed. Part of the routine 
I remembered I had food so I could take it 
…with my breakfast… in the evening 
Took it with my breakfast every morning 
A regular habit 
TZ03 
UK01 
UK01 
UK02 
UK03 
UK03 
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Table 26: Interview content matched to S7, Value cocreation (P-C value) 
No. Factor Interview example Interview 
code 
S7 Motivation I take it up to the last one 
Sometimes I take the medicine I feel like vomiting. But I 
continued 
You feel like not taking it 
There didn’t seem to be a lot of point 
Only because he said to take them I took them 
I was sad… but I took it 
KN05 
KN06 
 
TZ01 
UK01 
UK04 
UK05 
 Belief I could not actually imagine that there will be a 
prescription or directive on how to take [it] 
I’m just so grateful for getting the right treatment 
I took my pawpaws which I heard about on the radio and I 
was ok in 2 days 
I went to the clinic… I took some lemonade 
KN07 
 
UK06 
ZM01 
 
ZM01 
 Agency …it was my first time to use the medicine and so I did not 
know how to take it 
My teacher told me to follow the doctor’s prescription 
Take 2 tablets 3 times in a day 
Two tablet after every six hours 
I don’t find it easy 
I followed the instruction given to me by the doctor 
I forgot to take it 
Maybe you can miss in that case in the evening, or forget 
in the morning and then take in the afternoon and miss in 
the evening, or someone can take 6 at once 
I was told how to take them 
KN08 
 
KN11 
KN05 
KN11 
NG01 
TZ03 
TZ03 
TZ04 
 
 
UK05 
 Affordance The prescription should say when the medicine should be 
taken 
…medicines are difficult for me to take 
It is quite difficult for me to take them because of the smell 
but I sacrifice… 
…this medicine has a smell… disturbs me a lot when 
taking this medicine 
I take it until I use all the tablets 
Took it strictly according to the prescription 
Written on the doctor’s prescription 
Some medicines… smell… nausea and vomiting… 
[sufficient to stop you taking?] Yes! 
KN01 
 
KN04 
KN05 
 
KN08 
 
NG01 
TZ02 
UK03 
ZI01 
 
 Context when the time reaches to take the medicines you 
realise… you have nothing to eat 
I was occupied maybe from work… I just forgot 
If I was staying at someone’s house I’d forget to take it 
When I unexpectedly stayed over at someone’s house 
It was quite easy as long as I’d got them with me 
We had to eke them out instead of having like 2 tablets 
twice a day we have to have 1 
KN03 
 
TZ03 
UK01 
UK01 
UK03 
UK04 
 Norms “today’s a party” 
I’m quite happy to take whatever he has prescribed 
I just do as I’m asked to do 
KZ01 
UK02 
UK06 
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Table 27: Interview content matched to S8, A-C value assessment ex post 
No. Factor Interview example Interview 
code 
S8 Motivation the moment you start to feel better you stop taking them 
sometimes I stop when I’m feeling better 
When they see they’re little better they stop taking the 
tabs 
Since I knew the effect of drug pills, I just had to take it 
…you become very tired… it is difficult [to] finish the dose 
I stopped [taking when better] 
They take long to heal, it’s a long dosage 
I bought a large jar of Candarel… and of course I stopped 
making cake and eating it… 
The results were absolutely magical, marvellous, a 
miracle 
I would not risk stopping taking them even though I’ve no 
swelling now 
Not completing the full dosage… caused by early signs of 
healing… 
KN03 
 
NG01 
 
TZ01 
TZ02 
TZ04 
TZ04 
UG01 
 
UK03 
 
UK06 
 
ZI01 
 Belief Sometimes it can harm your body 
…it weakens my body for sometime 
Better to take herbs 
If I [stop] I could have maybe been in danger 
I can go a fortnight without taking them. I’m not sure what 
I’m taking them for 
I doubt his diagnosis 
I don’t want to risk a return to the swelling and pain 
KN10 
KN15 
NG01 
TZ02 
UK05 
 
UK05 
UK06 
 Agency …first two tablets of the day were regular and then not… I 
again collapsed 
It said take 2 twice a day but I didn’t know what that meant 
Not completing the full dosage… caused by… difficulty in 
taking the medicine 
KZ01 
 
UK01 
ZI01 
 Affordance According to my experience, some medicine [makes you] 
develop boils, get sick, get weak, sweat a lot 
I’ve had a [bad] taste after taking drugs, now vomit 
Some people are having problems in taking medicine 
I prefer short dose 
[preferred] through syringe 
I hate medicine… they are bitter 
Large medicine are unfavourable for me 
I prefer the injection 
The medicine itself was reactive… I was afraid of taking it 
Some medicines do emit a pungent smell 
Sick for a whole week… headaches, stomach stuff, the 
pains. I thought not to go through all that 
They feel like there’s too many, and you swallow them 
and it feels like you haven’t… and you wonder how you’re 
going to take the next tablets 
I took one but couldn’t take more because of the nasty 
taste 
KN01 
 
KN03 
KN05 
KN06 
KN07 
KN09 
KN11 
KN13 
NG01 
TZ02 
ZI01 
 
ZM01 
 
 
ZM01 
 Context I think I’m doing the NHS a service by not taking tablets 
Not completing the full dosage… caused by lack of 
monitoring of the sick by family members 
UK05 
ZI01 
 Norms Later on I realised that each and every person can get this 
sick… I [took] medicine openly 
TZ02 
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I don’t want to have any problem coming up because 
I’ve… decided not to take the medicine he’s prescribed 
If I’ve got no pain then I don’t need it preventing 
UK02 
 
UK05 
 
These tables show that interview extracts are present for each of the factors 
putatively identified as being present in each of the subordinate propositions 
identified in Table 7. 
This result aligns with and supports Qualitative Proposition 2. It can said with 
some confidence that the positioning and grouping of the adherence factors 
within the S-D Logic-derived initial process of adherence is reasonable. 
It is now possible to visualise the initial process with this pattern of placement. 
Firstly, the factors in each grouping are displayed in Figure 25 below. Those 
which are patient-related are in red, with medicine-related factors in blue. Context 
is in black text. This figure shows how widespread is the patient’s involvement in 
the process of adherence. While it shows a useful amount of detail, that amount 
may be too much for when rapid analysis in needed. 
 
 
Figure 25: Initial process with groupings broken out 
In order to make the figure more easily assimilable, it is possible to simplify it 
while still retaining its essential characteristics. This is the purpose of Figure 26. 
This will be referred to as the qualitative process of adherence. It retains the basic 
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underlying structure while removing the depictions of the Integrative Framework 
of Value and the service ecosystems since these are encapsulated in A-C value 
assessments and norms respectively. The unnecessary repetitions of agency 
and context are also removed, and norms has been moved to the ex ante A-C 
value assessment, not to take it out of context but to show that norms is important 
throughout the value assessment and value cocreation process. 
The result of this work is a figure which is proposed to permit an enhanced 
understanding of the interactions that happen before, during and after the act of 
adherence. By this visualisation it is possible to see more clearly where each of 
the factors of adherence fits within the process and how the three constructs of 
patient, medicine and context come together to enable adherence. 
 
 
Figure 26: Qualitative process of adherence 
Through this diagram it is made obvious the importance of the patient bringing all 
their resources with those of the medicine and the context in order to cocreate 
value, or to follow the process and so be adherent. This also indicates that many 
of the interactions both between patient and medicine as well as between 
medicine and context can be seen as a reaction to each other. By this is meant 
that, for example, a lack of affordance in the medicine may be made up by patient 
agency or context, or something lacking in the context could potentially be 
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addressed by the medicine or the patient. There are many examples of how these 
interactions might work out. 
11.5 Summary 
An initial discussion focused on descriptive details including interviewee 
demographics. This was followed by an analysis of the two Qualitative 
Propositions. 
The two parts of Qualitative Proposition 1 looked at whether the interview data 
was comprehensive. Proposition 1a considered interview content bottom-up, 
categorising and then condensing categories until a taxonomy of adherence-
related issues was created. This taxonomy demonstrated that all six factors of 
adherence identified from the literature and considered in Proposition 2 were 
indeed present in the interviews. This indicates that interviews and Proposition 
1a are aligned. 
Proposition 1b analysed the interview extracts to determine their coverage of the 
55 causes of non-adherence. It found all but ten of the 55 were present in the 
interviews, and also uncovered 19 new causes not found in the 55 causes. This 
suggests that the interviews align with Proposition 1b. The alignment of interviews 
with both parts of Qualitative Proposition 1 increase confidence that Qualitative 
Proposition 2 is aligned with the interview data. 
Moving to Proposition 2, eight subordinate propositions were created in support 
of its analysis. This analysis suggests that it is aligned with the interviews. 
The visualisation of how the factors of adherence can be positioned within the S-
D Logic-derived process, and how patient, medicine and context can be seen in 
the process, led to the creation of the qualitative process of adherence. 
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12 Qualitative Research Conclusions 
12.1 Introduction 
This chapter provides an overall summary of the research and results, and draws 
conclusions. 
The structure of this chapter is as shown in Figure 27. 
 
Figure 27: Chapter structure 
12.2 Summary of research 
A case-based approach was taken, commencing with qualitative research. Thirty 
semi-structured interviews were conducted over a period of about six months. 
Interviewees were deliberately selected to provide a wide range of experiences 
of medicine consumption in both developed and developing worlds. Interviews 
were transcribed and then analysed using Nivo10 and manual means. 
The analysis was performed as an exploratory exercise to investigate two 
Qualitative Propositions, the first of which was in two parts. The second was to 
explore whether the placement onto the S-D Logic flow of the six adherence-
related factors emerging from the literature was supported in reality rather than 
just theoretically. 
The first proposition investigated the quality of the data emerging from the 
interviews in order to build confidence that Proposition 2 was well aligned with 
the interviews and so had good coverage of the six adherence factors. This was 
done in two ways. Firstly, the interview results were measured for their coverage 
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of the six adherence factors. Secondly, the results were processed to evaluate 
the extent to which they had uncovered the 55 causes of non-adherence. 
12.3 Summary of results 
Qualitative Proposition 1 was intended to give confidence in the quality of data 
coming out of the interviews. The means for so doing was to process the 
transcripts in two ways. The first was to find evidence for all six of the adherence 
factors by bottom-up analysis. This was achieved, showing an alignment with the 
Proposition. The second was to determine the extent of coverage of the 55 
causes in the interviews. This work indicated that all but ten causes had been 
found – these being difficult to identify without face-to-face interviews where the 
interviewer is able to make personal assessments of the interviewees – and also 
discovered 19 new causes. This also suggests good alignment. 
The interviews also aligned with Qualitative Proposition 2. This implies that it is 
indeed possible to position all six of the adherence factors appropriately onto the 
S-D Logic-derived initial view of the process. This gives confidence that the initial 
view is a reasonable depiction of the process of adherence, and has resulted in 
the creation of the qualitative process of adherence. 
12.4 Conclusions 
It seems evident that the qualitative research results have indeed provided a rich 
view of adherence as part of people’s lived lives in a range of environments from 
extreme poverty to relative comfort. The results of analyses for Proposition 1 
indicate that the interviews were of sufficient quality to demonstrate alignment 
with Proposition 2. 
The alignment of Proposition 2 gives confidence that end-to-end adherence on a 
per-opportunity level can be described by the qualitative process. This is a 
potentially significant step forwards in the understanding of the reasons for 
adherence and non-adherence which has not been achieved before using 
expectancy-value theories. 
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Based on the qualitative view of the process of adherence, it may be seen that 
some of the factors can actually be traded off against each other. For example, if 
the affordance of the medicine is perceived by the patient as being inadequate in 
itself to permit adherence to take place they may be able to call on other 
resources from norms, context and agency to overcome such inadequacy. If the 
medicine is bitter then the patient may be able to use their agency to bring sugar 
into context to sweeten it. If it requires food to be eaten at the point of 
consumption and there is none available then support may be obtained from an 
alternative service ecosystem. These simple examples demonstrate the 
potentially complex interactions between adherence factors. 
What the qualitative research has not achieved is a detailed picture of those 
interactions between the six factors in the adherence process. It is possible that 
a more ethnographic approach to the qualitative research may have facilitated 
this. This was the purpose of the quantitative research. It was intended to identify 
moderating effects of the factors against each other. Such a step would require 
a drastically simplified model of interactions and therefore the removal from its S-
D Logic base. 
12.5 Summary 
In this chapter it has been shown that the Qualitative Propositions appear to align 
well with the initial process, and that the interview data is robust. This suggests 
that it is a good model for understanding adherence and so the qualitative 
process of adherence can be built on this. 
The qualitative process was then tested quantitatively. The next chapter 
deconstructs the process in preparation for that quantitative work. 
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13 Developing a Quantitative Process of Adherence 
13.1 Introduction 
This chapter takes the results of the qualitative research and simplifies the 
qualitative process to make it more suitable for testing quantitatively. The result 
is a quantitative process of adherence. 
The structure of this chapter is as in Figure 28. 
 
Figure 28: Chapter structure 
13.2 Initial analysis 
In support of the quantitative research it is now necessary to start from the 
qualitative process in which the adherence factors were placed in order to create 
a process which can be tested. This process will be referred to as the quantitative 
process of adherence. 
The following points about adherence may be made from the qualitative process. 
Firstly, the patient must have sufficient motivation and belief to put time, money 
and effort both into obtaining the medicine at the start of the process and bringing 
the required skills and competencies to bear to consume it. 
Secondly, the affordance of the value proposition must be sufficient to provide 
the required resources into the consumption context. 
Thirdly, the norms need to be favourable to consumption. 
Fourthly, the A-C value ex ante assessment must indicate that, all things 
considered, consuming the medicine is the right thing to do. 
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Fifthly, at the point at which consumption takes place, all the required factors are 
positively aligned and remain so for the duration of the event. 
Sixth and finally, although it does not affect consumption at the point of 
adherence, a favourable assessment must be made of the consumption event 
afterwards if further adherence is to be attempted. This ex post A-C value 
assessment may legitimately be made shortly after the adherence event or at a 
later time, depending on the time it takes for the effects of the medicine to be 
seen. 
By deconstructing the qualitative view of the process of adherence it is possible 
to create a process which can be tested quantitatively. 
13.3 Development of the process 
Clearly, the starting point of the process of adherence is the patient while the 
endpoint is adherence. Without diminishing the importance of the medicine, it 
should be remembered that it is no more than an operand resource in the 
adherence context. 
Considering the six points above it is possible to make the following observations 
based on the learning from the qualitative process. 
Firstly, there are two sets of interacting factors: motivation, beliefs and agency 
one the one hand and affordance, norms and context on the other. 
Secondly, if motivation and belief are sufficient for the patient to obtain the 
medicine and to bring agency to bear, then agency may become the factor 
affecting the patient’s contribution to their adherence. If agency is adequate then 
the medicine’s and the context’s factors come into play. Affordance, norms and 
context could potentially each affect adherence. If they do not completely inhibit 
consumption then it may be assumed that consumption will occur and therefore 
that adherence will be achieved. 
Therefore it is possible to see the three non-patient factors moderating the 
contributions of the three patient factors. 
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The Hypotheses for the quantitative research can now be presented. 
Hypothesis 1: Patient-related factor motivation contributes to adherence 
Hypothesis 2: Patient-related factor beliefs contributes to adherence 
Hypothesis 3: Patient-related factor agency contributes to adherence 
Hypothesis 4: The effect of patient-related factor motivation on adherence 
is moderated by affordance 
Hypothesis 5: The effect of patient-related factor beliefs on adherence is 
moderated by affordance 
Hypothesis 6: The effect of patient-related factor agency on adherence is 
moderated by affordance 
Hypothesis 7: The effect of patient-related factor motivation on adherence 
is moderated by context 
Hypothesis 8: The effect of patient-related factor beliefs on adherence is 
moderated by context 
Hypothesis 9: The effect of patient-related factor agency on adherence is 
moderated by context 
Hypothesis 10: The effect of patient-related factor motivation on 
adherence is moderated by norms 
Hypothesis 11: The effect of patient-related factor beliefs on adherence 
is moderated by norms 
Hypothesis 12: The effect of patient-related factor agency on adherence 
is moderated by norms. 
This may be depicted as in Figure 29. This can form the basis for quantitative 
evaluation. In statistical terms each oval is a latent variable. 
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Figure 29: Quantitative process of adherence 
This is clearly significantly simpler than even the S-D Logic-based qualitative 
process of adherence since none of the factors is placed into the multiple 
positions where they appear to have effects. As a result, this view of the process 
of adherence loses significant detail. Nevertheless it is a process which can be 
statistically tested. 
13.4 Summary 
The qualitative process of adherence has been reviewed. This has been 
deconstructed and a quantitative process created in order to test it statistically. 
Hypotheses 1-12 have been proposed. 
It is now possible to move to the quantitative research. This is the first opportunity 
to test the quantitative process of adherence. 
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14 Quantitative Research Method 
14.1 Introduction 
This chapter describes the development and implementation of the quantitative 
research. The research was the first opportunity to evaluate the qualitative 
process of adherence quantitatively. The initial process emerging from the 
literature review aligned with the Qualitative Propositions, allowing a theoretical 
qualitative adherence process to be derived from it. However, the interview 
approach – mainly at a distance rather than ethnographic – was less successful 
in determining the interactions between the six factors. This understanding would 
provide more confidence that the qualitative process is valid for investigating 
adherence in future work, and also potentially identify survey instruments for the 
future. For these reasons quantitative research was performed. In the absence 
of statistically significant quantitative results it should be emphasised that the 
qualitative process of adherence stands alone, while it may be possible for the 
quantitative process of adherence to be explored in future research. 
The structure of this chapter is shown in Figure 30. 
 
Figure 30: Chapter structure 
14.2 Approach 
The qualitative research consisted of semi-structured interviews to explore the 
Qualitative Propositions in an open-ended way. The results of these interviews 
aligned with the qualitative process of adherence. The opportunity was now taken 
to explore the interactions of the six factors in the qualitative process using a 
quantitative survey. 
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A survey was used as part of the mixed methods case in order to enhance 
triangulation, but to rely on this as the only research instrument would have 
restricted investigation to pre-determined questions rather than permitting the 
flexible approach to questioning that can be part of semi-structured interviews. 
Using a survey as an attempt to quantify the impacts of the various qualitative 
“insights, explanations, and meanings” (Yin 2013) on consumption permitted 
statistical analysis of the interactions between the six factors. The use of a cross-
sectional survey, collecting data at a point in time, can make it possible to identify 
moderators of relationships between variables (Visser et al. 2000). 
The approach to the design and execution of the survey followed the 
recommendations of Walonick (2013) and is shown in Figure 31. 
 
Figure 31: Survey design and execution process (Walonick 2013) 
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14.3 Survey methodology and feasibility 
14.3.1 Questionnaire 
As previously indicated, the main purpose of this exploratory survey was to 
examine the potential interactions between the six adherence factors proposed 
by the quantitative process of adherence (Figure 29). To achieve this it was 
necessary to utilise survey instruments to investigate each of the seven latent 
variables. This implied a complex questionnaire design. In order to maximise the 
validity of the survey results while making the questionnaire as easy to complete 
as practicable, the following seven principles were implemented as 
recommended by Visser et al. (2000), Walonick (2013) and others. 
Firstly, except for the initial questions about the medicine being reported on and 
the final demographic questions, all questions sought a response on a 7-point 
Likert scale. The 7-point scale has been shown to provide the highest levels of 
reliability and validity. 
Secondly, the scale points were all labelled. This can improve data quality. 
Thirdly, some questions had their scales inverted (reversed) in an attempt to 
prevent respondents answering without thought. These questions had their scale 
reinverted before analysis was performed. Table 43 (Appendix C.1) lists all 
questions, and notes with an asterisk those which were inverted. 
Fourthly, questions were grouped by latent variable but then randomised within 
each group. This allows respondents to think about one latent variable at a time 
rather than have to move backwards and forwards between topics. 
Fifthly, all questions were closed rather than open. This simplifies the analysis of 
survey answers. On their own, closed questions do not provide the opportunity to 
obtain the variety of input offered by open questions. However, by including in 
the questionnaire some questions derived directly from the qualitative interviews 
it was felt that this would maximise the range of information gathered. This would 
therefore contribute to the validity of the results. 
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Sixthly, and connected with the fifth, one method of improving face validity of the 
questionnaire is to consult with experts on the questions to be used (for example 
Rattray & Jones 2007; Hinkin et al. 1997). In this case, the qualitative 
interviewees were used as the experts. The reasons for non-adherence which 
they proffered were used either to enrich existing instruments or in some cases 
to replace them. 
Seventh and finally, no questions were used which were obviously ambiguous, 
double-barrelled or contained a double negative. 
14.3.2 Survey invitation and completion 
There are several approaches to gathering survey data. These include: face-to-
face or telephone interviews using structured questions; printed questionnaires; 
and computer or smartphone questionnaires. These are not mutually exclusive, 
and the use of several approaches may make it possible to reach a wider range 
of respondents. 
The approach selected for this survey was primarily to deliver the survey online 
via a web browser or mobile phone, thus allowing respondents to use their 
computer or smartphone for their responses. This permitted data to be gathered 
and stored online and then later to be downloaded for analysis. Some responses 
were gathered through printed questionnaires, with the data entered into the 
online database so that all responses were held online. 
Similarly, there are multiple non-exclusive ways of inviting participation. Postal 
mail, email, SMS messages, social media, newsletters, and word-of-mouth are 
just a few. There are indications that some modes of invitation can work more 
effectively than others in certain circumstances, for example email compared to 
SMS messages (De Bruijne & Wijnant 2014). 
For this survey, the selected means of publicity were social media, newsletters, 
email and word-of-mouth. Relative effectiveness of the methods was not thought 
important since invitations were issued several times on social media in order to 
 131 
  
both remind potential respondents who had already seen the invitation and to 
reach those who had not previously seen it. 
14.4 Development of survey instruments 
The purposes of developing the survey instruments were primarily to explore the 
relationships between the six adherence factors and secondly to identify possible 
instruments for use in future surveys. 
This section considers each instrument in turn. Each instrument contributed to 
one latent variable or construct – the six factors plus adherence itself. They are 
presented alphabetically. Many potentially relevant existing survey instruments 
were explored and assessed before selecting the ones appropriate to the survey. 
In most cases the instrument was augmented with additional questions arising 
from the qualitative research in order to benefit from the insights gathered from 
them. These are labelled “Own” in the “Scale” column of the tables which follow. 
Ultimately a selection of the items was combined into a new survey instrument 
for each construct. 
14.4.1 Adherence (consumption) 
The most popular scale for measuring adherence was created by Morisky et al. 
and is known as the Morisky Medication Adherence Scale (MMAS) (Culig & 
Leppée 2014; Morisky et al. 1986). The 8-question version, MMAS-8, is preferred. 
The questions and the scoring are as in Table 28. 
Although this scale has been used in surveys, it was primarily created for use in 
face-to-face discussions between patient and physician (Culig & Leppée 2014). 
It consists of several types of question which are treated as a single-dimension 
variable. Not surprisingly, papers have reported its validity measured by 
Cronbach alpha (Cronbach 1951) as being as low as 0.60 (for example Zongo et 
al. 2016). 
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Table 28: Questions and scoring for MMAS-8 (Morisky et al. 1986) 
No. Question 
1 Do you sometimes forget to take your pills? 
2 People sometimes miss taking their medications for reasons other than forgetting. 
Thinking over the past two weeks, were there any days when you did not take your 
medicine? 
3 Have you ever cut back or stopped taking your medicine without telling your doctor 
because you felt worse when you took it? 
4 When you travel or leave home, do you sometimes forget to bring along your medicine? 
5 Did you take all your medicine yesterday? 
6 When you feel like your symptoms are under control, do you sometimes stop taking your 
medicine? 
7 Taking medicine every day is a real inconvenience for some people. Do you ever feel 
hassled about sticking to your treatment plan? 
8 How often do you have difficulty remembering to take all your medicine? 
___A. Never/rarely 
___B. Once in a while 
___C. Sometimes 
___D. Usually 
___E. All the time 
 Scoring (number of questions answered “no”) 
0 High Adherence 
1-2 Medium Adherence 
3-8 Low Adherence 
 
As well as its low alpha score, it is apparent that the MMAS-8 scale also only 
assesses a small subset of the very many reasons why patients may not be 
adherent. It looks at patient memory (3 questions), patient non-adherence due to 
feeling worse, patient non-adherence due to feeling better, and patient 
inconvenience. While it has proven to be valuable in clinical practice as a basis 
for face-to-face adherence interventions with patients (Culig & Leppée 2014), it 
is unsuitable for use in a survey which is aiming to understand reasons for non-
adherence caused by a range of factors. 
Instead, a set of four parallel questions was used to assess adherence as a latent 
variable, considering the basic level of consuming medicine. These questions 
were used simply to determine whether adherence was achieved. The other 
questions in the survey then addressed the reasons for non-adherence. 
Therefore, the questions used in the survey to represent adherence are listed in 
Table 29. 
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Table 29: Adherence questions 
No. Scale Question 
1a Own I take my medicine according to the instructions 
1b Own I take my medicine correctly 
1c Own I take my medicine as prescribed 
1d Own I take my medicine as I have been instructed 
 
14.4.2 Affordance 
Affordances arise from the value proposition of the medicine. While in other 
spheres affordances might encourage consumption, the key consideration with 
medicine is that it and its packaging do not inhibit consumption. 
There are some scales in the literature for product adoption which contain some 
relevant questions. For example, Flight et al. (2011) create 15 short scales 
relating to topics such as “Social compatibility”, “Personal compatibility” and 
“Product performance”. However, the 2-4 questions in each of these scales are 
at a very high level. For example, “Product performance” is examined using the 
following 3 questions: 
“1. This product will do what it claims it will do 
“2. This product will perform reliably and consistently 
“3. I am confident that this product will perform as expected”. 
Questions such as these do not explore the detail of the potential issues which 
have been uncovered in interviews. Therefore a set of questions was created by 
reference to insights from the qualitative research interviews (Table 30). 
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Table 30: Affordance questions from interviews 
No. Scale Question 
1a Own There is nothing about the medicine itself which puts me off 
1b Own This medicine’s features do not prevent me taking it 
1c Own The medicine itself gives me no problems taking it 
1d Own I have no problems taking the medicine itself 
2 Own There is something about the medicine’s taste that puts me off 
3 Own There is something about the tablet size of this medicine that stops me taking it 
4 Own There is something about the medicine’s smell that stops me taking it 
5 Own There is something about the form of this medicine that stops me taking it 
6 Own There is something about the duration of course of treatment that stops me 
taking it 
7 Own There is something about the medicine’s packaging that stops me opening and 
taking it 
8 Own I do not take my medicine because I know the bad side-effects it has had on 
others 
9 Own I don’t take this medicine because it is made by a profit-making company 
10 Own I don’t take this medicine because it contains unknown chemicals 
 
14.4.3 Agency 
Alkire (2005) defines agency as the “ability to act on behalf of goals that matter”. 
He goes on to define agency as having four characteristics: 
“…is part of one’s own well-being (intrinsic value), can cause positive 
changes in some dimensions of one’s well-being (instrumental value), can 
create further changes [which] one values (instrumental value), [and] may 
conflict with other dimensions of one’s well-being”. 
The two “instrumental value” characteristics are very well aligned with taking 
medicine, while the fourth characteristic of “conflict” recognises that taking 
medicine may have short-term negative consequences. 
Some scales claim to focus on self-efficacy but are more to do with motivation. 
For example, the MASES (Medication Adherence Self-Efficacy Scale) scale 
(Ogedegbe et al. 2003) includes “[How sure are you that you can take your… 
medicine all of the time] when you do not have symptoms” and “….when you do 
not like the taste”. These questions do not reflect “ability to act” but motivation. 
However the MUSE (Medication Understanding and Use Self-Efficacy) scale 
(Cameron et al. 2010) offers questions from the perspective of agency rather than 
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motivation and can be used in this survey. In addition, questions were developed 
from the qualitative interview and included in the instrument. Table 31 includes 
the MUSE questions and others developed from the interviews. These questions 
commence “It is easy for me to…”, reflecting the focus of agency on the patient’s 
ability to apply their skills and competences. However, “easy” may not be the 
appropriate definition and so this was changed to “I am able to…” in the survey. 
While some of the MUSE questions may be considered less relevant than others, 
the same approach was taken as with other scales: all questions were included 
in the expectation that the unpromising questions would be shown to be so in the 
statistical analysis. 
 
Table 31: Agency questions from MUSE (Cameron et al. 2010) and interviews 
No. Scale Question 
1 MUSE It is easy for me to take my medicine on time 
2 MUSE It is easy for me to remember to take all my medicines 
3 MUSE It is easy for me to set a schedule to take my medicines each day 
4 MUSE It is easy for me to take my medicines every day 
5 MUSE It is easy for me to ask my pharmacist questions about my medicine 
6 MUSE It is easy for me to understand my pharmacist’s instructions for my medicine 
7 MUSE It is easy for me to understand instructions on medicine bottles 
8 MUSE It is easy for me to get all the information I need about my medicine 
9 Own It is easy for me to take my medicine without help 
10 Own It is easy for me to know when to take my medicine 
11 Own It is easy for me to understand why I should take my medicine 
 
14.4.4 Beliefs 
Two scales were compared before settling on the one potentially most practical.  
Firstly, the Beliefs about Medicines Questionnaire (BMQ) (Horne et al. 1999). 
This was derived from a consideration of theories such as the Theory of Planned 
Behaviour (Ajzen 1991; Ajzen 1985) plus empirical research. The resulting 
questionnaire contains questions in two sections labelled “BMQ-General” and 
“BMQ-Specific”. The two lists are contained in Table 32. Each question is rated 
on a 5-item Likert scale ranging from strongly agree to strongly disagree. 
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Table 32: Beliefs about Medicines Questionnaire (BMQ) (Horne et al. 1999) 
No. BMQ-Specific 
1 My health, at present, depends on my medicines 
2 Having to take medicines worries me 
3 My life would be impossible without my medicines 
4 Without my medicines I would be very ill 
5 I sometimes worry about long-term effects of my medicines 
6 My medicines are a mystery to me 
7 My health in the future will depends [sic] on my medicines 
8 My medicines disrupt my life 
9 I sometimes worry about becoming too dependent on my medicines 
10 My medicines protect me from becoming worse 
 BMQ-General 
1 Doctors use too many medicines 
2 People who take medicines should stop their treatment for a while every now and again 
3 Most medicines are addictive 
4 Natural remedies are safer than medicines 
5 Medicines do more harm than good 
6 All medicines are poisons 
7 Doctors place too much trust on medicines 
8 If doctors had more time with patients they would prescribe fewer medicines 
 
These questions cover a range of beliefs and are stated with varying levels of 
definiteness. For example, responding “strongly agree” to questions starting with 
“I sometimes worry…” and “Most medicines…” has a different level of force to 
responding in the same way to “My health depends on…” or “My life would be 
impossible without…”. Even though internal consistency and discriminant validity 
were reported by its creators as being satisfactory, their robustness is 
questionable in this research context. This instrument was therefore passed over. 
Secondly, the Drug Attitude Inventory (DAI). This was created by Kane et al. 
(2008). The DAI-30 scale consists of 30 questions aiming to understand attitudes 
towards medicine. Attitudes and beliefs are considered to be synonymous in this 
context. This instrument was selected (Table 33). 
Although some of the questions may not precisely relate to ex ante beliefs and 
the instrument as a whole is too long, all questions were retained and it was 
augmented by outputs from the qualitative interviews in the expectation that 
subsequent statistical analysis would resolve the issue. The full list is in Table 33. 
In the survey the DAI-30 questions were reworded to focus on the particular 
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medicine under consideration, while to make it explicit that they are to do with 
beliefs about the medicine they were prefixed with “I believe [that]…”. 
Four of the beliefs questions relate to norms rather than beliefs. These are in 
italics in Table 33 and were separated out to form the norms instrument when 
processing the results. 
 
Table 33: Belief questions from DAI-30 (Kane et al. 2008) and interviews 
No. Scale Question 
1 DAI-30 I don't need to take medication once I feel better 
2 DAI-30 For me, the good things about medication outweigh the bad 
3 DAI-30 I feel strange, "doped up", on medication 
4 DAI-30 Even when I am not in hospital I need medication regularly 
5 DAI-30 If I take medication, it's only because of pressure from other people 
6 DAI-30 I am more aware of what I am doing, of what is going on around me, when I 
am on medication 
7 DAI-30 Taking medications will do me no harm 
8 DAI-30 I take medications of my own free choice 
9 DAI-30 Medications make me feel more relaxed 
10 DAI-30 I am no different on or off medication 
11 DAI-30 The unpleasant effects of medication are always present 
12 DAI-30 Medication makes me feel tired and sluggish 
13 DAI-30 I take medication only when I feel ill 
14 DAI-30 Medications are slow-acting poisons 
15 DAI-30 I get along better with people when I am on medication 
16 DAI-30 I can't concentrate on anything when I am taking medication 
17 DAI-30 I know better than the doctors when to stop taking medication 
18 DAI-30 I feel more normal on medication 
19 DAI-30 I would rather be ill than taking medication 
20 DAI-30 It is unnatural for my mind and body to be controlled by medications 
21 DAI-30 My thoughts are clearer on medication 
22 DAI-30 I should keep taking medication even if I feel well 
23 DAI-30 Taking medication will prevent me from having a breakdown 
24 DAI-30 It is up to the doctor to decide when I should stop taking medication 
25 DAI-30 Things that I could do easily are much more difficult when I am on medication 
26 DAI-30 I am happier and feel better when I am taking medications 
27 DAI-30 I am given medication to control behaviour that other people (not myself) don't 
like 
28 DAI-30 I can't relax on medication 
29 DAI-30 I am in better control of myself when taking medication 
30 DAI-30 By staying on medications I can prevent myself getting sick 
31 Own I have to take this medicine because my religious faith has not cured me 
32 Own It is not good to be seen taking this medicine 
33 Own Natural remedies are safer for me to take than this medicine 
34 Own I am getting better because of taking this medicine 
35 Own I can get better in other ways than taking this medicine 
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14.4.5 Context 
S-D Logic shows that the value proposition of the medicine only permits value 
cocreation when appropriate additional value propositions are also present. 
These might include water, food, containers, or even appropriate assistance. 
Adherence studies tend to assume that these are generally available, since a 
developed-world mindset would never anticipate them to be missing. This can 
mean that processes by which they come into context may be overlooked in such 
studies. However, it is clear from qualitative interviews that this assumption is not 
always valid and that context questions should be included in the survey. These 
questions were generated from interviews and are listed in Table 34. In the survey 
these questions were prefixed with “In my situation…” to emphasise the question 
was about context and not the medicine itself (affordance) or the patient’s 
capabilities (agency). 
 
Table 34: Context questions from interviews 
No. Scale Question 
1a Own I have everything I need to take my medicine 
1b Own There is nothing missing at the time I need to take my medicine 
1c Own When the time comes to take my medicine I have all the things I need 
1d Own I have everything available to me to allow me to take my medicine 
2 Own At the time I take my medicine I have the food I need to allow me to do so 
3 Own At the time I take my medicine I have the water I need to allow me to do so 
4 Own At the time I take my medicine I have the utensils (spoon, syringe, etc) I need to 
allow me to do so 
5 Own At the time I take my medicine I have the help I need to allow me to do so 
6 Own At the time I take my medicine I have the containers (cup, measuring jug, etc) I 
need to allow me to do so 
7 Own I do not take my medicine because of the stigma attached to it or to my illness 
 
14.4.6 Motivation 
Ryan & Deci (2000) state that motivation may be both intrinsic (“for its inherent 
satisfactions”) and extrinsic (“in order to attain some separable outcome”). They 
define four dimensions of motivation: “external regulation”, “introjection”, 
“identification” and “integration”. As it has been indicated earlier, there may be 
occasions when medicine is consumed for its intrinsic “inherent satisfactions” but 
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this is likely to be an unusual event. The focus is therefore on the four dimensions 
of extrinsic motivation as listed in Table 35. 
Each of these can be assessed with appropriate questions. A comprehensive 
approach to looking at each of these dimensions can be found in a paper by 
Pelletier et al. (1997). It assesses motivation for therapy using what the authors 
refer to as the “Client Motivation for Therapy Scale” (CMOTS). The authors found 
their questions for each dimension to be internally consistent and with good 
construct validity, while the results when moving up from “external” to “integrated” 
were positively correlated with increasing effectiveness of (and by implication 
adherence to) therapy. Therefore the more a respondent’s “centre of gravity” of 
answers lie in the higher dimensions, the more motivated they are. This is 
valuable for assessing a respondent’s motivation for being adherent to medicine 
prescriptions. 
 
Table 35: The four levels of extrinsic motivation (Ryan & Deci 2000) 
Level of extrinsic 
motivation 
Definition 
External “to satisfy an external demand… externally regulated” 
Introjected “feeling of pressure in order to avoid guilt or anxiety” 
Identification “identified with the personal importance of a behaviour… accepted its 
regulation as his or her own” 
Integrated “when identified regulations have been fully assimilated… into 
congruence with one’s other values and needs” 
 
Although there are many questions in this instrument, the same approach was 
taken and all questions retained. Some minor wording adjustments were made 
such that they focused on medicine rather than therapy. The original CMOTS 
questions are in Table 36, and were reworded to refer to medicine for the 
survey. 
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Table 36: Motivation questions from CMOTS (Pelletier et al. 1997) 
Dimension Question 
External Because other people think that it's a good idea for me to be in therapy 
 Because my friends think I should be in therapy 
 Because I don't want to upset people close to me who want me to be in therapy 
 To satisfy people close to me who want me to get help for my current situation 
Introjected Because I would feel guilty if I were not doing anything about my problem 
 Because I would feel bad about myself if I didn't continue my therapy 
 Because I should have a better understanding of myself 
 Because it is important for clients to remain in therapy until it's finished 
Identification Because I would like to make changes to my current situation 
 Because I believe that eventually it will allow me to feel better 
 Because I believe that therapy will allow me to deal with things better 
 Because I believe it's a good thing to do to find solutions to my problem 
Integrated Because through therapy I've come to see a way that I can continue to 
approach different aspects of my life 
 Because through therapy I feel that I can now take responsibility for making 
changes in my life 
 Because I feel that changes that are taking place through therapy are 
becoming part of me 
 Because I value the way therapy allows me to make changes in my life 
 
14.4.7 Norms 
As noted in the section above, some of the beliefs questions relate to norms. The 
norms questions in the belief table are extracted and repeated here in Table 37 
together with the numbering from that table for ease of reference. 
 
Table 37: Norms questions extracted from the list in the beliefs table 
No. Scale Question 
5 DAI-30 If I take medication, it's only because of pressure from other people 
27 DAI-30 I am given medication to control behaviour that other people (not myself) don't 
like 
31 Own I have to take this medicine because my religious faith has not cured me 
32 Own It is not good to be seen taking this medicine 
 
14.4.8 Finalising the questionnaire 
As a result of the preceding subsections it was possible to finalise the list of 
survey questions. These are listed in Table 43 (Appendix C.1). It will be seen that 
there were approximately 100 questions. This is considered to be an acceptable 
length for survey methods such as paper-based questionnaires, but may be too 
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long for use online where surveys should take no longer than 15 minutes (de 
Leeuw et al. 2008). 
14.5 Sample selection 
Inappropriate respondent selection is a potential source of bias in a survey. There 
are two general approaches to selection: probability and non-probability (Visser 
et al. 2000). 
Probability sampling refers to random selection of respondents using methods 
such as simple, systematic, stratified and cluster. All such methods are 
susceptible to sampling errors when the sampled population does not fully reflect 
the nature of the overall population. The greater the divergence, the larger the 
coverage error. However, these methods are more likely to achieve a 
representative sample of the population than non-probability samples. 
Non-probability sampling refers to selection of respondents using methods such 
as haphazard (convenience), snowball, purposive, and quota. The limitations of 
such methods are recognised in the warnings which are voiced about drawing 
conclusions about a population on the basis of likely non-representative samples 
(de Leeuw et al. 2008; Visser et al. 2000). 
Respondents were recruited via a combination of methods. The main method 
was via the social media of Facebook, Twitter and WeChat. Other methods 
included a departmental postgraduate newsletter. Some respondents invited their 
friends and family to participate. While this may have achieved some probability 
sampling, the majority was likely to have been convenience and snowball 
sampling. 
14.6 Survey process 
The survey was presented online using Qualtrics (warwickwmg.eu.qualtrics.com) 
software. This is the preferred survey tool for the WMG department of the 
University of Warwick. However, coverage errors are hard to assess with online 
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surveys, meaning that there is uncertainty over whether respondents can ever be 
representative of the population. 
All those surveyed confirmed their willingness to participate as they commenced 
the survey. 
14.6.1 Pilot test and instrument revision 
The pilot test provides the opportunity to assess the survey before it is launched. 
There are essentially two non-exclusive ways to achieve this. Each uses a small 
number of respondents recruited for the task. 
The first is simply to obtain feedback. This is sometimes called the conventional 
approach  (Visser et al. 2000). Questions which are problematic, such as being 
badly worded, confusing, or with a high rate of non-response, can be corrected 
or removed. 
The second is to analyse the results statistically. It is recommended that the same 
approach to statistical analysis be applied to the pilot results as will be used for 
the final results (Rattray & Jones 2007). This permits analysis of internal and 
external validity, Cronbach alpha assessment for each latent variable, Principal 
Component analysis, and so on. By these means, and applied iteratively where 
appropriate, the items for each construct are refined until only those which 
significantly represent each construct remain. 
A validation version of the survey requesting feedback was publicised using 
Facebook and personal emails, and 19 respondents completed the survey. The 
first approach was taken, and feedback from the pilot led to minor wording 
changes to two questions. 
14.6.2 Full survey 
The final version was publicised through Facebook, Twitter, WeChat, University 
of Warwick newsletters and postgraduate communications. Several follow-up 
communications were sent out to prompt greater participation. 
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Data collection ran for a period of approximately four months, with responses 
recorded from 1st July to 26th October 2016. 
14.7 Analysis process 
Each of the latent variables was defined by the set or a subset of survey questions 
(items) making up an instrument. As can be seen from Table 43 in Appendix C.1, 
each question was given a variable name and a number. 
As a result of the qualitative research determining that developing and developed 
world adherence issues were substantially similar, answers from the both worlds 
were processed together. 
All questions with inverted Likert scales had their answers re-inverted before 
analysis. The software package Stata v14 was used for the analysis. 
Processing was as follows. 
Step 1. The responses were downloaded from the Qualtrics survey management 
tool. The data was then cleansed to remove all responses where there were 
missing answers to questions. This was so that no data had to be interpolated by 
Stata v14 to infill missing answers. This left only fully completed responses. 
Step 2. Questions which were coded on an inverted Likert scale were re-inverted. 
A descriptive analysis was then performed for each instrument using the 
summarize command. 
Step 3. Items were selected which best represented each instrument in order to 
create a latent variable from them. The factor command was used on each 
instrument in turn, with the options pcf and factors(1) to obtain one Principal 
Component. Because only one factor was selected there was no need to check 
for discriminant validity. Then the rotate command was used for each instrument, 
with the option orthogonal on the assumption that factors were not correlated. 
This was done in order to identify the items which most strongly contributed to 
the first Principal Component. The same commands were then used iteratively 
on the items selected, eliminating those not contributing strongly, until there was 
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a group of items each with a contribution to the first factor of more than 0.7. This 
figure shows that the items demonstrated acceptable convergent validity. The 
proportion contribution of each to that Principal Component was then captured. 
The alpha command was then run against these items to determine the reliability 
of the scale. Finally, a latent variable was created from the selected items of each 
instrument by using the generate command to create the mean of the item scores. 
Step 4. A correlation analysis for the seven latent variables was performed using 
the pwcorr pairwise correlation command with options obs and sig. This was to 
discover whether there were any statistically significant correlations between 
them. A correlation matrix was created from this result.  
Step 5. A moderation analysis was performed. The three medicine and context 
variables were tested for their moderating effects on the three patient-
representing latent variables. These tests align with the latent variables in Figure 
29 and represent hypotheses 4-12. If moderating effects were present then the 
interaction term would be significant. Through these tests, evaluation of the 
hypotheses 1-3 was included since if there were low or no moderating effects 
then the direct effect would be shown if the direct relationship were to be 
significant; however, it could be argued that even though there was a lack of 
significant relationships there was perhaps some evidence of a contribution. 
14.8 Summary 
The quantitative survey was a first step towards testing the qualitative process of 
adherence (Figure 26) through its deconstruction into the quantitative process 
(Figure 29), and also for investigating potential new instruments for measuring 
factors affecting adherence. The questions in the survey were primarily derived 
from existing survey instruments with the addition of questions created from 
answers provided in the qualitative interviews. Recommended processes were 
followed for design, development, validation, production and analysis of the 
survey. In particular, a careful step-by-step procedure was followed for statistical 
analysis.  
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15 Quantitative Research Results and Analysis 
15.1 Introduction 
This chapter covers the results and analysis of the quantitative survey. Results 
begin with the selection of items for each latent variable then proceed with a 
correlation matrix of those variables. Moderation analysis then follows. 
The structure of this chapter is as in Figure 32. 
 
Figure 32: Chapter structure 
15.2 Five steps of results and analysis 
This section records the results obtained from the quantitative research and 
analyses them. The process that was followed is documented in the previous 
chapter. 
15.2.1 Step 1: Download and initial analysis 
Survey data was downloaded from the Qualtrics survey management tool into a 
spreadsheet. A total of 192 surveys was recorded. 
Upon investigation it was discovered that the majority of respondents had 
commenced the survey but had not completed it. Some had stopped towards the 
end but many had stopped much earlier. 
Removing the incomplete responses resulted in a total of 49 valid respondents. 
15.2.2 Step 2: Descriptive analysis for each instrument 
Each question in Table 43 in Appendix C.1 which is noted as “inverted” was re-
inverted such that the high score indicated the best result for adherence. For 
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example, question “Belief35” makes the statement, “I believe that I can get better 
in other ways than taking this medicine” with a range of “Strongly Disagree” (1) 
to “Strongly Agree” (7). However, so that higher scores gave most positive results 
for adherence, the scores were re-inverted so that it effectively was rated from 
“Strongly Agree” (1) to “Strongly Disagree” (7). 
The results of the summarize commands for each instrument are recorded in 
Appendix C.2. 
One notable feature of the results is that almost every question shows a range of 
scores from 1 to 7. This results in high standard deviations. The reason for this is 
hard to determine. It may be because the wide range of views represents a wide-
ranging experience of medicine consumption. It is also possible that it originates 
from a failure to understand the questions or a lack of interest in the survey 
leading to multiple selections of the same score for multiple questions. There is 
some evidence of the latter. 
15.2.3 Step 3: Selection of representative items 
This process iterated the factor and rotate commands, then calculated the level 
of convergent validity with Cronbach’s alpha by using the alpha command. Only 
the first Principal Component was extracted because of the lack of valid 
responses. 
The results of the final iteration are shown in each figure in this section, together 
with Cronbach’s alpha coefficient. The section provides a table summarising the 
information. Details for each latent variable follow. 
Suitable statistical processes were applied to analysing the data. However it 
should be noted that, since the number of completed survey responses was 
inadequate for statistically valid results to be obtained, no conclusions can be 
drawn from the quantitative research. As part of this it should be recognised that 
the extraction of items satisfactorily loading the first Principal Component is not 
statistically supported. 
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The Adhere(nce) latent variable reflects respondents’ level of adherence to 
instructions. Four items made up this instrument. 
All four Adhere items loaded factor 1 at 0.7 or above. They were all taken as the 
first Principal Component representing adherence. Cronbach’s alpha was good 
at 0.76. The proportion of variance explained was 0.58. 
 
. factor Adhere1a Adhere1b Adhere1c Adhere1d, pcf factors(1) 
 
. rotate, orthogonal 
 
Factor analysis/correlation                      Number of obs    =         49 
    Method: principal-component factors          Retained factors =          1 
    Rotation: orthogonal varimax (Kaiser off)    Number of params =          4 
 
    -------------------------------------------------------------------------- 
         Factor  |     Variance   Difference        Proportion   Cumulative 
    -------------+------------------------------------------------------------ 
        Factor1  |      2.33651            .            0.5841       0.5841 
    -------------------------------------------------------------------------- 
    LR test: independent vs. saturated:  chi2(6)  =   51.45 Prob>chi2 = 0.0000 
 
Rotated factor loadings (pattern matrix) and unique variances 
 
   --------------------------------------- 
        Variable |  Factor1 |   Uniqueness  
    -------------+----------+-------------- 
        Adhere1a |   0.7003 |      0.5096   
        Adhere1b |   0.7904 |      0.3752   
        Adhere1c |   0.7866 |      0.3812   
        Adhere1d |   0.7762 |      0.3975   
    --------------------------------------- 
 
. alpha Adhere1a Adhere1b Adhere1c Adhere1d 
 
Test scale = mean(unstandardized items) 
 
Average interitem covariance:     .6570295 
Number of items in the scale:            4 
Scale reliability coefficient:      0.7587 
Figure 33: Final selection of items for Adhere(nce) latent variable 
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The Aff(ordance) latent variable reflects the qualities which the medicine brings 
to the consumption context. 
Five out of the 13 Aff items loaded factor 1 at 0.7 or above. These were taken as 
the first Principal Component representing affordance. Cronbach’s alpha was 
high at 0.87. The proportion of variance explained was 0.66. 
The items which load the Principal Component most strongly form a logical group 
of the questions. Aff1c is to do with problems taking medicine. Aff2, Aff3, Aff4 and 
Aff5 relate directly to reasons why the medicine is not easy to consume. 
Therefore the first Principal Component represents this. 
 
. factor Aff1c Aff2 Aff3 Aff4 Aff5, pcf factors(1) 
 
. rotate, orthogonal 
 
Factor analysis/correlation                      Number of obs    =         49 
    Method: principal-component factors          Retained factors =          1 
    Rotation: orthogonal varimax (Kaiser off)    Number of params =          5 
 
    -------------------------------------------------------------------------- 
         Factor  |     Variance   Difference        Proportion   Cumulative 
    -------------+------------------------------------------------------------ 
        Factor1  |      3.31572            .            0.6631       0.6631 
    -------------------------------------------------------------------------- 
    LR test: independent vs. saturated:  chi2(10) =  123.29 Prob>chi2 = 0.0000 
 
Rotated factor loadings (pattern matrix) and unique variances 
 
    --------------------------------------- 
        Variable |  Factor1 |   Uniqueness  
    -------------+----------+-------------- 
           Aff1c |   0.7184 |      0.4840   
            Aff2 |   0.8116 |      0.3413   
            Aff3 |   0.8406 |      0.2933   
            Aff4 |   0.8343 |      0.3039   
            Aff5 |   0.8592 |      0.2618   
    --------------------------------------- 
 
. alpha Aff1c Aff2 Aff3 Aff4 Aff5 
 
Test scale = mean(unstandardized items) 
 
Average interitem covariance:     2.029365 
Number of items in the scale:            5 
Scale reliability coefficient:      0.8710 
Figure 34: Final selection of items for Aff(ordance) latent variable 
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The Agency latent variable explains the patient’s resources which they bring to 
consuming the medicine. 
Four out of the 11 Agency items loaded factor 1 at 0.7 or above. These were 
taken as the first Principal Component representing agency. Cronbach’s alpha 
was good at 0.79. The proportion of variance explained was 0.61. 
The four items are aligned in the Agency items. They all relate to respondents’ 
ability to consume their medicine at the right time in the right way. 
 
. factor Agency1 Agency2 Agency8 Agency10, pcf factors(1) 
 
. rotate, orthogonal 
 
Factor analysis/correlation                      Number of obs    =         49 
    Method: principal-component factors          Retained factors =          1 
    Rotation: orthogonal varimax (Kaiser off)    Number of params =          4 
 
    -------------------------------------------------------------------------- 
         Factor  |     Variance   Difference        Proportion   Cumulative 
    -------------+------------------------------------------------------------ 
        Factor1  |      2.44275            .            0.6107       0.6107 
    -------------------------------------------------------------------------- 
    LR test: independent vs. saturated:  chi2(6)  =   55.17 Prob>chi2 = 0.0000 
 
Rotated factor loadings (pattern matrix) and unique variances 
 
    --------------------------------------- 
        Variable |  Factor1 |   Uniqueness  
    -------------+----------+-------------- 
         Agency1 |   0.8630 |      0.2552   
         Agency2 |   0.7508 |      0.4362   
         Agency8 |   0.7589 |      0.4241   
        Agency10 |   0.7472 |      0.4417   
    --------------------------------------- 
 
. alpha Agency1 Agency2 Agency8 Agency10 
 
Test scale = mean(unstandardized items) 
 
Average interitem covariance:      1.21875 
Number of items in the scale:            4 
Scale reliability coefficient:      0.7859 
Figure 35: Final selection of items for Agency latent variable 
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The Belief latent variable relates to the patient’s beliefs about themselves and 
their medicines. 
Four out of the 31 Belief items loaded factor 1 at 0.7 or above. These were taken 
as the first Principal Component representing belief. Cronbach’s alpha was good 
at 0.78. The proportion of variance explained was 0.61. 
These four items form a group which refer to qualities of the medicine. These 
beliefs are therefore directly related to the decision on whether to consume the 
medicine. 
 
. factor Belief3 Belief14 Belief25 Belief28, pcf factors(1) 
 
. rotate, orthogonal 
 
Factor analysis/correlation                      Number of obs    =         49 
    Method: principal-component factors          Retained factors =          1 
    Rotation: orthogonal varimax (Kaiser off)    Number of params =          4 
 
    -------------------------------------------------------------------------- 
         Factor  |     Variance   Difference        Proportion   Cumulative 
    -------------+------------------------------------------------------------ 
        Factor1  |      2.42067            .            0.6052       0.6052 
    -------------------------------------------------------------------------- 
    LR test: independent vs. saturated:  chi2(6)  =   51.52 Prob>chi2 = 0.0000 
 
Rotated factor loadings (pattern matrix) and unique variances 
 
    --------------------------------------- 
        Variable |  Factor1 |   Uniqueness  
    -------------+----------+-------------- 
         Belief3 |   0.8081 |      0.3469   
        Belief14 |   0.7565 |      0.4276   
        Belief25 |   0.7837 |      0.3858   
        Belief28 |   0.7622 |      0.4190   
    --------------------------------------- 
 
. alpha Belief3 Belief14 Belief25 Belief28 
 
Test scale = mean(unstandardized items) 
 
Average interitem covariance:     1.789966 
Number of items in the scale:            4 
Scale reliability coefficient:      0.7817 
Figure 36: Final selection of items for Belief latent variable 
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The Con(text) variable is to do with the context in which the patient consumes 
their medicine. 
Four out of the ten Con items loaded factor 1 at around 0.7 or above. These were 
taken as the first Principal Component representing context. Cronbach’s alpha 
was good at 0.78. The proportion of variance explained was 0.61. 
The items selected relate directly to the patient having the contextual resources 
required to consume their medicine. 
 
. factor Con1c Con1d Con2 Con3, pcf factor(1) 
 
. rotate, orthogonal 
 
Factor analysis/correlation                      Number of obs    =         49 
    Method: principal-component factors          Retained factors =          1 
    Rotation: orthogonal varimax (Kaiser off)    Number of params =          4 
 
    -------------------------------------------------------------------------- 
         Factor  |     Variance   Difference        Proportion   Cumulative 
    -------------+------------------------------------------------------------ 
        Factor1  |      2.42453            .            0.6061       0.6061 
    -------------------------------------------------------------------------- 
    LR test: independent vs. saturated:  chi2(6)  =   54.13 Prob>chi2 = 0.0000 
 
Rotated factor loadings (pattern matrix) and unique variances 
 
    --------------------------------------- 
        Variable |  Factor1 |   Uniqueness  
    -------------+----------+-------------- 
           Con1c |   0.6913 |      0.5221   
           Con1d |   0.8673 |      0.2478   
            Con2 |   0.7411 |      0.4508   
            Con3 |   0.8032 |      0.3548   
    --------------------------------------- 
 
. alpha Con1c Con1d Con2 Con3 
 
Test scale = mean(unstandardized items) 
 
Average interitem covariance:     1.767432 
Number of items in the scale:            4 
Scale reliability coefficient:      0.7754 
Figure 37: Final selection of items for Con(text) latent variable 
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The Mot(ivation) variable relates to the patient’s motivation to consume the 
medicine. 
Four out of the 16 Mot items loaded factor 1 at 0.7 or above. These were taken 
as the first Principal Component representing motivation. Cronbach’s alpha was 
high at 0.81. The proportion of variance explained was 0.64. 
This group of four items reflect a strong level of motivation since they are very 
high up the scale at the “Identification” (one question) and “Integrated” (three 
questions) levels (see Table 35). This is therefore a sensible grouping of items 
into a latent variable. 
 
. factor Mot11 Mot13 Mot15 Mot16, pcf factors(1) 
 
. rotate, orthogonal 
 
Factor analysis/correlation                      Number of obs    =         49 
    Method: principal-component factors          Retained factors =          1 
    Rotation: orthogonal varimax (Kaiser off)    Number of params =          4 
 
    -------------------------------------------------------------------------- 
         Factor  |     Variance   Difference        Proportion   Cumulative 
    -------------+------------------------------------------------------------ 
        Factor1  |      2.56899            .            0.6422       0.6422 
    -------------------------------------------------------------------------- 
    LR test: independent vs. saturated:  chi2(6)  =   65.92 Prob>chi2 = 0.0000 
 
Rotated factor loadings (pattern matrix) and unique variances 
 
    --------------------------------------- 
        Variable |  Factor1 |   Uniqueness  
    -------------+----------+-------------- 
           Mot11 |   0.7229 |      0.4775   
           Mot13 |   0.8009 |      0.3585   
           Mot15 |   0.8644 |      0.2529   
           Mot16 |   0.8111 |      0.3422   
    --------------------------------------- 
 
Factor rotation matrix 
 
    ----------------------- 
                 | Factor1  
    -------------+--------- 
         Factor1 |  1.0000  
    ----------------------- 
 
  
. alpha Mot11 Mot13 Mot15 Mot16 
 
Test scale = mean(unstandardized items) 
 
Average interitem covariance:     2.648597 
Number of items in the scale:            4 
Scale reliability coefficient:      0.8103 
Figure 38: Final selection of items for Mot(ivation) latent variable 
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Norms relates to the service ecosystems in which the patient is located, and the 
rules and support obtained from them. 
Three out of the four Norm items loaded factor 1 at 0.7 or above. These were 
taken as the first Principal Component representing norms. Cronbach’s alpha 
was low at 0.65 but this is a new instrument. The proportion of variance explained 
was 0.60. 
This group of three items reflect a coherent view of norms which clearly relate to 
others’ perception of the patient. 
 
. factor Belief5 Belief31 Belief32, pcf factors(1) 
 
. rotate, orthogonal 
 
Factor analysis/correlation                      Number of obs    =         49 
    Method: principal-component factors          Retained factors =          1 
    Rotation: orthogonal varimax (Kaiser off)    Number of params =          3 
 
    -------------------------------------------------------------------------- 
         Factor  |     Variance   Difference        Proportion   Cumulative 
    -------------+------------------------------------------------------------ 
        Factor1  |      1.78478            .            0.5949       0.5949 
    -------------------------------------------------------------------------- 
    LR test: independent vs. saturated:  chi2(3)  =   19.86 Prob>chi2 = 0.0002 
 
Rotated factor loadings (pattern matrix) and unique variances 
 
    --------------------------------------- 
        Variable |  Factor1 |   Uniqueness  
    -------------+----------+-------------- 
         Belief5 |   0.7932 |      0.3709   
        Belief31 |   0.7511 |      0.4359   
        Belief32 |   0.7691 |      0.4084   
    --------------------------------------- 
 
. alpha Belief5 Belief31 Belief32 
 
Test scale = mean(unstandardized items) 
 
Average interitem covariance:     1.056548 
Number of items in the scale:            3 
Scale reliability coefficient:      0.6520 
Figure 39: Final selection of items for Norm latent variable 
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Based on the latent variable creation process above, it is now possible to display 
them in tabular form. 
 
Table 38: Table of latent variables 
Latent variable Question Factor loading Variance 
explained 
Cronbach’s 
alpha 
Adhere(nce) Adhere1a 0.70 0.58 0.76 
 Adhere1b 0.79   
 Adhere1c 0.79   
 Adhere1c 0.78   
Aff(ordance) Aff1c 0.72 0.66 0.87 
 Aff2 0.81   
 Aff3 0.84   
 Aff4 0.83   
 Aff5 0.86   
Agency Agency1 0.86 0.61 0.79 
 Agency2 0.75   
 Agency8 0.76   
 Agency10 0.75   
Belief Belief3 0.81 0.61 0.78 
 Belief14 0.76   
 Belief25 0.78   
 Belief28 0.76   
Con(text) Con1c 0.69 0.61 0.78 
 Con1d 0.87   
 Con2 0.74   
 Con3 0.80   
Mot(ivation) Mot11 0.72 0.64 0.81 
 Mot13 0.80   
 Mot15 0.86   
 Mot16 0.81   
Norm Belief5 0.79 0.60 0.65 
 Belief31 0.75   
 Belief32 0.77   
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15.2.4 Step 4: Principal Component correlation matrix 
The next step in statistical analysis was to create a correlation matrix of the eight 
first-level latent variables. This is shown in Figure 40. 
 
. pwcorr Adhere Aff Agency Belief Con Norm Mot, obs sig 
 
             |   Adhere      Aff   Agency   Belief      Con     Norm      Mot 
-------------+--------------------------------------------------------------- 
      Adhere |   1.0000  
             | 
             |       49 
             | 
         Aff |   0.2093   1.0000  
             |   0.1490 
             |       49       49 
             | 
      Agency |   0.4944   0.4413   1.0000  
             |   0.0003   0.0015 
             |       49       49       49 
             | 
      Belief |  -0.0665  -0.1070  -0.1347   1.0000  
             |   0.6497   0.4641   0.3561 
             |       49       49       49       49 
             | 
         Con |   0.1165   0.2452   0.4299  -0.3233   1.0000  
             |   0.4254   0.0895   0.0021   0.0235 
             |       49       49       49       49       49 
             | 
        Norm |  -0.0798  -0.1610  -0.0070   0.4585  -0.1688   1.0000  
             |   0.5859   0.2692   0.9617   0.0009   0.2463 
             |       49       49       49       49       49       49 
             | 
         Mot |   0.0102   0.0375   0.0423  -0.0813  -0.0003  -0.1063   1.0000  
             |   0.9448   0.7979   0.7730   0.5785   0.9984   0.4674 
             |       49       49       49       49       49       49       49 
             | 
Figure 40: Correlation matrix for the seven first-level latent variables 
 
This matrix shows statistically significant correlations between Adhere(nce) and 
Agency, between Aff(ordance) and Agency, between Norm and Belief, between 
Con(text) and Agency, and between Con(text) and Belief. These are highlighted 
in bold text. However, it must be reiterated that any such relationship is not 
statistically supported and is therefore likely to be spurious. 
Although no correlations are strong, any greater than 0.3 may indicate a possible 
regression result. However, the lack of a statistically significant relationship 
between latent variables does not necessarily mean that those variables are not 
involved in any relationships. There may be moderating relationship in which they 
play a part. This was examined next. 
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15.2.5 Step 5: Moderation analysis 
This step tested for any moderating effects of the three non-patient variables on 
the three patient variables. The interaction term was in each case created by 
multiplying together the independent and putative moderation terms. 
In summary, there were no statistically significant moderating effects between 
any of the moderating variables and the relationship of the independent variables 
to Adhere(nce). This means that none of the hypotheses 4-12 were found to be 
supported. In addition, there were no significant relationships found between the 
independent variables and Adhere(nce). This means that none of the hypotheses 
1-3 were found to be supported. 
 
. regress Adhere Aff Mot AffXMot 
 
      Source |       SS           df       MS      Number of obs   =        49 
-------------+----------------------------------   F(3, 45)        =      0.97 
       Model |  2.51425967         3  .838086555   Prob > F        =    0.4172 
    Residual |  39.0520669        45  .867823708   R-squared       =    0.0605 
-------------+----------------------------------   Adj R-squared   =   -0.0021 
       Total |  41.5663265        48  .865965136   Root MSE        =    .93157 
 
------------------------------------------------------------------------------ 
      Adhere |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         Aff |   -.031653   .1912674    -0.17   0.869    -.4168853    .3535793 
         Mot |  -.1891048    .225437    -0.84   0.406    -.6431582    .2649485 
     AffXMot |    .038963   .0435711     0.89   0.376    -.0487938    .1267198 
       _cons |   6.095623   .9748666     6.25   0.000     4.132141    8.059106 
------------------------------------------------------------------------------ 
Figure 41: Regression of Aff(ordance) on Mot(ivation) 
 
. regress Adhere Aff Belief AffXBelief 
 
      Source |       SS           df       MS      Number of obs   =        49 
-------------+----------------------------------   F(3, 45)        =      1.93 
       Model |  4.73152456         3  1.57717485   Prob > F        =    0.1388 
    Residual |   36.834802        45  .818551155   R-squared       =    0.1138 
-------------+----------------------------------   Adj R-squared   =    0.0548 
       Total |  41.5663265        48  .865965136   Root MSE        =    .90474 
 
------------------------------------------------------------------------------ 
      Adhere |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         Aff |   -.232689   .2063445    -1.13   0.265     -.648288    .1829101 
      Belief |  -.4837987     .26034    -1.86   0.070     -1.00815     .040553 
  AffXBelief |   .0977215   .0525599     1.86   0.070    -.0081397    .2035826 
       _cons |   7.132278   1.045872     6.82   0.000     5.025785    9.238772 
------------------------------------------------------------------------------ 
Figure 42: Regression of Aff(ordance) on Belief 
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. regress Adhere Aff Agency AffXAgency 
 
      Source |       SS           df       MS      Number of obs   =        49 
-------------+----------------------------------   F(3, 45)        =      4.89 
       Model |  10.2184868         3  3.40616227   Prob > F        =    0.0050 
    Residual |  31.3478397        45  .696618661   R-squared       =    0.2458 
-------------+----------------------------------   Adj R-squared   =    0.1956 
       Total |  41.5663265        48  .865965136   Root MSE        =    .83464 
 
------------------------------------------------------------------------------ 
      Adhere |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         Aff |  -.1135334   .3988689    -0.28   0.777    -.9168966    .6898299 
      Agency |   .2622998   .4178315     0.63   0.533     -.579256    1.103856 
  AffXAgency |   .0216227   .0787534     0.27   0.785    -.1369948    .1802401 
       _cons |   4.565583    2.01078     2.27   0.028     .5156641    8.615503 
------------------------------------------------------------------------------ 
Figure 43: Regression of Aff(ordance) on Agency 
 
. regress Adhere Con Mot ConXMot 
 
      Source |       SS           df       MS      Number of obs   =        49 
-------------+----------------------------------   F(3, 45)        =      0.32 
       Model |   .88018161         3   .29339387   Prob > F        =    0.8076 
    Residual |  40.6861449        45  .904136554   R-squared       =    0.0212 
-------------+----------------------------------   Adj R-squared   =   -0.0441 
       Total |  41.5663265        48  .865965136   Root MSE        =    .95086 
 
------------------------------------------------------------------------------ 
      Adhere |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         Con |  -.0421469   .2142862    -0.20   0.845    -.4737414    .3894475 
         Mot |   -.150803   .2763637    -0.55   0.588    -.7074281    .4058221 
     ConXMot |   .0325358    .055405     0.59   0.560    -.0790555    .1441271 
       _cons |   6.119774   1.077935     5.68   0.000       3.9487    8.290847 
------------------------------------------------------------------------------ 
Figure 44: Regression of Con(text) on Mot(ivation) 
 
. regress Adhere Con Belief ConXBelief 
 
      Source |       SS           df       MS      Number of obs   =        49 
-------------+----------------------------------   F(3, 45)        =      0.36 
       Model |  .964441475         3  .321480492   Prob > F        =    0.7848 
    Residual |  40.6018851        45  .902264112   R-squared       =    0.0232 
-------------+----------------------------------   Adj R-squared   =   -0.0419 
       Total |  41.5663265        48  .865965136   Root MSE        =    .94988 
 
------------------------------------------------------------------------------ 
      Adhere |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         Con |   .2030566   .2376968     0.85   0.397    -.2756893    .6818024 
      Belief |   .1613811   .3018131     0.53   0.595    -.4465016    .7692638 
  ConXBelief |  -.0405974   .0641236    -0.63   0.530     -.169749    .0885543 
       _cons |   5.050185   1.212841     4.16   0.000     2.607397    7.492973 
------------------------------------------------------------------------------ 
Figure 45: Regression of Con(text) on Belief 
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. regress Adhere Con Agency ConXAgency 
 
      Source |       SS           df       MS      Number of obs   =        49 
-------------+----------------------------------   F(3, 45)        =      5.31 
       Model |    10.86838         3  3.62279333   Prob > F        =    0.0032 
    Residual |  30.6979465        45   .68217659   R-squared       =    0.2615 
-------------+----------------------------------   Adj R-squared   =    0.2122 
       Total |  41.5663265        48  .865965136   Root MSE        =    .82594 
 
------------------------------------------------------------------------------ 
      Adhere |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         Con |  -.2821813   .3667365    -0.77   0.446    -1.020827    .4564639 
      Agency |   .2509379   .2861342     0.88   0.385    -.3253661    .8272418 
  ConXAgency |   .0373864   .0635394     0.59   0.559    -.0905885    .1653613 
       _cons |   5.030977   1.553724     3.24   0.002     1.901615    8.160338 
------------------------------------------------------------------------------ 
Figure 46: Regression of Con(text) on Agency 
 
. regress Adhere Norm Mot NormXMot 
 
      Source |       SS           df       MS      Number of obs   =        49 
-------------+----------------------------------   F(3, 45)        =      0.20 
       Model |  .545404186         3  .181801395   Prob > F        =    0.8962 
    Residual |  41.0209223        45  .911576052   R-squared       =    0.0131 
-------------+----------------------------------   Adj R-squared   =   -0.0527 
       Total |  41.5663265        48  .865965136   Root MSE        =    .95476 
 
------------------------------------------------------------------------------ 
      Adhere |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        Norm |   .1025168   .3093491     0.33   0.742    -.5205444    .7255779 
         Mot |    .099448   .1934503     0.51   0.610    -.2901808    .4890769 
    NormXMot |  -.0388464   .0699946    -0.55   0.582    -.1798227    .1021299 
       _cons |   5.667572   .8767793     6.46   0.000     3.901647    7.433496 
------------------------------------------------------------------------------ 
Figure 47: Regression of Norm on Mot(ivation) 
 
. regress Adhere Norm Belief NormXBelief 
 
      Source |       SS           df       MS      Number of obs   =        49 
-------------+----------------------------------   F(3, 45)        =      0.12 
       Model |  .318520704         3  .106173568   Prob > F        =    0.9504 
    Residual |  41.2478058        45  .916617907   R-squared       =    0.0077 
-------------+----------------------------------   Adj R-squared   =   -0.0585 
       Total |  41.5663265        48  .865965136   Root MSE        =     .9574 
 
------------------------------------------------------------------------------ 
      Adhere |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        Norm |  -.0186241   .3368917    -0.06   0.956    -.6971588    .6599106 
      Belief |  -.0071644   .2143651    -0.03   0.973    -.4389179    .4245892 
 NormXBelief |  -.0062159   .0723429    -0.09   0.932     -.151922    .1394902 
       _cons |   6.072117    .840775     7.22   0.000     4.378709    7.765525 
------------------------------------------------------------------------------ 
Figure 48: Regression of Norm on Belief 
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. regress Adhere Norm Agency NormXAgency 
 
      Source |       SS           df       MS      Number of obs   =        49 
-------------+----------------------------------   F(3, 45)        =      5.12 
       Model |  10.5777174         3  3.52590578   Prob > F        =    0.0039 
    Residual |  30.9886092        45   .68863576   R-squared       =    0.2545 
-------------+----------------------------------   Adj R-squared   =    0.2048 
       Total |  41.5663265        48  .865965136   Root MSE        =    .82984 
 
------------------------------------------------------------------------------ 
      Adhere |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        Norm |   -.284294   .4643208    -0.61   0.543    -1.219484    .6508961 
      Agency |   .2683728   .2222455     1.21   0.234    -.1792527    .7159982 
 NormXAgency |   .0431002   .0857565     0.50   0.618    -.1296223    .2158226 
       _cons |   4.702696   1.207763     3.89   0.000     2.270135    7.135256 
------------------------------------------------------------------------------ 
Figure 49: Regression of Norm on Agency 
 
15.3 Analysis of new survey instruments 
Because of shortcomings in the quantitative research, no conclusions could be 
drawn on the validity of any new or modified survey instruments. While future 
research may prove more fruitful, at this stage there will be no further discussion 
of these. 
15.4 Summary 
A logical step-by-step process was followed in an attempt to extract any 
significant relationships; none were found. 
The next chapter closes the quantitative research with some conclusions. 
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16 Quantitative Research Conclusions 
16.1 Introduction 
This chapter sums up and draws conclusions on the quantitative research. Its 
structure is as per Figure 50. 
 
Figure 50: Chapter structure 
16.2 Conclusions 
This first step towards testing the qualitative process of adherence by means of 
the quantitative process was unsuccessful in identifying significant moderating 
effects. Issues arose at several points in the procedure. 
Firstly, the overall purpose of the survey was blurred. While it was aimed at 
understanding the interrelationships between adherence factors, there was also 
a desire to capture much more detail on reasons for non-adherence than was 
necessary for this purpose alone. 
Secondly, the pilot test results were not exploited. This meant that the survey 
contained too many questions for most people to be willing to complete. This 
should have been noticed and addressed, but since no statistical analysis was 
performed on the pilot results there was no basis for exclusion of any questions. 
Thirdly, the methods used to invite participants did not reach far enough into the 
overall population to consider the selection process random. Instead, point 
solutions to boost participation were used, resulting in both convenience and 
snowball sampling. One reason for this was that most recruitment was performed 
online thus disenfranchising the section of the population which was unable to 
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receive such invitations. This meant that even if statistically significant results had 
been obtained it would still not have been possible to make broad claims for the 
general population. 
Fourthly, the means of completing the survey was not generally accessible. An 
online survey may have encouraged the young to participate rather than the more 
mature, all things being equal. It also meant that in the developing world it 
enabled only the more relatively wealthy, who had smartphones, to participate; 
this therefore missed out the true Base-of-the-Pyramid residents who were much 
more fairly represented in the qualitative results. 
Fifth and finally, there were too few respondents to achieve statistically valid 
results. The analysis process used was statistically sound but it did not yield any 
valid results. 
16.3 Summary 
This first attempt to test the quantitative process was unsuccessful. This was as 
a result of shortcomings at some points in the survey procedure from design to 
implementation. However, the appropriate statistical approach was taken in the 
analysis of the results. 
The value and validity of the qualitative process of adherence is not negated by 
disappointing quantitative results. The quantitative process of adherence may yet 
be found to be relevant. 
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17 Conclusions 
17.1 Introduction 
In this final chapter the research threads are brought together, views of the 
qualitative and quantitative processes discussed, and some answers proposed 
for the question, what is adherence from a process perspective? Following this, 
managerial implications are raised, limitations discussed and recommendations 
for follow-on work suggested. 
The structure of this chapter is as in Figure 51. 
 
Figure 51: Chapter structure 
17.2 Conclusions 
17.2.1 Literature review 
It became clear through the literature review that there has been little theoretical 
research into adherence. Most has had practical bent, and the relatively few 
which have employed theory as a basis have used an expectancy-value one such 
as the Theory of Planned Behaviour. 
As a result of the literature review, six adherence factors were identified for taking 
forward: beliefs, motivation, agency, context, norms and affordance. These were 
applied to a process derived through the lens of Service-Dominant Logic. This 
led to the creation of an initial process of adherence. This was then examined for 
validity in the qualitative research. 
17.2.2 Qualitative research 
Two Qualitative Propositions were created. 
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Qualitative Proposition 1 proposed that the interviews were satisfactorily 
comprehensive and could therefore be used as a basis for endorsing the 
soundness of the second proposition and therefore the process of adherence. 
This was approached in two ways. The first examined the interviews to establish 
whether interview responses adequately covered all of the six factors of 
adherence. The second used a bottom-up method to determine the number of 
causes from the list of 55 causes in the ASA & ASCPF (2006) report, Adult 
Meducation. Forty-five of the 55 causes were found, the other ten requiring either 
an undue level of personal exposure by the interviewees or the possibility of 
personal assessment and recording by the interviewer. In addition, 19 causes of 
adherence not mentioned in the list of 55 causes were identified from the 
interviews. The results of these validations were considered to be in good 
alignment with Proposition 1 and therefore Qualitative Proposition 2 was 
supported. 
Proposition 2 proposed that the initial process was a useful way of understanding 
the process of adherence. Performing and analysing 30 qualitative interviews 
showed good alignment with the process, and as a result a refined version was 
proposed as the qualitative process of adherence. This was on the basis that the 
interviews did in fact comprehensively cover the ground, which was the subject 
of the first proposition. 
One important facet of this research is the focus on adherence as an individual 
act rather than an average of all adherence events for a patient or even a cohort 
of patients. The viewpoint of Service-Dominant Logic inherently supports this 
perspective, which allows a focus on what factors and rules are uppermost in the 
patient’s mind at that point of adherence. While this is innately a qualitative 
approach, it may provide greater insights into causes of non-adherence in 
practice, and therefore guide adherence interventions more effectively than 
repeated quantitative approaches which often produce inconclusive results. 
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17.2.3 Quantitative research 
This research was performed in order to operationalise the major factors of 
adherence. A quantitative process of adherence was created from the qualitative 
process which was suitable for statistical analysis. The research failed to provide 
support to validate that process. 
17.3 What is adherence from a process perspective? 
The purpose of the thesis was to attempt to answer the question, what is 
adherence from a process perspective? Based on this research there are 
potentially three answers. 
17.3.1 Answer 1: the triad 
This is the coming-together of patient and medicine in context to create value, 
controlled by the three rules of medicine instructions, contextual norms and 
patient beliefs. It might be visualised as in Figure 52. 
 
Figure 52: Triad perspective of adherence 
This answer in itself is a development of previous adherence research. So far, 
research has been focused on dyads such as patient and context or patient and 
medicine. The three parts of the triad, with the three controlling rules, have not 
been brought together in this way before. However, this is quite a simple 
definition. 
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17.3.2 Answer 2: the qualitative process of adherence 
This is a significant further development of the first answer. It brings in details 
which cannot be shown in the triad perspective. Based on the depiction of 
Service-Dominant Logic, it positions the six factors of adherence into a view of 
the process in order to show how they dovetail. In addition, the use of a lens 
which encompasses the full adherence process from absence to post-
consumption value assessment significantly extends the theories currently 
applied to adherence research. 
It also shows some of the irreducible complexity innate in adherence when it is 
understood as a complex interaction of service systems. Through this depiction 
it can be understood just why adherence is so hard to pin down empirically and 
perhaps explains why there is so much inconclusive research. Using a view of 
the process like this can provide a basis for future empirical research since it can 
illuminate reasons for results. Its depiction is repeated here as Figure 53. 
 
Figure 53: Qualitative process of adherence 
This is the view of the process which provides the greatest insights into 
adherence. It has been developed through a range of theoretical and practical 
measures. This process is considered to be the most developed of the three 
presented here. It goes well beyond previous theories, which have here been 
built on to gain a theoretical understanding of the adherence process. Therefore 
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this theoretical view of the adherence process is proposed as the answer to the 
question, what is adherence from a process perspective? 
17.3.3 Answer 3: the quantitative process of adherence 
This is a deconstruction of the qualitative process. Although its first test had no 
success it may still provide a basis for future adherence research. It pictures a 
series of factors moderating the patient’s attempt at adherence. Each attempt is 
enabled or driven by beliefs, motivation and agency, and is potentially moderated 
by the medicine’s affordance, the context, and the norms arising from relevant 
service ecosystems. One attraction of this view of the process is its extensibility, 
since other factors can be introduced. However, as a simplified statistical model 
it cannot give the fine-grained insights of the qualitative view of the process. It is 
repeated here as Figure 54. 
 
Figure 54: Quantitative process of adherence 
17.4 Contributions to knowledge 
This research has made the following seven contributions to knowledge. Firstly, 
it has extended existing partial theories to establish a theoretical view of the 
adherence process. This qualitative theoretical view describing the process of 
adherence is considered to be a significant step forward from the theories 
currently applied to adherence research. This qualitative process of adherence 
process could potentially inform future empirical research and so improve the 
effectiveness of interventions aimed at increasing adherence. 
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Secondly, it has delivered a new understanding of adherence as an individual 
opportunity to be adherent rather than as an average of all consumption 
opportunities over a course of treatment. This permits a closer focus on just what 
enables or hinders adherence at a point in time and this in turn allows the 
investigation to be at a point when as many as possible of the factors affecting 
adherence are as constant as possible. This encourages a qualitative approach 
to adherence research. It could potentially reduce the need for quantitative 
research, since that has been shown to be weak in determining actual causes 
and therefore in the selection of optimum interventions in various contexts. 
Thirdly, it has enhanced the general understanding of adherence. It can now be 
seen as a complex interrelationship of factors involved from the initial recognition 
of absence that triggers motivation right through to the ex post assessment of 
value gained from being adherent. To enable this, it has visualised adherence as 
a complex interaction of service systems, and so has developed a theoretical 
view of the adherence process which goes beyond the expectancy-value theories 
and permits the point of adherence to be included theoretically for the first time. 
Fourthly, it has developed a quantitative perspective for the adherence process. 
This view could potentially inform quantitative research into adherence. 
Fifthly, it has contributed a pictorial representation of the flow of Service-
Dominant Logic which has not been presented before. It has also incorporated 
and positioned service ecosystems and the Integrative Framework of Value 
within the flow. This representation was used as the basis for developing the 
qualitative theoretical view of the process of adherence. 
Sixthly, although the interviewees were not intended to be representative 
samples of their populations, the qualitative interviews suggested that reasons 
for non-adherence are broadly the same – although not necessarily for the same 
reasons – across developed and developing worlds. This surprising finding may 
have implications for future medicine formulations, since assumptions on agency 
and context may be causing adherence issues in the developed world in the same 
ways as for the developing world. 
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Seventhly, but less importantly from a theoretical perspective, is the addition of 
19 new causes to the existing 55 causes of non-adherence (ASA & ASCPF 
2006). 
17.5 Managerial implications 
Adherence is critical to clinical outcomes. Therefore there are several implications 
emerging from this research. 
Firstly, it is clear that there are several factors affecting adherence, and that the 
qualitative process of adherence can help in understanding their 
interrelationships and where they act in the end-to-end process of adherence. 
These insights should help pharmaceutical manufacturers to make their 
medicines more applicable to the patients in their contexts whom they are 
targeting with each medicine. In particular, medicines which more completely 
address contextual challenges could be more successful in raising adherence 
than those which at present might be perceived as “one size fits all”. There is 
much discussion about manufacturers becoming more patient-centric; this 
provides a means by which it might be possible to deliver on that commitment. 
Secondly, and extending the first, it has become clear from the research that 
some adherence factors are effectively “mirror images” of each other. For 
example, a patient’s context may not be contributing sufficient resources to permit 
adherence, but if the medicine’s affordance were to be enhanced then 
consumption might still be able to occur. Perhaps a patient’s context cannot 
provide food or water, but if these could be incorporated into the medicine in some 
way then the patient may still be able to be adherent. Similarly, the patient’s 
agency may be limited – perhaps not being able to open the bottle or to swallow 
large pills – but enhancements to the medicine’s value proposition might address 
such limitations. This is potentially a very valuable area to investigate as 
manufacturers aim to deliver outcomes rather than just inputs as part of “beyond 
the pill” initiatives (Bloomberg 2014; Dasgupta & Wenzel 2013). 
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17.6 Limitations 
There are two limitations which hampered the research. The first was the inability 
to perform more ethnographic research as part of the qualitative research. By 
removing the possibility of speaking to most interviewees face to face it reduced 
the opportunity to gain the deepest insights. It also prevented other types of 
interviews such as with medical staff, family members, and the like. It may be that 
a face-to-face approach would have uncovered further causes of non-adherence. 
However the interviews, even though mostly remote, did succeed in gaining 
insights into a large range of causes of non-adherence and so lent weight to the 
validity of the qualitative process of adherence.  
The second was the quantitative survey. There were major weaknesses in this 
part of the research. Firstly, an insufficient number of people were recruited for 
the survey. This was likely to have been caused by the means of reaching 
potential respondents. The use of social media, on-campus advertising and word-
of-mouth requests did not exhaust the range of methods which could have been 
used. The hoped-for 500 or more people was reduced to just less than 200 as a 
result. 
Secondly, the respondents who did participate in the survey were not a random 
sample that was representative of the population as a whole. Despite using the 
survey tool recommended by the university, it would in fact have been challenging 
to obtain a representative sample. To achieve a more random sample it may have 
been necessary to engage a company specialising in surveys. The method of 
presenting the survey online, which required the use of a laptop or smartphone, 
is likely to have inhibited the participation of those who were not computer-literate 
or who did not have access to a smartphone. This is in contradistinction to the 
qualitative interviews, which reached a much more representative sample 
because only a basic phone was required. 
Thirdly, when respondents did engage with the survey it was found that most of 
them did not fully complete it. This was most likely due to the inappropriately large 
number of questions in the survey – almost 100. This number was caused by 
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including too many items for each of the seven instruments. While most of the 
instruments themselves were generally sound since they had already been 
utilised in surveys performed by others, their use in this combination was 
excessive. In addition, in an attempt to gather as much detail as possible based 
on the rich data obtained from the qualitative interviews, further items were 
appended to some instruments which only exacerbated the issues. 
Fourthly, when responses were examined in detail it was found that the number 
of respondents completing the survey was only 49. This is a small number for any 
survey, and wholly inadequate for drawing any conclusions from a survey of 
almost 100 questions involving seven instruments. 
Fifth and finally, some of the 49 respondents who completed the survey appeared 
not to provide thoughtful answers to all questions. Upon inspection of the raw 
data there was found to be evidence of question after question being given the 
same score of either 1 or 7 on the 7-point Likert scale. This is also manifest in 
very high standard deviations in the instrument summaries (Stata “summarize” 
command) for most questions; this can be seen in the figures in Appendix C.2. 
This in itself suggests that the results of the quantitative analysis should be 
discounted. 
Therefore, a combination of an excessively long questionnaire and a limited 
number of respondents meant that the quantitative research was unlikely to 
provide any statistically significant results. This turned out to be the case. 
Although valid processes were used to analyse the results, no useful conclusions 
can be drawn that have any relevance to the quantitative process. 
Nevertheless, although the quantitative process has not been validly tested by 
this research it may yet be shown to be valuable in future research if used with a 
more appropriate set of items for each instrument. 
17.7 Recommendations 
These are considered in two parts. Firstly, research that could follow on directly 
from this thesis. Secondly, wider investigations in associated areas. 
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17.7.1 Direct follow-on research 
There are five particular themes. Firstly, the quantitative research could possibly 
be performed again. It would require several elements to be amended. (1) The 
questionnaire must be much shorter so as to focus on only the major aspects of 
each factor. (2) Many more responses should be captured. (3) Respondents 
should be a more representative sample of the population; this may require the 
survey to be offered in more ways, to permit everyone to respond whether they 
are online or not – from the Base-of-the-Pyramid to the older generation. 
Secondly, research into factors of adherence was necessarily simplified for this 
research such that only six factors were examined in detail. It was assumed that 
instructions were one of the medicine’s affordances, and that the patient-clinician 
relationship was one of the institutions of the norm of the medicine supply service 
ecosystem. It may be valuable in future research to break these out so that they 
can be explored independently. While this will not negate the findings in this 
research and may simply confirm the assumptions, it may uncover further 
richness of detail which will contribute to the ongoing development of the 
theoretical view of the process of adherence. 
Thirdly, as an extension to the second point it would potentially be useful to 
perform further qualitative research face to face with interviewees in their 
contexts. This would potentially reveal greater depth and so permit further 
refinements and developments of the process of adherence. Looking more 
deeply into the factors would perhaps expose further layers of detail that would 
permit a greater understanding of each one. 
Fourthly, it would be beneficial to review the results of this research with members 
of the various ecosystems such as clinicians, NGOs, pharmaceutical 
manufacturers and suppliers. It is expected that they would receive benefit from 
the insights already gained which would permit them to deliver medicines which 
are more suitable for their patients in their own contexts. 
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Fifth and finally, it may be useful to explore adherence from the perspective of it 
being the responsibility of the patient to decide on their level of adherence and 
therefore being responsible for their own health outcomes. There has been 
significant time expended on improving adherence without necessarily 
recognising patient autonomy. Once again, qualitative research would be one 
way of achieving these insights. 
17.7.2 Wider extensions 
There are two possible opportunities to take this research into adherence beyond 
what has been achieved here.  
The first is in response to medicine consumption being a form of consumption. If 
it is accepted that all consumption of a consumable is performed in context and 
governed by the three rules of instructions, norms and beliefs, then there is 
potential benefit in researching how adherence can be applied to other 
consumables. 
For example, it could be argued that this could beneficially be applied to the 
understanding of consumption of illicit drugs. The application of the qualitative 
view of the process of adherence could be used to gain insights and therefore 
define more theoretically supported interventions. Another example might be the 
consumption of fruit and vegetables, looking through the lens of the qualitative 
process at why some people do not or cannot eat their “five a day”. 
Secondly, the application of behavioural theories to adherence may imply that 
there is less difference between consumption and behaviour than might at first 
sight be the case. In fact, it seems reasonable to consider behaviour as being 
“consumption” of a “consumable” in context governed by rules. 
The “consumable” will not be edible but could, perhaps, be a piece of flat-pack 
furniture to be assembled. The assembly context, the constructor’s beliefs, the 
contextual norms, the flat-pack’s affordances, could all be relevant to being 
adherent to the instructions, and so be worth considering when designing 
interventions which might make assembly easier. 
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Perhaps it might be less physical than furniture. Consumption of the experience 
of reading a recipe book might be another. Is it read for pleasure or to guide food 
preparation? Similar questions as above can be asked when considering how the 
book is experienced in various ways, from both the pleasure perspective and its 
use for cooking. How are the pictures consumed? How are the recipes followed 
in users’ many contexts? Perhaps the book’s affordances could be enhanced if 
these things were known. 
Applying the qualitative view of the adherence process to wider consumption and 
to behaviour might therefore be fruitful avenues of future research. 
17.8 Summary 
This chapter has brought the thesis to a conclusion. It has reprised the findings 
of the literature review and the empirical research. It has proposed the qualitative 
theoretical view of the process of adherence as an answer to the overarching 
research question, what is adherence from a process perspective? It has 
delineated the contributions to knowledge of the work. And it has discussed 
management implications, research limitations and recommendations for further 
research. 
 
 
 
 
 
 
Deo gratias; soli Deo gloria.  
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Appendices 
 Appendix A: Service-Dominant Logic Foundational 
Premises 
Table 39 lists the Foundational Premises of Service-Dominant Logic. The table 
draws together definitions from the three papers Vargo & Lusch (2008), Lusch 
& Vargo (2014) and Vargo & Lusch (2015). 
 
Table 39: Foundational Premises of Service-Dominant Logic 
FP Foundational Premise 
(axioms highlighted) 
Comment/explanation 
1 Service is the fundamental basis of 
exchange 
The application of operant resources (knowledge 
and skills), “service”, as defined in S-D logic, is the 
basis for all exchange. Service is exchanged for 
service 
2 Indirect exchange masks the 
fundamental basis of exchange 
Because service is provided through complex 
combinations of goods, money, and institutions, 
the service basis of exchange is not always 
apparent 
3 Goods are a distribution mechanism for 
service provision 
Goods (both durable and non-durable) derive their 
value through use – the service they provide 
4 Operant resources are the fundamental 
source of strategic benefit 
The comparative ability to cause desired change 
drives competition 
5 All economies are service economies Service (singular) is only now becoming more 
apparent with increased specialization and 
outsourcing 
6 Value is co-created by multiple 
actors, always including the 
beneficiary 
Implies value creation is interactional 
7 Actors cannot deliver value but can 
participate in the creation and offering 
of value propositions 
Enterprises can offer their applied resources for 
value creation and collaboratively (interactively) 
create value following acceptance of value 
propositions, but cannot create and/or deliver 
value independently 
8 A service-centered view is inherently 
beneficiary-oriented and relational 
Because service is defined in terms of customer-
determined benefit and co-created it is inherently 
customer oriented and relational 
9 All social and economic actors are 
resource integrators 
Implies the context of value creation is networks of 
networks (resource integrators) 
10 Value is always uniquely and 
phenomenologically determined by 
the beneficiary 
Value is idiosyncratic, experiential, contextual, and 
meaning-laden 
11 Value co-creation is coordinated 
through actor-generated institutions 
and institutional arrangements 
“[S-D Logic] is a narrative of cooperation and 
coordination in ecosystems, as well as the 
reconciliation of conflict between them. Institutions 
are instrumental in these cooperation and 
coordination activities by providing the building 
blocks for increasingly complex and interrelated 
resource-integration and service-exchange 
activities in nested and overlapping ecosystems 
organized around shared purposes” (Vargo & 
Lusch 2015) 
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 Appendix B: Qualitative Research 
B.1 Participant Information Leaflet (PIL) 
 
Figure 55: Participant Information Leaflet for qualitative research (1 of 2) 
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Figure 56: Participant Information Leaflet for qualitative research (2 of 2) 
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B.2 Consent form 
 
Figure 57: Consent Form for qualitative research 
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B.3 Research approval letter
 
Figure 58: BSREC approval for qualitative research 
B.4 List of interviewees 
See Table 40 for a detailed list of interviewees. Local costs were converted to 
UK pounds on 12/12/15. Dates are dd/mm/yy.  
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Table 40: Interviewee details 
Code No. Sex Age 
range 
Country Medicine Cost Location 
type 
Distance/ 
cost to 
obtain 
Interview 
type 
Interview 
date 
Transcript 
date 
EG 01 F 20-40 Egypt Cough medicine  City Close F2F 30/04/15 12/05/15 
KN 01 M 20-40 Kenya Antibiotics £0.03 Village  Phone 27/02/15 11/06/15 
KN 03 M 40-60 Kenya Amoxycilin  Village 1km Phone 27/02/15 12/06/15 
KN 04 M 20-40 Kenya Malaria tablets £3.23 Village 5km/£2.59 Written 27/02/15 07/05/15 
KN 05 M 60+ Kenya Coartem £0.13 City Close Phone 27/02/15 15/06/15 
KN 06 F 20-40 Kenya Malaria tablets  Town Close Phone 27/02/15 11/05/15 
KN 07 M 20-40 Kenya Pain killer, curatives £0.66 Village Close Written 15/04/15 07/05/15 
KN 08 M 40-60 Kenya Malaria (AL) £0.97 Village 2km Written 03/06/15 03/06/15 
KN 09 M 20-40 Kenya Panadol £0.84 Village 2km Written 26/05/15 08/06/15 
KN 10 M 40-60 Kenya Chrotin B £1.29 Village 6km Written 26/05/15 08/06/15 
KN 11 F 20-40 Kenya Quinine £2.91 Village 2km Written 26/05/15 08/06/15 
KN 12 F 20-40 Kenya Panadol £0.45 Village 4km Written 26/05/15 10/06/15 
KN 13 F 20-40 Kenya Flugone £1.29 Village 3km/£1.94 Written 26/05/15 10/06/15 
KN 14 M 40-60 Kenya Cold Cups £0.32 Village 1km Written 26/05/15 10/06/15 
KN 15 M 20-40 Kenya Ibuprofen £1.62 Village 2km Written 02/06/15 10/06/15 
KS 01 F 20-40 Kazakhstan Repronact £2.09 Village 3.5km F2F 02/02/15 10/05/15 
NG 01 M 40-60 Nigeria Artesunate £1.49 Town Close Phone 28/02/15 11/05/15 
TZ 01 M 40-60 Tanzania Coartem  Village 4 hours Phone 26/02/15 11/05/15 
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Code No. Sex Age 
range 
Country Medicine Cost Location 
type 
Distance/ 
cost to 
obtain 
Interview 
type 
Interview 
date 
Transcript 
date 
TZ 02 M 60+ Tanzania Paladrin £1.53 Town Close Phone 26/02/15 15/06/15 
TZ 03 M 60+ Tanzania for Stomach Abscess £0.31 Town Close Phone 27/02/15 11/06/15 
TZ 04 F 40-60 Tanzania Malafin, Panadol, Maleratab £1.53 Town 10-15 mins Phone 26/02/15 12/06/15 
UG 01 M 40-60 Uganda Quinine £3.95 Village 30km/£6.59 Written 02/03/15 07/05/15 
UK 01 F <20 UK Roacutane, Erythromycin Free Village 5km F2F 30/12/14 07/05/15 
UK 02 M 40-60 UK (multiple) Free Town 1km F2F 01/01/15 07/05/15 
UK 03 F >60 UK Metformin Free Town 1km F2F 01/01/15 14/06/15 
UK 04 M >60 UK Antibiotics £8.20 City 5km F2F 07/01/15 12/06/15 
UK 05 M >60 UK for Angina Free Town 2km F2F 04/02/15 14/06/15 
UK 06 F >60 UK Sulfasalazine, Methotrexate Free Town 2km F2F 04/02/15 15/06/15 
ZI 01 F 20-40 Zimbabwe Amoxycilin  Village  Written 25/03/15 07/05/15 
ZM 01 M 40-60 Zambia Coartem Free Village Close Phone 26/02/15 11/05/15 
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B.5 Interview transcripts 
Every interview was transcribed and imported into Nvivo10 for analysis. 
Analysis was also performed manually directly from the transcripts. The 
transcripts are not reproduced here due to their length but they are available 
with certain conditions to those with a legitimate research need. 
B.6 Interview coding: Qualitative Proposition 1a 
Table 41 and Table 42 in this section contain analysis codes, extracts from the 
interviews, and the interview from which each extract was taken. The first table 
is for developing countries and transition countries (in this case, Egypt and 
Kazakhstan) – together referred to here as the developing world – while the 
second is for developed countries (in this case, UK). The country definitions 
are from the United Nations (UN Development Policy and Analysis Division 
2016). Although separate analyses for different “worlds” was not part of this 
research, the two tables are separate to facilitate possible future research 
which may which to look at the differences. 
In these two tables, codes are defined as “positive” or “negative”. As an 
example of what “positive” and “negative” mean, see these two interview 
extracts: 
Effects, positive, side, none: “[Any side effects?] Not to my knowledge” 
(UK06) 
Taste, negative, bad: “I took one but couldn’t take more because of the 
nasty taste” (ZM01). 
 
Table 41: Interview coding with random order of codes, developing world 
Transcription code Interview example Interview 
ref. 
Distance, positive, close …pharmacies in every street… just down the road from our flat 
But if I need to get it from a pharmacy it’s a kilometre 
I walk, I take one minute to get to the health centre 
Not very far. Just walk to get them 
It was 2km away 
2km from my home 
EG01 
 
KN03 
KN05 
KN06 
KN08 
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Transcription code Interview example Interview 
ref. 
2km from my home 
2km from home 
About 1km 
Pharmacy isn’t far, about 10 minute walk from my house 
Just nearby. Two minutes 
Just a few meters… two minutes’ walk 
Not too far 
Only 10 minutes’ walk to the [small] pharmacy… when you want to go to 
the big pharmacy it takes about 15 minutes 
KN09 
KN11 
KN15 
KN14 
KZ01 
NG01 
TZ02 
TZ03 
TZ04 
Instructions, negative, 
foreign language, verbal 
I don’t understand colloquial Arabic EG01 
Instructions, negative, 
foreign language, 
written 
I think we figured out the written instructions 
…you really don’t understand the reading 
…people who can’t even read 
EG01 
EG01 
EG01 
Utensils, negative, 
missing 
I don’t think there was a spoon. I think we had to buy it separately EG01 
People, positive, 
present 
Probably my husband was there sometimes 
Mum and my younger sisters were there 
It’s better for someone to make sure you get the full dose 
Mother and brothers were there 
Grandmother was there with me as I have no parents 
I was with the physician only 
Family members 
With a friend 
My parents 
My wife is the one who was always reminding me to take it 
EG01 
KN04 
KN06 
KN09 
KN11 
KN13 
KN14 
KN15 
KZ01 
TZ03 
Content, negative, 
unknown 
…you really don’t have a clue what’s in it... [it’s] at the back of your head 
that it could be anything 
I don’t like taking medicine…because of the idea that it’s chemicals… 
natural ones are better than synthetic 
EG01 
 
NG01 
Branding, positive, 
known 
I suppose the branding just makes you trust it more EG01 
Motivation, negative, 
last resort 
I think I sort of used it as a last resort 
Just like when I’m really sick, I’m like distressed for getting better… 
makes me take the pills 
Urge to get healed 
I was physically weak and mentally disturbed… I felt desperate 
Totally disturbed… Eager to know its [effect] 
Felt hard to use since I don’t like medicines 
I’d have taken anything 
EG01 
KN03 
 
KN07 
KN08 
KN10 
KN15 
KZ01 
Diagnosis, negative, 
foreign language, verbal 
…would have helped if the person that we saw could speak English EG01 
Taste, negative, bad Sometimes obviously the taste of the medicine 
…the taste of the drugs 
I don’t like it. I don’t like taking medicine because of the taste 
They don’t taste well when you swallow them. Bad taste 
[not completing the full dosage] is primarily caused by… difficulty in 
taking the medicine due to… taste… 
I took one but couldn’t take more because of the nasty taste 
EG01 
KN03 
NG01 
TZ03 
ZI01 
 
ZM01 
Effects, negative, bad …it’s not good for you… 
Sometimes it can harm the body 
…if I take the medicine it weakens my body for some time 
…in fact the body constitution was changed… 
The medicine itself was reactive… 
…the Coartem seems to be a bit too much for me 
I hear about these doctors saying about how conventional medicines 
affect the liver 
EG01 
KN10 
KN15 
TZ02 
TZ02 
ZM01 
ZM01 
Effects, negative, side, 
general 
…there’s all these side effects… 
I don’t like taking medicine because… there’s side effects 
…taking tablets irritates them 
EG01 
NG01 
TZ01 
Beliefs, negative, 
others, too dependent 
…“Paracetamol doesn’t work for you because you keep taking it” 
…so I’ll have to bargain for half a tablet of Paracetamol if my temperature 
is high as a kid, they didn’t believe in medicine much 
EG01 
KZ01 
Beliefs, negative, profit, 
pharma 
…this thing about the pharmaceutical industry and how they’re making 
profit 
EG01 
Beliefs, negative, profit, 
herbal 
…the natural remedy people are also making their profit as well EG01 
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Transcription code Interview example Interview 
ref. 
Stop, negative, better I wouldn’t even [complete the course] if the GP said “make sure you finish 
the course” 
…after 3 days you feel like you’re ok. You’re like, “No I don’t need to get 
more medicines then” 
Many people [stop when they feel better] 
Sometimes I’ll take it according to the prescription but sometimes I stop 
when I feel better 
Sometimes I feel that I’m feeling better 
When they see they’re a little better they stop taking the tabs 
…then I got well… feeling well before finishing the dose 
When one takes the medicine and gets better maybe he feels fine, so it’s 
difficult for him to finish the dose 
And some, when they feel better, then drop the medicine 
[not completing the full dosage] is primarily caused by early signs of 
healing… 
For some, I think the moment they feel better they choose not to take 
any more 
EG01 
 
KN03 
 
KN06 
NG01 
 
TZ01 
TZ01 
TZ03 
TZ04 
 
TZ04 
ZI01 
 
ZM01 
Cost, positive, low At the hospital sometimes we don’t pay 
About 100 Tz Shillings [£0.03, $0.05] 
Ksh20 [£0.13, $0.20] 
Ksh70 [£0.47, $0.72] 
Ksh50 [£0.33, $0.52] 
Tsh1000 [£0.30, $0.46] 
We go to the hospitals. They give out malaria tablets for free 
For things like Coartem… they don’t really charge 
KN03 
KN01 
KN05 
KN12 
KN14 
TZ03 
TZ04 
ZM01 
Instructions, positive, 
clear, written 
The prescription should say when the medicine should be taken 
They write on the cover 
Because it was written 2x3 meaning 6 tabs per day 
I knew… reading the prescription 
The prescription was indicated on the cover 
I knew by the doctor’s prescription 
Yes it was written 2x2. Consume with a lot of water 
I followed the physician prescriptions 
KN01 
KN03 
KN04 
KN07 
KN09 
KN12 
KN13 
KN15 
Reminder, positive, 
alarm 
I use an alarm for night 
Some medicines I have to put alarm on reminding myself not to forget 
this 
KN01 
KZ01 
Taste, negative, bitter It’s… bitter 
I think there should be much… reduce the bitterness 
Some medicines are bitter this makes it hard to consume 
too… bitter 
Bitterness of the medicine… it is so bitter 
I hate medicine. They are bitter 
Reduce the bitterness… of the tabs 
It becomes easier to take if medicine is tasty… 
[Make them] a bit sweet 
Better something that is sweet 
Some are very, very… some are not sweet, you know. They’re so sour. 
I think if maybe sweeter, then somebody can swallow it easier 
And some, because the medicine is soooo bitter, drop it from taking the 
whole dose 
KN01 
KN01 
KN07 
KN09 
KN11 
KN12 
KN04 
KN07 
KN09 
NG01 
TZ04 
 
TZ04 
Size, negative, big It’s big… 
One is like the size of the pill 
This tablets are in large sizes and so swallowing becomes a problem 
The size is too big 
Size of this medicine is so big 
…at least the size of it should be moderate to make easier swallowing 
Reduce… the largeness of the tabs 
A bit… small[er] 
[not completing the full dosage] is primarily caused by… difficulty in 
taking the medicine due to… size… 
…you swallow them and it feels like you haven’t swallowed them and 
you wonder how you’re going to take the next tablets… 
KN01 
KN03 
KN08 
KN09 
KN11 
KN01 
KN04 
KN09 
ZI01 
 
ZM01 
Formulation, negative, 
injection 
I fear injections! 
I prefer medicines than the injection 
I prefer oral 
KN01 
KN03 
KN07 
Effects, negative, side, 
specific 
I’ve read about side effects like your digestive system… 
Some people develop boils, others get sick, get weak, sweat a lot 
…now vomit… 
EG01 
KN01 
KN03 
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Transcription code Interview example Interview 
ref. 
…I feel like vomiting 
…I could feel dizziness in me 
…they take medicines and end up vomiting 
…you become very tired 
It makes me feel so dizzy, a lot of noise in the ears, chilling of the body, 
loss of appetite, sometimes vomiting. This makes [me] feel bad, dodge 
the dosage 
…even produce a smell when urinating or on the skin or in sweat… 
Sick for a whole week and all that, the headaches, stomach stuff, the 
pains. I thought not to go through all that [by consuming the medicine] 
KN06 
TZ02 
TZ02 
TZ04 
UG01 
 
 
ZI01 
ZM01 
Taste, positive, sweet The ones we have around here are very sugary so very easy for 
someone to take 
I liked it 
KN03 
 
KN14 
Distance, negative, far If I need to get from the hospital I have to go 4km away 
5km from home. Travelled by Nissan at a cost of ksh400 [$3.95, £3] 
…good pharmacy shops are not available in the rural areas 
Almost 6km 
4km from home 
3km from home. Used a motorbike which costed ksh200 [£1.33, $2.06] 
The problem is the pharmacy doesn’t open on Monday so we had to 
drive to her home about 3.5km away 
4 hours [travel time] 
It’s 30km to and from, to the pharmacy. $10 [£6.57] transport 
KN03 
KN04 
KN07 
KN10 
KN12 
KN13 
KZ01 
 
TZ01 
UG01 
Beliefs, negative, 
others, stigma 
…when I’m there I’m not feeling comfortable to take the pills… so stigma 
itself can cause or make someone not to take the medicines… stigma is 
a major issue 
I sometimes I never just wanted to take medicine, because that I feared 
for stigma… sometimes when I wanted to take that medicine I could just 
hide 
People are afraid of that stigma… when people have HIV and AIDS they 
always try to hide it from people 
KN03 
 
 
TZ02 
 
 
TZ02 
Food, positive, present Use of porridge 
Porridge 
I had eaten 
My mum was cooking 
Yes [I have food]. Normally you have to eat for medicine 
I do take it with… porridge 
KN11 
KN12 
KN15 
KZ01 
NG01 
TZ04 
Food, negative, absent If you don’t have something to eat you won’t take the drug… you have 
nothing to eat 
…take them after every meal. This was not possible due to poorness. 
We cannot afford 3 meals a day so it was hard to take the tabs in the 
afternoon… 
I did not take it at that time because I was hungry and tired 
No [I did not consume] I was hungry 
I wasn’t getting enough food… I really felt that drug if I hadn’t eaten 
It’s difficult to have enough food to visit the prescription 
We Africans take some medicines with not enough food 
They require a lot of drinks and eating well but we are poor we can’t 
afford most of the requirements. Sometimes we have a single meal a day 
KN03 
 
KN04 
 
 
KN04 
KN11 
KZ01 
TZ01 
TZ01 
UG01 
Beliefs, negative, 
foreign origin 
I don’t like taking medicine because… it’s foreign NG01 
Beliefs, negative, lack of 
faith 
…if you don’t have that [faith to be healed] then you’ll have to take 
medicine 
TZ02 
Course, negative, long …sometimes prescriptions take long time, many days for you to finish 
the dose 
I wished I could consume them once and over… I thought I would be 
given medicine to consume once and over… In general medicines are 
difficult for me to take. The dosage may be long 
It becomes easier to take medicine… does not taking too long 
To get relieved at once 
Others they are not following the information [from the doctor] 
They take long to heal, it’s a long dosage of 3-6 days 
KN03 
 
KN04 
 
 
KN07 
KN09 
TZ04 
UG01 
Stop, negative, replaced 
by other 
…maybe going for other drugs to see if they treat quicker… I end up not 
taking the other dose… 
KN03 
Stop, negative, keep They act like emergency for my family 
I keep it just in case I get a re-occurrence of same symptom. Then I take 
the leftover when I cannot get to buy another 
Here in Africa, many people… keeping a dose… 
KN03 
NG01 
 
TZ01 
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Transcription code Interview example Interview 
ref. 
Motivation, positive, 
stay well 
I don’t want to feel sick again tomorrow so I must complete the medicine 
If maybe I could default then I could have been maybe in danger 
In general I think it’s good for taking all malaria tabs because if you 
don’t… then you can feel worse when malaria attacks again 
KN06 
TZ02 
TZ04 
Motivation, positive, get 
well 
Hopes came with the medicine… I used my illnesses as a reason to take 
it right away 
I knew soon I will be well 
KN13 
 
KN14 
Effects, positive, others Also, experience from other people. If maybe my [family] used the same 
drug and she got well, definitely that helps me to finish… 
KN03 
Regimen, negative, 
unacceptable 
You realise it’s hard for me to wake up in the midnight to take pills 
Personally I go for prescription guidelines [as cause of failure]. They 
easily make me not to finish the prescription 
And with the tablets, they feel like there’s too many 
KN03 
KN03 
 
ZM01 
Cost, negative, high Ksh500 [$4.95, $3.75] was the cost of the medicine 
Ksh150 [£1, $1.53] 
Ksh130 [£0.87, $1.33] 
Ksh200 [£1.34, $2.05] 
Ksh450 [£3.01, $4.60] 
Ksh300 [£2, $3.09] to buy the medicine 
Ksh250 [£1.67, $2.57] 
Fairly expensive for Kazakhstan…about £3-4… they tend to look at how 
you’re dressed 
450 Nira [£1.49, $2.27] 
…malaria medicine is not affordable to a lot of people… 
Tsh2000, 5000 [£0.58, $0.91; £1.46, $2.27] depending on the quantity 
… but mainly in hospitals there are less malaria tabs so most people go 
to buy them in the pharmacy… there are some tablets from India, there 
are some tabs from Western countries and then there are some tablets 
from the local, from within the country. So within the country you can find 
them at tsh1000 [£0.29, $0.45]. And then tabs from outside the country 
goes to tsh3000 [£0.88, $1.36] to tsh5000 [£1.47, $2.27] 
…some cannot afford the full dose 
$6 [£3.94] medicine 
KN04 
KN08 
KN09 
KN10 
KN11 
KN13 
KN15 
KZ01 
 
NG01 
NG01 
TZ02 
TZ04 
 
 
 
 
 
TZ04 
UG01 
Instructions, negative, 
misunderstood 
I know how to take Coartem… we take two tabs, two times a day KN05 
Instructions, positive, 
clear, verbal 
They explained it clearly how to take it 
I knew… by listening 
My teacher told me to follow the doctor’s prescription 
…the doctor showed me the correct way 
I just listened to a doctor so that I can follow what he has told me 
I followed the instruction given to me by the doctor 
I realised its importance… after being taught the effects of that medics 
when taken wrongly 
KN05 
KN07 
KN11 
KN14 
TZ01 
TZ03 
UG01 
Course, positive, 
acceptable 
I take it up to the last one 
I take it until I use all the tablets 
I do follow the information 
KN05 
NG01 
TZ04 
Effects, negative, others I just see them, they want to go vomit KN06 
Stop, negative, 
discarded 
They throw it away, because you can’t go on taking the medicine KN06 
Access, negative, hard …with curative I found after going to various pharmacy shops 
I did not obtain the medicine [until]… the third shop 
KN07 
KN08 
Formulation, positive, 
liquid 
Personally I would go for liquid 
People around here with children they like syrups 
If they can convert this tabs into syrup… the better 
KN03 
KN07 
KN08 
Regimen, negative, 
unexpected 
I could not actually imagine there will be a prescription or directive on 
how to take the medicine… I thought I could just… consume 
regardless… 
I thought I will get better at that moment 
I get a medicine to drink once and get cured 
I had planned to take large amounts 
It was not in my plan to consumer it according to the prescriptions… 
KN08 
 
 
KN11 
KN13 
KN14 
UG01 
Water, negative, absent The medicine was to be consumed… with a lot of water which I did not 
have sufficient of… I lacked water… I was thinking of taking the medicine 
without water 
KN08 
 
People, negative, 
absent 
There was no body… No [I did not consume] 
On my own… No, I stopped 
KN08 
TZ04 
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Transcription code Interview example Interview 
ref. 
[not completing the full dosage] is primarily caused by… difficulty in 
taking the medicine due to… lack of monitoring of the sick by fit family 
members 
ZI01 
Smell, negative, bad This medicine has a smell and this smell surely disturbs me a lot when 
taking the medicine 
Some medicines do emit a pungent smell that will cause nausea and 
vomiting… [Is the smell sufficient to stop taking?] Yes bro absolutely! As 
soon as you open the package you actually feel the strong smell 
KN08 
 
ZI01 
 
Beliefs, positive, 
confidence 
I had confidence that it will relieve my pain KN09 
Water, positive, present Water helped me to consume 
Water… helped 
Water 
…with a lot of water. Yes, I have enough water 
I do take it with tea… 
Yes, yes. I have access 
Yes, my eldest sister, they take their medicine with Coca-Cola 
KN09 
KN11 
KN12 
TZ03 
TZ04 
ZM01 
ZM01 
Formulation, positive, 
injection 
[Easier] through syringe 
I prefer the injection before because I don’t like the taste of medicine 
…in the east region [of Africa] there are some people… the majority… 
who prefer injections… 
The other [sister], they prefer the injections to tablets 
KN09 
NG01 
TZ02 
 
ZM01 
Beliefs, positive, others I had been informed about its advantages KN10 
Instructions, negative, 
unclear, written 
So even though the packaging said something else, the doctor specified 
“something something 3 times”. I had to ask my parents to decode the 
curvier writing. [without that] it would have been a bit of a guess 
KZ01 
Regimen, positive, 
acceptable 
I didn’t mind for instance at night-time to wake up KZ01 
Regimen, negative, 
complex 
[Prefer] once per day 
[Prefer to] take many dosage for a quick recovery 
I would like to take it whenever I go to bed 
I had to make sure that they eat in the morning… the first two tablets of 
the day were regular and then not 
When I go to the clinic, I just get the diagnosis and I go for other 
medications… there were too many tablets. So I took my pawpaws and 
I was ok in 2 days. The malaria was all gone 
KN12 
KN14 
KN15 
KZ01 
 
ZM01 
Regimen, negative, 
forgot 
And then once I forgot, I misplaced it, so I missed it 
The time I forgot to take it. I repeated the dose that I did not take 
KZ01 
TZ03 
Instructions, negative, 
unclear, verbal 
So it was a very vague direction so I didn’t assume that it was critical KZ01 
Routine, negative, 
absent 
…if your day gets mixed up with night and you’re really not sure any more 
what to stick to 
That occurs so much in Africa! Maybe you can miss in that case in the 
evening, or forget in the morning and then take in the afternoon then miss 
in the evening, or someone can take 6 at once! 
…some people I know only take them in the night 
KZ01 
 
TZ04 
 
 
TZ04 
Routine, positive, 
present 
I tend to be pedantic about those things… I’ve been given a task… I’m 
going to do this… I might as well do it properly 
I try as much as possible to get it at home. After my meal, my breakfast, 
and when I return from work 
I make sure that I am in the house 
I just started following the prescription strictly… I was at home 
I remember if I want to eat I have to take medicine 
[Are you always at home?] Yes, it is 
KZ01 
 
NG01 
 
TZ01 
TZ02 
TZ03 
TZ04 
Cost, negative, herbal, 
low 
…the herbal [malaria medicines] are very cheap 
…medicines from China… food supplement… cheaper 
Or if you don’t have money you just can take some local medicine 
NG01 
NG01 
TZ04 
Beliefs, negative, value Sometimes they say that the tablets are weak TZ01 
Stop, negative, busy I was occupied maybe from work 
Because maybe they’re occupied 
TZ03 
TZ03 
Storage, negative, 
unsafe 
…maybe the people being lazy can just put them where children are 
reaching and then the children can consume them… it can be more 
dangerous 
TZ04 
Stop, negative, run out …some cannot afford the full dose TZ04 
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Table 42: Interview coding with random order of codes, developed world 
Transcription code Interview example Interview 
ref. 
Distance, positive, close Walk… 
We don’t live too far away, about half a mile 
10 yards. The doctor’s and the chemist’s are together 
About a quarter of a mile 
About a mile 
UK02 
UK03 
UK04 
UK05 
UK06 
People, positive, 
present 
[What made applying it possible?] Someone else did it 
Obviously have breakfast together and dinner… 
…with the family 
I took the responsibility on so she didn’t have to think about it 
Yes. “Have you taken your tablets?” 
UK01 
UK02 
UK04 
UK04 
UK05 
Content, negative, 
unknown 
I wouldn’t want to be putting a lot of stuff into my body that I didn’t know 
what it was doing 
UK06 
Motivation, negative, 
last resort 
I never want to take drugs… only because he said to take them I took 
them 
I was sad that I was prescribed it for the illness I was said to have, but 
I took it 
UK04 
 
UK05 
Stop, negative, better I don’t take the prescribed dose every day… I can go a fortnight without 
taking them… when I haven’t got the symptoms I’ll knock them… 
I’ll take them for several days until I notice it’s subsided and then I’ll 
stop 
UK05 
 
UK05 
Cost, positive, low [They’re all free?] Yes 
[It didn’t cost you anything?] No 
Fortunately [wife] had an exemption… 
Free 
[You don’t have to pay?] No 
UK01 
UK03 
UK04 
UK05 
UK06 
Instructions, positive, 
clear, written 
[Easy to understand?] Yes 
It was written on the doctor’s prescription. And a copy on the packet 
I think the label on the tablet bottle said that 
…it has a little leaflet inside 
Because it was on the box that the tablets came in 
UK01 
UK03 
UK04 
UK05 
UK06 
Size, negative, big The Sulfasalazine are quite large and hard but no, no problem… just 
the size, but as long as my tea is not too hot 
UK06 
Food, negative, absent Sometimes when I remembered there wasn’t another chance to eat UK01 
 
Stop, negative, keep I don’t feel any ill effects by not taking them… I’ve got those in stock 
that I can draw on if I need 
UK05 
Motivation, positive, stay 
well 
I don’t want to have any problem coming up because I’ve forgotten to 
take them or decided not to take the medicine he’s prescribed. That 
would be foolish 
And from starting to take those tablets I have had no swelling and no 
pain. I still take them 
I was extremely grateful that there was something I was being given to 
keep down the… pain, and it did 
I don’t want to risk a return to the swelling and pain… I would not risk 
stopping taking them 
UK02 
 
 
UK06 
 
UK06 
 
UK06 
Motivation, positive, get 
well 
[Positive results encouraged you to carry on?] Yes 
I was happy because it would take away a lot of the pain 
The results were absolutely magical, marvellous, a miracle 
UK03 
UK04 
UK06 
Regimen, negative, 
unacceptable 
I didn’t put it on my back very often because it was hard to get to… I 
had to clean it before, so that was annoying as well 
UK01 
Cost, negative, high Yes, £7 or whatever UK04 
Instructions, negative, 
misunderstood 
It said take 2 twice a day but I didn’t know what that meant UK01 
Instructions, positive, 
clear, verbal 
I think he must have said “take one per day”, which I did every morning 
I was told how to take them 
UK03 
UK05 
Course, positive, 
acceptable 
[Take in accordance with the prescription?] Yes UK01 
Water, negative, absent Sometimes. Not always UK01 
People, negative, 
absent 
[And when you didn’t apply it you were on your own?] Yes UK01 
Water, positive, present […take them all with water?] Yes 
I took it with a drink 
…with a cup of tea 
Water 
..with a cup of tea 
UK02 
UK03 
UK04 
UK05 
UK06 
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Transcription code Interview example Interview 
ref. 
Regimen, positive, 
acceptable 
…breakfast time is set and teatime is set so twice a day fits in quite 
happily with that 
I didn’t need to take one 3 times a day. I could take the 3 at breakfast 
time 
UK04 
 
UK06 
Regimen, negative, 
complex 
I had to take it with food 8 hours apart, an hour before I ate…I had to 
take it during the gap between my lessons before lunch but that’s 
actually 50 minutes… and then on the bus as soon as I got on, for tea… 
there were a lot of times I actually forgot 
[If you had a choice of how to take...?] I’d say not with food 
Especially the hour before food, you don’t know when you’re next going 
to have food 
…it was a real concoction of working out what she needed at each time 
so I devised a spreadsheet 
It was something that sounds simple but was such an onerous task day 
after day 
You might have run out of 50s but you’ve got 25s so you give three 25s 
or combinations of… it was an absolute logistical nightmare 
UK01 
 
 
 
UK01 
UK01 
 
UK04 
 
UK04 
 
UK04 
Regimen, negative, 
forgot 
Perhaps very very occasionally if we’ve been out to a late dinner… I 
might have forgotten 
Well very rarely 
UK02 
 
UK03 
Instructions, negative, 
unclear, verbal 
…and the pharmacist might have grunted that at me as he passed it 
over 
Initially, yes, but everything was so fluid… that it became evident that it 
didn’t really matter too much 
UK04 
 
UK04 
Routine, negative, 
absent 
…change in routine, like on a weekend… or I was staying in someone’s 
house, I’d forget to take it 
…but if we ate upstairs or in a different room I wouldn’t take it 
UK01 
 
UK01 
Routine, positive, 
present 
…one in the morning and one at night. Getting up and going to bed. 
Part of the routine… 
Just sort of when getting up or going to bed it jogged my memory 
I put it in the dining room because I had to take it with a meal 
I take certain ones with a drink with my breakfast or before my 
breakfast, and I have some… in the evening also before I take a drink 
I fill the containers… for 7 days… [then] I don’t forget them… I’m 
capable of remembering what should be in each 
I always took the packet out and took it with my breakfast 
So it was quite easy as long as I’d got them with me 
In the morning with breakfast with a cup of tea… evening meal again 
with a cup of tea 
In a morning [At breakfast?] Yes 
[Do you have them in a box with flaps?] Yes. [Does that help?] Very 
much so 
I got a little box with a week of separated compartments… I don’t have 
to think about it in a morning 
At the breakfast table 
UK01 
 
UK01 
UK01 
UK02 
 
UK02 
 
UK03 
UK03 
UK04 
 
UK05 
UK05 
 
UK06 
 
UK06 
Stop, negative, run out We had to eke them out instead of having like 2 tablets twice a day we 
had to have 1… 
UK04 
Access, positive, easy Mum picked it up 
Walk, or perhaps drive in if I’m going to town… it’s a standing order… 
it’s very simple 
Collected from Boots… they have an arrangement by which you collect 
regular medicines 
[It wasn’t inconvenient?] No 
We just go and pick it up from the chemist 
It could be delivered to me but I’m usually out… so I call 
UK01 
UK02 
 
UK03 
 
UK03 
UK05 
UK06 
Motivation, negative, 
tired 
[When you didn’t apply it, you were…?] Tired UK01 
Beliefs, negative, 
pointless 
There didn’t seem to be a lot of point [in consuming]… 
I don’t know really what I’m taking tablets for… I doubt his diagnosis 
actually… If I’ve no pain then I don’t need it preventing 
UK01 
UK05 
Reminder, positive, 
general 
Some kind of reminder, especially when I’m staying over UK01 
Instructions, positive, 
compliant 
I have been advised by my doctor to take these… and therefore I’m 
quite happy to take whatever he has prescribed… 
I just do as I’m asked to do 
UK02 
 
UK06 
Formulation, positive, 
tablet 
No it was very simple as it is, in foil 
In my case, no. They’re just tablets 
[wife] was always very good at swallowing tablets 
UK03 
UK04 
UK04 
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Transcription code Interview example Interview 
ref. 
I find tablets pretty easy 
[What you’ve got is fine?] Yes 
UK05 
UK06 
Size, positive, small [Any problems?] No. [Small enough?] Swallow them down UK05 
Effects, positive, side, 
none 
[Any side effects?] Not to my knowledge UK06 
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 Appendix C: Quantitative Research 
C.1 Survey questions 
This section lists the questions included in the survey. These were postfixed 
with demographic questions relating to age, sex, and country where the 
medicine-taking experience occurred. 
 
Key to Table 43: 
N/A  Not applicable 
N—A  Never – Rarely – Occasionally – Sometimes – Frequently – Usually – Always 
SD—SA Strongly disagree – strongly agree 
Table 43: Final list of survey questions 
Variable Origin of 
question 
Question Scale 
All 7-point Likert 
unless specified 
*=inverted 
N/A Own Please enter the name or a description of 
the medicine you are thinking of 
(Text input) 
N/A Own What form did your medicine take? Tablet/capsule 
Chewable 
Sublingual 
Powder/granules 
Syrup 
Solution/emulsion 
Injection 
Inhaler 
Ointment/cream 
Spray 
Drops 
Pessary/ 
suppository 
N/A Own How often did you have to take it? Less than once a 
week 
Once a week 
Several times a 
week 
Once a day 
Twice a day 
Three or more 
times a day 
N/A Own How long was the course of treatment? Single dose 
1-3 days 
4-7 days 
7-14 days 
15-28 days 
More than 28 days 
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Variable Origin of 
question 
Question Scale 
All 7-point Likert 
unless specified 
*=inverted 
 
Resources (34 questions) 
Thinking of a particular time when you had this medicine, select the frequency that applies 
to you. 
 
Agency1 MUSE I am able to take my medicine on time N—A 
Agency2 MUSE I am able to remember to take all my 
medicines 
N—A 
Agency3 MUSE I am able to set a schedule to take my 
medicines each day 
N—A 
Agency4 MUSE I am able to take my medicines every day N—A 
Agency5 MUSE I am able to ask my pharmacist questions 
about my medicine 
N—A 
Agency6 MUSE I am able to understand my pharmacist’s 
instructions for my medicine 
N—A 
Agency7 MUSE I am able to understand instructions on 
medicine bottles 
N—A 
Agency8 MUSE I am able to get all the information I need 
about my medicine 
N—A 
Agency9 Own I am able to take my medicine without help N—A 
Agency10 Own I am able to know when to take my 
medicine 
N—A 
Agency11 Own I am able to understand why I should take 
my medicine 
N—A 
Aff1a Own There is nothing about the medicine itself 
which puts me off 
N—A 
Aff1b Own This medicine has features which stop me 
taking it 
N—A * 
Aff1c Own The medicine itself gives me problems 
taking it 
N—A * 
Aff1d Own I have no problems taking the medicine 
itself 
N—A 
Aff2 Own There is something about this medicine’s 
taste that puts me off 
N—A * 
Aff3 Own There is something about the tablet size of 
this medicine that stops me taking it 
N—A * 
Aff4 Own There is something about this medicine’s 
smell that stops me taking it 
N—A * 
Aff5 Own There is something about the form of this 
medicine that stops me taking it 
N—A * 
Aff6 Own There is something about the duration of 
course of treatment that stops me taking 
this medicine 
N—A * 
Aff7 Own There is something about this medicine’s 
packaging that stops me opening and 
taking it 
N—A * 
Aff8 Own I do not take my medicine because I know 
the bad side-effects it has had on others 
N—A * 
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Variable Origin of 
question 
Question Scale 
All 7-point Likert 
unless specified 
*=inverted 
Aff9 Own I don’t take this medicine because it is 
made by a profit-making company 
N—A * 
Aff10 Own I don’t take this medicine because it 
contains unknown chemicals 
N—A * 
Con1a Own In my situation I have everything I need to 
take this medicine 
N—A 
Con1b Own In my situation I am missing something at 
the time I need to take it 
N—A * 
Con1c Own In my circumstances when the time comes 
to take this medicine I have all the things I 
need 
N—A 
Con1d Own In my situation I have everything available 
to me to allow me to take this medicine 
N—A 
Con2 Own In my circumstances, at the time I take this 
medicine I have the food I need to allow me 
to do so 
N—A 
Con3 Own In my situation, at the time I take this 
medicine I have the water I need to allow 
me to do so 
N—A 
Con4 Own In my circumstances, at the time I take this 
medicine I have the utensils (spoon, 
syringe, etc) I need to allow me to do so 
N—A 
Con5 Own In my situation, at the time I take this 
medicine I have the help I need to allow me 
to do so 
N—A 
Con6 Own In my circumstances, at the time I take this 
medicine I have the containers (cup, 
measuring jug, etc) I need to allow me to 
do so 
N—A 
Con7 Own In my situation, I do not take this medicine 
because of the stigma attached to it or to 
my illness 
N—A * 
 
Beliefs and Norms (35 questions) 
Thinking still of this particular medicine, how much do you agree with the following 
statements? 
 
Belief1 DAI-30 I believe that I don't need to take this 
medicine once I feel better 
SD—SA * 
Belief2 DAI-30 I believe that for me, the good things about 
this medicine outweigh the bad 
SD—SA 
Belief3 DAI-30 I believe that I feel strange, "doped up", on 
this medicine 
SD—SA * 
Belief4 DAI-30 I believe that even when I am not in 
hospital I need this medicine regularly 
SD—SA 
Belief5 
NORM 
DAI-30 I believe that if I take this medicine, it's only 
because of pressure from other people 
SD—SA * 
Belief6 DAI-30 I believe that I am more aware of what I am 
doing, of what is going on around me, 
when I am on this medicine 
SD—SA 
 208 
  
Variable Origin of 
question 
Question Scale 
All 7-point Likert 
unless specified 
*=inverted 
Belief7 DAI-30 I believe that taking this medicine will do 
me no harm 
SD—SA 
Belief8 DAI-30 I believe that I take this medicine of my own 
free choice 
SD—SA 
Belief9 DAI-30 I believe that this medicine makes me feel 
more relaxed 
SD—SA 
Belief10 DAI-30 I believe that I am no different on or off this 
medicine 
SD—SA * 
Belief11 DAI-30 I believe that the unpleasant effects of this 
medicine are always present 
SD—SA * 
Belief12 DAI-30 I believe that this medicine makes me feel 
tired and sluggish 
SD—SA * 
Belief13 DAI-30 I believe that I take this medicine only when 
I feel ill 
SD—SA * 
Belief14 DAI-30 I believe that this medicine is a slow-acting 
poison 
SD—SA * 
Belief15 DAI-30 I believe that I get along better with people 
when I am on this medicine 
SD—SA 
Belief16 DAI-30 I believe that I can't concentrate on 
anything when I am taking this medicine 
SD—SA * 
Belief17 DAI-30 I believe that I know better than the doctors 
when to stop taking this medicine 
SD—SA * 
Belief18 DAI-30 I believe that I feel more normal on this 
medicine 
SD—SA 
Belief19 DAI-30 I believe that I would rather be ill than 
taking this medicine 
SD—SA * 
Belief20 DAI-30 I believe that it is unnatural for my mind and 
body to be controlled by this medicine 
SD—SA * 
Belief21 DAI-30 I believe that my thoughts are clearer on 
this medicine 
SD—SA 
Belief22 DAI-30 I believe that I should keep taking this 
medicine even if I feel well 
SD—SA 
Belief23 DAI-30 I believe that taking this medicine will 
prevent me from having a breakdown 
SD—SA 
Belief24 DAI-30 I believe that it is up to the doctor to decide 
when I should stop taking this medicine 
SD—SA 
Belief25 DAI-30 I believe that things that I could do easily 
are much more difficult when I am on this 
medicine 
SD—SA * 
Belief26 DAI-30 I believe that I am happier and feel better 
when I am taking this medicine 
SD—SA 
Belief27 
NORM 
DAI-30 I believe that I am given this medicine to 
control behaviour that other people (not 
myself) don't like 
SD—SA * 
Belief28 DAI-30 I believe that I can't relax on this medicine SD—SA * 
Belief29 DAI-30 I believe that I am in better control of myself 
when taking this medicine 
SD—SA 
Belief30 DAI-30 I believe that by staying on this medicine I 
can prevent myself getting sick 
SD—SA 
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Variable Origin of 
question 
Question Scale 
All 7-point Likert 
unless specified 
*=inverted 
Belief31 
NORM 
Own I believe that I have to take this medicine 
because my religious faith has not cured 
me 
SD—SA * 
Belief32 
NORM 
Own I believe that it is not good to be seen 
taking this medicine 
SD—SA * 
Belief33 Own I believe that natural remedies are safer for 
me to take than this medicine 
SD—SA * 
Belief34 Own I believe that I am getting better because 
of taking this medicine 
SD—SA 
Belief35 Own I believe that I can get better in other ways 
than taking this medicine 
SD—SA * 
 
Motivation (16 questions) 
Thinking of the particular time when you had this medicine, why were you motivated to take 
it? 
Mot1 CMOTS I am motivated because other people think 
that it's a good idea for me to take it 
N—A 
Mot2 CMOTS I am motivated because my friends think I 
should take it 
N—A 
Mot3 CMOTS I am motivated because I don't want to 
upset people close to me who want me to 
take it 
N—A 
Mot4 CMOTS I am motivated to satisfy people close to 
me who want me to get better 
N—A 
Mot5 CMOTS I am motivated because I would feel guilty 
if I were not doing anything about my 
illness 
N—A 
Mot6 CMOTS I am motivated because I would feel bad 
about myself if I didn't continue my course 
N—A 
Mot7 CMOTS I am motivated because I should have a 
better understanding of myself 
N—A 
Mot8 CMOTS I am motivated because it is important for 
me to continue the course until it's finished 
N—A 
Mot9 CMOTS I am motivated because I would like to 
make changes to my current situation 
N—A 
Mot10 CMOTS I am motivated because I believe that 
eventually it will allow me to feel better 
N—A 
Mot11 CMOTS I am motivated because I believe that 
taking it will allow me to deal with things 
better 
N—A 
Mot12 CMOTS I am motivated because I believe it's a 
good thing to find solutions to my illness 
N—A 
Mot13 CMOTS I am motivated because through taking it 
I've come to see a way that I can approach 
different aspects of my life 
N—A 
Mot14 CMOTS I am motivated because through taking it I 
feel that I can now take responsibility for 
making changes in my life 
N—A 
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Variable Origin of 
question 
Question Scale 
All 7-point Likert 
unless specified 
*=inverted 
Mot15 CMOTS I am motivated because I feel that the 
changes that are taking place through 
taking it are becoming part of me 
N—A 
Mot16 CMOTS I am motivated because I value the way it 
allows me to make changes in my life 
N—A 
 
Adherence (4 questions) 
Thinking of the particular time when you had this medicine, select the frequency that applies 
to you 
 
Adhere1a Own I take my medicine according to the 
instructions 
N—A 
Adhere1b Own I take my medicine correctly N—A 
Adhere1c Own I take my medicine as prescribed N—A 
Adhere1d Own I take my medicine as I have been 
instructed 
N—A 
Total = 89 questions 
 
C.2 Statistical summary data 
This section provides high-level statistical description of each measured 
variable arising from the survey whose contents are provided above. 
. summarize Adhere1a Adhere1b Adhere1c Adhere1d 
 
    Variable |        Obs        Mean    Std. Dev.       Min        Max 
-------------+--------------------------------------------------------- 
    Adhere1a |         49    6.040816    1.322233          1          7 
    Adhere1b |         49    5.673469    1.214286          2          7 
    Adhere1c |         49    6.040816    1.189523          2          7 
    Adhere1d |         49           6    1.154701          2          7 
Figure 59: Summary of Adhere(nce) items 
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. summarize Aff1a Aff1b Aff1c Aff1d Aff2 Aff3 Aff4 Aff5 Aff6 Aff7 Aff8 Aff9 
Aff10 
 
    Variable |        Obs        Mean    Std. Dev.       Min        Max 
-------------+--------------------------------------------------------- 
       Aff1a |         49    3.836735    2.044779          1          7 
       Aff1b |         49    4.897959    1.884641          1          7 
       Aff1c |         49    4.795918    1.790945          1          7 
       Aff1d |         49    4.020408    2.184126          1          7 
        Aff2 |         49    4.632653    2.195582          1          7 
-------------+--------------------------------------------------------- 
        Aff3 |         49    4.632653    1.975832          1          7 
        Aff4 |         49    4.897959    2.172219          1          7 
        Aff5 |         49           5    1.670828          1          7 
        Aff6 |         49     4.77551    1.770891          1          7 
        Aff7 |         49    5.367347    1.922389          1          7 
-------------+--------------------------------------------------------- 
        Aff8 |         49    5.346939    1.702339          1          7 
        Aff9 |         49    6.387755     1.31998          1          7 
       Aff10 |         49    5.653061    2.097131          1          7 
Figure 60: Summary of Aff(ordance) items 
 
. summarize Agency1 Agency2 Agency3 Agency4 Agency5 Agency6 Agency7 Agency8 
Agency9 Agency10 Agency11 
 
    Variable |        Obs        Mean    Std. Dev.       Min        Max 
-------------+--------------------------------------------------------- 
     Agency1 |         49    4.897959    1.673879          1          7 
     Agency2 |         49    5.265306    1.425592          2          7 
     Agency3 |         49    4.428571    1.814295          1          7 
     Agency4 |         49    5.428571    1.354006          1          7 
     Agency5 |         49    4.571429     2.03101          1          7 
-------------+--------------------------------------------------------- 
     Agency6 |         49    5.897959    1.475422          1          7 
     Agency7 |         49    6.081633    1.288357          2          7 
     Agency8 |         49    5.061224    1.638192          1          7 
     Agency9 |         49    5.183673    2.127924          1          7 
    Agency10 |         49    5.530612    1.634294          1          7 
-------------+--------------------------------------------------------- 
    Agency11 |         49    5.673469    1.760537          1          7 
Figure 61: Summary of Agency items 
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. summarize Belief1 Belief2 Belief3 Belief4 Belief6 Belief7 Belief8 Belief9 
Belief10 Belief11 Belief12 Belief13 Belief14 Belief15 Belie 
> f16 Belief17 Belief18 Belief19 Belief20 Belief21 Belief22 Belief23 Belief24 
Belief25 Belief26 Belief28 Belief29 Belief30 Belief33 Bel 
> ief34 Belief35 
 
    Variable |        Obs        Mean    Std. Dev.       Min        Max 
-------------+--------------------------------------------------------- 
     Belief1 |         49    4.612245    1.977123          2          7 
     Belief2 |         49    2.734694    1.468779          1          7 
     Belief3 |         49    3.285714    1.892969          1          7 
     Belief4 |         49    4.346939    2.194226          1          7 
     Belief6 |         49    3.734694    1.765119          1          7 
-------------+--------------------------------------------------------- 
     Belief7 |         49    3.367347    1.943942          1          7 
     Belief8 |         49    4.346939    2.126725          1          7 
     Belief9 |         49    4.265306    1.966125          1          7 
    Belief10 |         49    3.346939    1.854623          1          7 
    Belief11 |         49    3.979592    2.135901          1          7 
-------------+--------------------------------------------------------- 
    Belief12 |         49    3.816327    1.965043          1          7 
    Belief13 |         49    4.877551    2.006579          1          7 
    Belief14 |         49    3.612245    1.966557          1          7 
    Belief15 |         49           4           2          1          7 
    Belief16 |         49    3.530612    1.969582          1          7 
-------------+--------------------------------------------------------- 
    Belief17 |         49    2.918367    1.789282          1          6 
    Belief18 |         49    3.755102      1.8988          1          7 
    Belief19 |         49    2.306122    1.474846          1          7 
    Belief20 |         49    3.571429     2.03101          1          7 
    Belief21 |         49    3.795918    1.825509          1          7 
-------------+--------------------------------------------------------- 
    Belief22 |         49    4.163265    2.124725          1          7 
    Belief23 |         49    4.387755    1.923715          1          7 
    Belief24 |         49    3.122449    1.932536          1          7 
    Belief25 |         49    3.408163    2.040408          1          7 
    Belief26 |         49    3.734694    1.944817          1          7 
-------------+--------------------------------------------------------- 
    Belief28 |         49    3.530612    1.883061          1          7 
    Belief29 |         49    4.081633    1.945473          1          7 
    Belief30 |         49    3.897959    2.084115          1          7 
    Belief33 |         49    3.653061    2.116906          1          7 
    Belief34 |         49           3    1.903943          1          7 
-------------+--------------------------------------------------------- 
    Belief35 |         49    3.693878    1.828069          1          7 
Figure 62: Summary of Belief items 
 
. summarize Con1a Con1b Con1c Con1d Con2 Con3 Con4 Con5 Con6 Con7 
 
    Variable |        Obs        Mean    Std. Dev.       Min        Max 
-------------+--------------------------------------------------------- 
       Con1a |         49    5.183673    1.911298          1          7 
       Con1b |         49    4.632653    1.764156          1          7 
       Con1c |         49    4.530612    2.052458          1          7 
       Con1d |         49    4.734694    1.890497          1          7 
        Con2 |         49    4.346939    2.067114          1          7 
-------------+--------------------------------------------------------- 
        Con3 |         49    5.612245    1.789045          1          7 
        Con4 |         49    4.408163    2.263095          1          7 
        Con5 |         49    3.959184    2.318038          1          7 
        Con6 |         49    4.877551    2.077986          1          7 
        Con7 |         49    5.571429    1.791182          1          7 
Figure 63: Summary of Con(text) items 
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. summarize Mot1 Mot2 Mot3 Mot4 Mot5 Mot6 Mot7 Mot8 Mot9 Mot10 Mot11 Mot12 
Mot13 Mot14 Mot15 Mot16 
    Variable |        Obs        Mean    Std. Dev.       Min        Max 
-------------+--------------------------------------------------------- 
        Mot1 |         49    3.408163    2.080849          1          7 
        Mot2 |         49    3.122449    2.127525          1          7 
        Mot3 |         49    2.795918     1.80254          1          7 
        Mot4 |         49    3.265306    2.059283          1          7 
        Mot5 |         49    3.877551     2.16634          1          7 
-------------+--------------------------------------------------------- 
        Mot6 |         49    3.693878    2.073685          1          7 
        Mot7 |         49    4.428571    2.254625          1          7 
        Mot8 |         49    5.265306    2.028706          1          7 
        Mot9 |         49    4.979592    1.853935          1          7 
       Mot10 |         49    5.673469    1.448962          1          7 
-------------+--------------------------------------------------------- 
       Mot11 |         49    4.040816    2.327008          1          7 
       Mot12 |         49    5.265306    1.934075          1          7 
       Mot13 |         49    3.632653    2.157293          1          7 
       Mot14 |         49    3.816327    2.251606          1          7 
       Mot15 |         49     3.77551    2.143452          1          7 
-------------+--------------------------------------------------------- 
       Mot16 |         49    4.061224    2.418748          1          7 
 
Figure 64: Summary of Mot(ivation) items 
 
. summarize Belief5 Belief27 Belief31 Belief32 
 
    Variable |        Obs        Mean    Std. Dev.       Min        Max 
-------------+--------------------------------------------------------- 
     Belief5 |         49    2.510204    1.542758          1          7 
    Belief27 |         49    2.653061    1.702339          1          7 
    Belief31 |         49    2.591837    1.881028          1          7 
    Belief32 |         49    2.612245    1.525018          1          7 
Figure 65: Summary of Norm items 
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